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 Bile acids and cortisol are steroid hormones derived from cholesterol that are important 
signaling molecules in the human body. Bile acids are essential for nutrient solubilization and 
absorption in the gut while cortisol is involved in stress response and metabolism throughout the 
body. The gut microbiome has evolved a network of enzymes that modify steroids produced by 
the host. One such enzyme activity is oxidoreduction of steroid hydroxyl groups by 
hydroxysteroid dehydrogenases (HSDHs). Pairs of HSDHs can reversibly epimerize α-hydroxyl 
groups through an oxo-intermediate to β-hydroxyl groups. These small modifications of steroid 
structure often greatly influence their physicochemical properties, leading to changes in toxicity, 
solubility, and their ability to activate or inhibit host receptors. 
 In this work, two types of bile acid HSDHs were explored: 12α-HSDH, which reversibly 
converts the C-12 position hydroxyl from the α-orientation to an oxo-group, and 12β-HSDH, 
which completes the epimerization by converting the C-12 oxo-group to the β-orientation. Three 
12α-HSDHs were identified in the human gut microbes Clostridium scindens ATCC 35704, C. 
hylemonae DSM 15053, and Peptacetobacter hiranonis DSM 13275. After cloning and 
overexpression of these enzymes in Escherichia coli, biochemical analysis revealed a preference 
for the oxo-intermediate, 12-oxolithocholic (12-oxoLCA), over the 12α-hydroxy substrate, 
deoxycholic acid (DCA). Phylogenetic analysis suggests 12α-HSDH is widespread across 
Firmicutes and Actinobacteria. The first gene encoding bile acid 12β-HSDH, converting 12-
oxoLCA to epiDCA, was discovered following a screen of 6 candidate enzymes from C. 
paraputrificum ATCC 25780. A phylogenetic analysis of 12β-HSDH led to the identification of 
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two additional validated bile acid 12β-HSDHs in Eisenbergiella sp. OF01-20 and Olsenella sp. 
GAM18. Comparison of the 12α- and 12β-HSDH phylogenies revealed two shared organisms 
between them, Collinsella tanakaei YIT 12063 and Collinsella stercoris DSM 13279. Although not 
yet confirmed in culture, these are the first strains identified with potential bile acid C-12 
epimerizing activity. 
 Additionally, two HSDHs metabolizing cortisol were characterized biochemically and 
structurally: 20β-HSDH, which interconverts cortisol and 20β-dihydrocortisol, and 20α-HSDH, 
which reversibly biotransforms cortisol to 20α-dihydrocortisol. A 20β-HSDH from 
Bifidobacterium adolescentis strain L2-32 was cloned, overexpressed and purified. The apo-form 
without ligands bound and the binary complex with cofactor bound were crystallized. A large, 
flexible N-terminal domain within the structures was investigated further by gel filtration 
chromatography and circular dichroism spectroscopy. Deletions of the extended N-terminus 
caused a loss of activity and structural changes, suggesting the N-terminus is critical for protein 
stability. Additionally, a 20α-HSDH from C. scindens ATCC 35704 was crystallized and its 
enzymatic mechanism predicted by hybrid quantum mechanics/molecular mechanics (QM/MM) 
simulations. In order to test the reaction mechanism, substrate-binding and catalytic residues 
were validated by site-directed mutagenesis and isothermal titration calorimetry. 
 Microbial HSDHs are predicted regulators of steroid pathways implicated in colorectal 
cancer, liver cancer, castration-resistant prostate cancer and polycystic ovary syndrome. Due to 
their regulatory potential, microbial HSDHs may have promise as therapeutics or druggable 
targets in the future. Thus, the characterization of new bile acid 12α/β-HSDH and cortisol 20α/β-
HSDH activities will serve as the foundation for future mechanistic studies on the role of HSDHs 
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REVIEW OF LITERATURE1 
 
ABSTRACT 
Bile acids (BAs) and glucocorticoids are steroid hormones derived from cholesterol that 
are important signaling molecules in humans and other vertebrates. Hydroxysteroid 
dehydrogenases (HSDHs) are encoded both by the host and by their resident gut microbiota, and 
they reversibly convert steroid hydroxyl groups to keto groups. Pairs of HSDHs can reversibly 
epimerize steroids from α-hydroxy conformations to β-hydroxy, or β-hydroxy to ω-hydroxy in 
the case of ω-muricholic acid. These reactions often result in products with drastically different 
physicochemical properties than their precursors, which can result in steroids being activators or 
inhibitors of host receptors, can affect solubility in fecal water, and can modulate toxicity. 
Microbial HSDHs modulate sterols associated with diseases such as colorectal cancer, liver 
cancer, prostate cancer, and polycystic ovary syndrome. Although the role of microbial HSDHs 
is not yet fully elucidated, they may have therapeutic potential as steroid pool modulators or 
druggable targets in the future. In this review, we explore metabolism of BAs and 





1 Adapted with permission from Doden HL, Ridlon JM. Microbial hydroxysteroid dehydrogenases: from alpha to 




Steroid hormones are signaling molecules derived from cholesterol that include 
glucocorticoids, mineralocorticoids, androgens, estrogens, progestogens, and bile acids (BAs).1 
Steroid hormones are essential for the regulation of various physiological processes, such as 
metabolism, salt and water balance, reproduction, inflammation, and stress response.2 These 
cholesterol-derived molecules are synthesized in the human adrenal glands, gonads, placenta, 
and liver.3,4 All steroids have a cyclopentanoperhydrophenanthrene ring structure, composed of 
three six-carbon rings denoted A, B, and C along with a five-carbon D ring (Figure 1.1), with 
differing hydroxyl groups and side-chains.1 Hydroxysteroid dehydrogenases (HSDH) are an 
important class of enzyme expressed by both host tissues and host-associated microbiota that 
modify the hydroxyl groups on steroids. These small modifications to steroids greatly impact 
their physicochemical properties and can change the steroid solubility, toxicity, host receptor 
affinity, and ability to activate or inhibit host receptors.5–8 The current review focuses on the 
importance of gut microbial HSDHs in cholesterol, BA, and glucocorticoid metabolism.  
 
HYDROXYSTEROID DEHYDROGENASES 
Hydroxysteroid Dehydrogenase Function 
Hydroxysteroid dehydrogenases are nicotinamide adenine dinucleotide (phosphate) 
(NAD(P)(H))-dependent oxidoreductases that catalyze the reversible conversion of hydroxyl 
groups to keto groups on steroids.9 HSDHs are regio- and stereospecific, meaning they are 
specific for the hydroxyl position on the steroid (C-3 vs. C-7) and for the orientation (α vs. β) of 
the hydroxyl group, respectively.5 Pairs of HSDHs can convert steroids from the α-orientation, 
through an oxo-intermediate, to the epimerized β-orientation and vice versa. 
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Hydroxysteroid dehydrogenases are found in both host and microbial genomes, although 
more is known about the physiological function of host hydroxysteroid dehydrogenases, which 
are typically abbreviated HSDs in literature. In this review, host hydroxysteroid dehydrogenases 
are denoted “HSD” while bacterial enzymes are denoted “HSDH”. Host HSDs are key enzymes 
in the biosynthesis of steroids in steroidogenic tissues.10 They also function to activate or 
inactivate steroids in peripheral tissues, thus regulating local concentrations of steroid 
hormones.5 Even though host HSDs catalyze reversible reactions in vitro, they typically function 
primarily in one direction in vivo on the basis of cofactor balance: either as dehydrogenases or as 
reductases.11 
Host HSDs are druggable targets important in the treatment of endocrine-dependent 
disorders, including cancers.12 Host-associated microbial HSDHs may also serve as 
pharmacological targets or, alternatively, may be enriched in the host through engineering and 
delivering probiotic bacteria with rational sterolbiome phenotypes. One recent example involves 
identification of a cholesterol 3β-HSDH involved in conversion of cholesterol to coprostanol, the 
enrichment of which may be important as a probiotic approach to reducing serum cholesterol.13 
 
Structural Biology of Hydroxysteroid Dehydrogenases 
Hydroxysteroid dehydrogenases belong to one of the following three large and diverse 
protein superfamilies: short-chain dehydrogenase/reductase (SDR), medium-chain 
dehydrogenase/reductase (MDR), or aldo-keto reductase (AKR).5,14 Many SDR and MDR family 
hydroxysteroid dehydrogenases have been identified in the gut microbiome.14–17 HSDHs in the 
AKR superfamily are generally found within mammals12, although microbial AKR family 
HSDHs have been reported.18 
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The SDR superfamily is one of the largest, containing proteins spanning all three 
domains of life.19 SDR proteins have highly diverse substrate specificities, ranging from sugars 
to dyes to steroids.20 Members of this superfamily are non-metalloenzymes and typically 250 
amino acids in length.5 Due to the dependence of dehydrogenase/reductase enzymes on 
NAD(P)(H) to carry out redox reactions, SDR proteins contain a Rossmann fold domain for 
binding cofactors. This domain consists of 6–7 β-strands with 3–4 peripheral α-helices on either 
side.21,22 Typically, the Rossmann fold domain is located near the N-terminus of SDR proteins, 
while the C-terminus binds substrates.20 Most SDR members have a conserved Tyr, Ser, and Lys 
at the catalytic site. The overall folding pattern is closely conserved across the superfamily, while 
amino-acid sequence varies greatly.22 This causes great difficulty in predicting substrate 
specificities by amino acid homology search alone. HSDHs within the SDR superfamily include 
but are not limited to host 11β-HSD and 17β-HSD5, and various microbial BA 12α-HSDHs (see 
Chapter 2)23, 12β-HSDH (see Chapter 3)24, 3α/β-HSDHs17, and glucocorticoid 20β-HSDH (see 
Chapter 4)15. 
The MDR family is similar to the SDR family both in number of members and in 
function, although their structures have marked differences. MDR proteins contain Rossmann 
fold domains for NAD(P)(H) binding like SDRs, but they are ~350 residues long and many are 
metal-dependent.25 They are typically dimeric or tetrameric and many contain a catalytic zinc 
ion, sometimes along with a structural zinc ion, while others are non-zinc-containing.26 The zinc-
containing MDRs share a strictly conserved Gly, His, and Glu for zinc binding.27 MDR family 
HSDHs include host BA 3β-HSD26 and microbial glucocorticoid 20α-HSDH (see Chapter 5)14,16. 
AKRs are NAD(P)(H)-dependent oxidoreductases acting on carbonyl groups or double 
bonds and are ~320 amino acids long. They are monomeric with diverse substrate recognition, 
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including steroids, monosaccharides, and isoflavonoids. An ordered bi–bi kinetic mechanism has 
been shown for multiple AKR family members, where the cofactor is first to bind and last to 
leave.28 Most have a conserved active site with residues Asp, Lys, Tyr, and His. Examples of 
members of this superfamily involved in steroid metabolism are human 3α-HSD29, human 20α-
HSD30, and bacterial BA 3β-HSDH18. 
 
BILE ACID METABOLISM 
Host Bile Acid Synthesis and Signaling 
Bile acids are amphipathic C24 steroids that play an important role in host nutrition
31. 
They are essential for solubilization and later absorption of cholesterol, dietary fatty acids, 
triglycerides, and lipid-soluble vitamins A, D, E, and K. Bile acids assemble into mixed micelles, 
forming a hydrocarbon interior in order to solubilize these molecules.31,32 
Bile acid biosynthesis occurs in the liver and begins with the rate-limiting step of 
cholesterol 7α-hydroxylation by cytochrome P450 7α-hydroxylase (CYP7A1) in hepatocytes 
(Figure 1.2).31,33 While other carbon positions on cholesterol can be hydroxylated first (C-24, C-
25, C-26, C-27), the classical pathway initiates through C-7 hydroxylation catalyzed by 
CYP7A1.34,35 The next step alters the ring structure through conversion to 3-oxo-Δ4 by 3β-
hydroxy-Δ5-C27-steroid oxidoreductase (HSD3B7).
34,36,37 After HSD3B7 action, the intermediate 
is converted by 12α-hydroxylase (CYP8B1) if the final product contains a 12α-hydroxyl group. 
Ensuing steps involve additional modification to the ring structure by AKR1D1 and AKR1C1.37 
Then, mitochondrial sterol 27-hydroxylase (CYP27A1) oxidizes the side-chain, followed by 
removal of three carbon atoms beginning with activation of the sterol by BA coenzyme A (CoA) 
synthase.34,38,39 Subsequent reactions are catalyzed by 2-methylacyl-CoA racemase, branched-
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chain acyl-CoA oxidase, D-bifunctional protein, and peroxisomal thiolase 2, which cleaves the C-
24–C-25 bond.34,37 The final step in BA biosynthesis is conjugation of the BA-CoA intermediate 
to either glycine or taurine, catalyzed by BA CoA:amino acid N-acyltransferase.34,40 
Conjugated BAs, called “bile salts” due to their ionized state at physiological pH, have 
increased solubility and greater amphipathicity. The biosynthetic pathway results in the 
formation of conjugated cholic acid (CA; 3α,7α,12α-hydroxy) or chenodeoxycholic acid 
(CDCA; 3α,7α-hydroxy) with their relative proportions determined by levels of 12α-hydroxylase 
in the liver.33,34 The ratio of taurine- to glycine-conjugated BAs is dependent on diet in humans. 
A high-protein diet results in greater taurine conjugation, while vegetarian diets lead to more 
glycine conjugation.33 CA and CDCA are the primary BAs produced in humans, whereas other 
vertebrates produce bile salts that differ in ring hydroxylation pattern, as well as side-chain 
length and functional groups. The main classes are C24 BAs, C27 BAs, and C27 bile alcohols.
41 
C24 BAs are common in all vertebrates, but with differing hydroxylation patterns. For example, 
mice produce CA and convert CDCA to muricholic acids (3,6,7-hydroxy) via hydroxylation and 
epimerization at C-6. C27 bile alcohols are typically synthesized in fish
42 and amphibians, while 
C27 BAs are present in reptiles and birds
41. 
Once synthesized, conjugated BAs are actively transported out of hepatocytes into the 
bile duct. Conjugated BAs are stored in the gallbladder until the gallbladder is emptied into the 
duodenum in response to a meal.43 Conjugated bile salts form mixed micelles with cholesterol, 
lipid-soluble vitamins, and dietary lipids throughout the small intestine. In the ileum, a sodium-
dependent transporter (IBAT) takes up BAs into ileocytes.44 From ileocytes, they are exported by 
organic solute transporter OSTα/β45,46 into the portal vein, where they circulate back to the liver 
in a process known as enterohepatic circulation.47 However, ~500 mg of BAs each day are not 
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taken up in the ileum and progress to the colon where they encounter gut microbiota.37 Microbial 
metabolites of BAs can be passively absorbed in the colon, travel through the portal vein, and 
join the recycled host-derived BAs in the liver. Thus, the biliary pool consists of both host- and 
microbiota-derived BAs that are re-conjugated and, in some species, 7-hydroxylated, as they 
return to the liver.48  
In addition to the digestive function of BAs, they are now known to act as hormone 
signaling molecules. BAs are involved in regulation of their own biosynthesis, as well as energy, 
glucose, and lipid metabolism.43 Farnesoid X receptor (FXR, NR1H4) is a BA-activated nuclear 
receptor expressed in tissues such as liver, intestine, and kidney.49,50 FXR regulates BA 
biosynthesis and enterohepatic circulation through many mechanisms. The FXR/SHP (small 
heterodimer partner) pathway of regulation involves the inhibition of CYP7A1, the rate-limiting 
step in BA formation. FXR induces the nuclear receptor, SHP, which inhibits liver-related 
homolog-1 (LRH-1) and hepatocyte nuclear factor 4α (HNF4α), both leading to inhibition of 
CYP7A1 transcription.51–53 Another pathway involves FXR, fibroblast growth factor 19 (FGF19), 
and FGF receptor 4 (FGFR4), which also results in inhibition of CYP7A1. Before recirculation 
back to the liver, BAs stimulate intestinal FXR, which induces FGF19 synthesis in ileocytes.54 
FGF19 is transported to the liver, where it binds FGFR4 and activates the c-jun N-terminal 
kinase (JNK) 1/2 signaling cascade, leading to downregulation of CYP7A1.33,55 
Pregnane X receptor (PXR) and vitamin D receptor (VDR) are both nuclear receptors 
activated by microbial-derived BAs that also lead to the binding of CYP7A1 promoter and 
repression of CYP7A1.8,56–58 Takeda G-protein receptor 5 (TGR5) is a G-protein-coupled 
receptor for BAs that is expressed in intestinal and biliary epithelial cells among other cell 
types.59,60 TGR5 has widespread effects throughout the body, including regulation of intestinal 
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motility.61 Taurine-conjugated BAs activate TGR5 more effectively than unconjugated or 
glycine-conjugated BAs.62 TGR5 signaling can activate epidermal growth factor receptor 
(EGFR).63 EGFR is also a BA receptor that, once bound, initiates a signaling pathway ending in 
inhibition of CYP7A1.43,64 In the gut, primary bile salts can be microbially biotransformed to 
dozens of metabolites whose concentrations and affinities can impact host physiological 
response in the intestine. 
 
Microbial Bile Acid Metabolism 
Bile acids that enter the colon are metabolized by gut microbiota through a combination 
of de(re)conjugation, 7α/β-dehydroxylation, and epimerization (Figure 1.2). The first step of 
microbial BA metabolism, known as deconjugation, mainly occurs in the small intestine and 
involves the hydrolysis of the C-24 N-acyl bond linking the conjugated amino acid to the BA. 
This reaction is catalyzed by bile salt hydrolase (BSH) encoded by diverse microbiota, including 
Clostridium65,66, Bacteroides67,68, Lactobacillaceae69, Bifidobacterium70,71, Enterococcus72, and 
archaea73. BSHs have differing substrate specificity and subunit size, but often have conserved 
active site Cys, Arg, Asp, Asn, and another Arg.74 BSHs have a pH optimum of 5–6 and are 
typically intracellular65,70, although activity has been reported extracellularly in some cases.66 
Interestingly, re-conjugation of BAs by gut microbiota has recently been observed with unique 
amino acids: Phe, Tyr, and Leu.75 
There are multiple hypotheses on the evolutionary role of BSH in microbial fitness: 
interspecies competition, detoxification, and release of an energy source. Deconjugated BAs are 
more toxic than conjugated bile salts to some bacterial species; thus, deconjugation may serve a 
competitive function to inhibit other bacteria.4 However, the reverse may also be true. Some 
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bacteria are more sensitive to conjugated BAs and, thus, BSH may help them detoxify their 
environment.76 Amino acids released from deconjugation could be an important energy source 
for certain microbiota, such as Clostridium that can utilize amino acids through Stickland 
fermentation.77 
Deconjugated primary BAs can be 7-dehydroxylated by a select few species within the 
gut, including Clostridium scindens, C. hylemonae, and C. hiranonis (now reclassified as 
Peptacetobacter hiranonis).4,78–80 Through this process, the primary BAs CA and CDCA are 
converted to “secondary” deoxycholic acid (DCA; 3α,12α-hydroxy) and lithocholic acid (LCA; 
3α-hydroxy), respectively. Although so few species encode the 7α-dehydroxylation pathway, 
secondary BAs make up the majority of excreted BAs74,81,82, meaning these microbiota have 
extensive dehydroxylation capacity. 
The 7-dehydroxylation pathway is encoded by the polycistronic BA-inducible 
(baiABCDEFGHI) operon.4,83,84 The first step is the import of unconjugated primary BAs by a 
BA transporter BaiG.85 Next, ligation of CoA to the unconjugated BA is catalyzed by BA CoA 
ligase encoded by baiB, requiring ATP and Mg2+.86 Then, the 3α-hydroxyl group is oxidized by 
BaiA.87 Three baiA genes from C. scindens have been reported in C. scindens VPI 12708, 
although completion of the C. scindens American Type Culture Collection (ATCC) 35704 
genome revealed the presence of only two, with baiA2 located in the bai operon 88–91 These 
enzymes are NAD(H)-dependent BA 3α-HSDHs that are specific for BA-CoA conjugates.87 
BaiCD is an NADH:flavin-dependent oxidoreductase that creates a C-4=C-5 double bond on 7α-
hydroxy BA intermediates, while BaiH has the same function on 7β-hydroxy BAs.92 CoA is then 
hydrolyzed by BaiF or BaiK and transferred without requirement of ATP to an incoming primary 
BA.93 Subsequent 7α-dehydration is the rate-limiting step in the pathway, catalyzed by the baiE 
10 
 
product.94 7β-Dehydration is predicted to be carried out by BaiI.95 Recently, a recombinant 
flavoprotein encoded by baiN, which is not a part of the bai operon, was shown to convert 3-
dehydro-DCA to a product 4 amu less than the substrate.96 Further characterization is necessary, 
but this suggests that baiN may catalyze reduction of both Δ4 and Δ6-intermediates following 7-
dehydration.96 Alternatively, BaiCD and BaiH were reported to be sufficient for C-4=C-5 and C-
6=C-7 metabolism in the oxidative and reductive arms of the pathway.97 The final step in the 
pathway, converting the 3-oxo intermediate to a secondary BA, is likely to be carried out by the 
products of one or both copies of baiA.98 The BA exporter is not yet known.4 However, two 
genes co-localized with baiN have been proposed, but not yet confirmed, to catalyze the final 
reaction and BA export, named BaiO and BaiP, respectively.99 Several additional candidate 
export proteins were identified through transcriptomic analysis of C. scindens ATCC 35704 after 
BA induction.91  
The 7α/β-dehydroxylation pathway results in a net two-electron reduction, meaning a net 
of one NAD+ is produced when a primary BA is used as an electron acceptor.74 The 7α/β-
dehydroxylation pathway is likely coupled to glucose metabolism, benefitting 7α/β-
dehydroxylating bacteria.91 The pathway may serve another function in producing secondary 
BAs, which are more hydrophobic and toxic to gut bacteria, to regulate the growth of competing 
gut microbiota.7,100 For example, DCA has a minimum inhibitory concentration tenfold lower 
than CA against many Lactobacillus and Bifidobacterium species.100 
Both primary and secondary BAs can be oxidized and epimerized at position C-3, C-7, 
and/or C-12 reversibly from the α-orientation to an oxo-intermediate and further to the β-
orientation by microbial HSDHs. Epimerized BAs have specific nomenclature: those containing 
3β-hydroxyl groups are iso-BAs, while 7β- and 12β-BAs are recommended to be denoted epi-
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BAs preceded by the hydroxyl position, according to Hofmann et al. (1992).101 However, 7β-
BAs are generally accepted to be named urso-BAs. For simplicity in this review, each prefix 
refers to only one of the β-hydroxyl positions: iso for 3β-, urso for 7β-, and epi for 12β-hydroxyl 
(Figure 1.3). Similarly to humans, mouse α-muricholic acid (3α,6β,7α-hydroxy) and β-
muricholic acid (3α,6β,7β-hydroxy) can be oxidized and epimerized to ω-muricholic acid 
(3α,6α,7β-hydroxy) via a 6-oxo-intermediate.102 Numerous microbiota are capable of 
oxidoreduction of BAs, including Eggerthella lenta103, C. scindens23,87, P. hiranonis23, C. 
hylemonae (see Chapter 2)23, Escherichia coli104, and Bacteroides fragilis105. 
 
Microbial Bile Acid Hydroxysteroid Dehydrogenases 
Microbial HSDHs catalyze the NAD(P)(H)-dependent oxidation and reduction of 
hydroxyl groups on BAs in the gut (Figure 1.3). Human interest in ursodeoxycholic acid 
(UDCA; 3α,7β-hydroxy) has a long and fascinating history. Asiatic black bear bile has been used 
in traditional Chinese medicine to treat disease for over 1000 years.106 In the early 1900s, a BA 
was isolated from polar bear bile and, later, the same BA was crystallized from the American 
black bear. This BA was named ursodeoxycholic acid after the Latin name ursus.107 UDCA 
makes up about 3–4% of the human BA pool but, in contrast to bear bile, is a secondary BA in 
humans.108,109 UDCA and other urso-BAs are produced by combined microbial 7α-HSDH and 
7β-HSDH activity in the human gut. Both microbial 7α- and 7β-HSDHs are typically NADP(H)-
dependent, and they frequently exhibit specificity for dihydroxy-BAs (e.g., CDCA and UDCA) 




Urso-BAs are more hydrophilic and less toxic both to microbiota and to the host than 
DCA or LCA.7 Indeed, DCA and LCA are involved in various diseases, such as cancers of the 
colon and liver.117–120 UDCA is currently approved for treatment of biliary disorders121, is being 
studied for both chemoprevention and chemotherapy of various cancers108,122, and is undergoing 
clinical trials as part of a combination chemotherapy for colorectal cancer (clinicaltrials.gov 
identifier: NCT00873275). Its mechanism of action likely involves the displacement of more 
toxic BAs in the BA pool and its choleretic effect of inducing secretion of BAs from the liver.123 
However, UDCA can be 7β-dehydroxylated by certain gut microbiota or isomerized back to 7α-
hydroxy prior to 7α-dehydroxylation.124,125 7β-Dehydroxylation of UDCA forms LCA, which 
may explain various toxicities associated with UDCA treatment.126 
The iso-BA pathway is catalyzed by the paired action of BA 3α- and BA 3β-HSDH. 
Generally, 3α-HSDHs utilize NAD(H), whereas 3β-HSDHs require NADP(H). They also usually 
prefer dihydroxy-BAs (derivatives of DCA or CDCA) over trihydroxy-BAs (derivatives of 
CA).17,18,112,127 BA 7α-dehydroxylating bacteria express a 3α-HSDH (BaiA) that differs greatly in 
substrate specificity as it reacts with CoA conjugates, not free BAs.87 Iso-BAs are present 
ranging from 0% to about 20% of the total BA pool in the gut.109 Iso-BAs have greatly decreased 
detergent nature and are thus less cytotoxic to gut microbiota, as well as the host, than DCA or 
LCA.6,17 3α/β-HSDHs may be of pharmaceutical use with respect to modulating the BA pool in 
favor of less toxic iso-BAs. Iso-BAs are intrinsically poor detergents and impede nutrient 
absorption. The liver epimerizes iso-BAs back to the 3α-hydroxyl form via a cytosolic 3β-




Compared to the iso- and urso-BA pathways, the least is known about the epi-BA 
pathway. While multiple 12α-HSDHs have been characterized18,23,103,116,129,130, BA 12β-HSDH 
was only studied in cell extracts until the discovery of the first gene encoding this activity in the 
current study (see Chapter 3).24,131,132 12-Oxolithocholic acid (12-oxoLCA; 3α-hydroxy,12-oxo), 
the product of 12α-HSDH oxidation of DCA, is often one of the most abundant oxo-BAs found 
in human feces, at concentrations of about one half DCA in some studies.81,133,134 Of note, levels 
of 12-oxoLCA were increased in rats with high incidence of tumors after being fed a diet high in 
corn oil or safflower oil.135 Measurement of epi-BAs is rare in the literature. EpiDCA (3α,12β-
hydroxy) was first identified in human feces by Eneroth et al. (1966).136 Recently, Franco et al. 
(2019) measured 3-oxo-12β-hydroxy-CDCA in humans, but little is known about concentrations 
of epiDCA or epiCA (3α,7α,12β-hydroxy) in feces.81 EpiDCA has also been identified in the 
biliary bile of angelfish; hence, 12β-HSDH activity is likely present within the microbiome of 
diverse vertebrates.41 
Many gut microbial 12α-HSDHs have NADP(H) specificity18,23,129,130, while others are 
NAD(H)-specific.116 12α-HSDHs generally have higher activity with free and dihydroxy-BAs 
than conjugated or trihydroxy-BAs.18,23,129 The only gut microbial BA 12β-HSDH characterized 
to date, from Clostridium paraputrificum ATCC 25780, has affinity for NADP(H) and greater 
activity with dihydroxy-BAs (see Chapter 3).24,132 Two additional 12β-HSDHs have been shown 
to react with 12-oxoLCA and epiDCA with NADP(H) as co-substrate, although their substrate 
specificities have not been fully characterized (see Chapter 3).24 Interestingly, 12β-HSDH 
activity recognizing side-chain cleaved steroids derived from BAs has been observed in multiple 
environmental microorganisms. This activity is displayed by Comamonas testosteroni TA441137 
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and Pseudomonas sp. strain Chol1138 as they convert a 12-oxo-intermediate into 7α,12β-
dihydroxy-androsta-1,4-diene-3,17-dione (12β-DHADD) in a cholic acid degradation pathway. 
Epi-BAs are understudied compared to urso- and iso-BAs. Thus, their toxicity relative to 
secondary BAs is untested, although epiDCA and 12-oxoLCA are less hydrophobic than DCA 
according to LC–MS (see Chapter 3).24 It is possible that isomerization of primary BAs to iso- or 
epi-BAs may impede formation of secondary BAs if they cannot be recognized by 7-
dehydroxylation pathway enzymes. This could be of therapeutic importance because secondary 
BAs DCA and LCA are not only toxic to gut microbiota, but also to the human host. 
Our knowledge of microbial HSDHs is largely limited to studies in humans and rodents. 
Notable recent studies extend to black bears in the search for HSDHs capable of forming UDCA 
139. There is a rich diversity of bile salts produced in vertebrates, such as pythocholic acid (16α-
hydroxycholic acid; 3α,12α,16α-trihydroxy-5β-cholan-24-oic acid) found in snakes, which is a 
16α-hydroxylated derivative of DCA.106,140 Avicholic acid (3α,7α,16α-trihydroxy-5β-cholan-24-
oic acid), found in birds, was identified in a drug screen as a TGR5 agonist.141 An NAD(P)-
dependent 16α-HSD was purified and characterized from rat kidney142; however, to our 
knowledge microbial 16α-HSDH activity has not yet been reported in snake or bird 
gastrointestinal content.  
 
Physiological Roles of Microbial Bile Acid Hydroxysteroid Dehydrogenases  
The physiological function of many microbial BA HSDHs remains unclear, although 
species and strain context seem likely to be important. In all cases, these redox reactions affect 
NAD(P)/NAD(P)H ratios and BA oxo-groups provide substrates for disposal of excess reducing 
equivalents or acquisition of hydrides in order to detoxify molecular oxygen close to the gut 
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mucosa. Oxidation and epimerization of BA α-hydroxyl groups to β-hydroxyl groups is also 
thought to function in detoxification by converting hydrophobic BAs to hydrophilic BAs that are 
less damaging to biological membranes.7,17 For example, isoDCA has a minimum inhibitory 
concentration of more than double that of DCA against various Gram-negative Bacteroides and 
Gram-positive species.17 In contrast, some HSDHs seem to favorably produce DCA from oxo-
derivatives, suggesting they may function to maintain high concentrations of DCA in the 
environment (see Chapter 2).23 
Culture-based studies indicate that the oxidation and epimerization of primary BAs 
affects the extent of BA 7α-dehydroxylation.143 There are several hypotheses that could explain 
this observation. First, there is currently a paucity of knowledge relating to substrate specificity 
of the BA transporter, BaiG, and whether oxo- and iso-BAs are efficiently imported. Our recent 
study indicates that 3,7-dioxoLCA is converted to CDCA and low levels of LCA by C. 
scindens143, albeit to lower levels than CDCA addition, suggesting import is occurring. Second, 
BA 7α-dehydroxylating bacteria appear to lack significant 3β-HSDH activity and, as a result, 
iso-primary BAs (3β-hydroxy) are not substrates for the BA 7α-dehydroxylation pathway.143 As 
noted above, the first oxidation step and the last reductive step in the BA 7α-dehydroxylation 
pathway are catalyzed by 3α-HSDH (BaiA). A 3β-hydroxyl group, thus, prevents key oxidation 
steps that lead to 7α-dehydration. Indeed, LCA was not observed in cultures of C. scindens VPI 
12708 induced with CA (resulting in upregulation of Bai enzymes) and then incubated with 
isoCDCA.143 While trace levels of isoLCA (<1%) have been reported in vitro during BA 
metabolism by C. scindens ATCC 35704144, this may be due to the minor promiscuity known for 
some bacterial HSDHs.96 Iso-secondary BAs (e.g., isoDCA and isoLCA) are second only to 
DCA and LCA in abundance in stool109 and are less toxic than LCA and DCA to intestinal 
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bacteria.17 Iso-BA epimerizing HSDHs also show substrate specificity preference toward 
secondary BAs.18 It is, therefore, hypothesized that isoLCA and isoDCA are generated from 
LCA and DCA, respectively, in the gastrointestinal tract. A third point is that enrichment of 
primary oxo- and β-hydroxy-BAs comes at the expense of primary BAs such as CA and CDCA, 
which induce expression of the bai operon.145 Indeed, culture-based studies indicate that C. 
scindens VPI 12708 is capable of converting 3,7-dioxocholanoic acid and 7-oxoLCA to LCA 
only if the cells were preincubated with CA.143 
Numerous gut bacteria, including Bacteroides spp. and E. coli, encode 7α-HSDH and 
produce 7-oxo-BAs that are released into the lumen.105,146,147 The formation of 7-oxo-primary 
BAs precludes 7α/β-dehydration by the bai pathway and must be reduced to proceed. It is, 
therefore, not surprising that BA 7α-dehydroxylating bacteria express NADP-dependent 7α-
HSDH.114 The BA 7α-HSDH is predicted to be important both in regulating the NAD(H)-
dependent BA 7α-dehydroxylating pathway intracellularly and in reducing 7-oxo-BAs imported 
from the environment. 
BA 7α-dehydroxylating bacteria also encode BA 12α-HSDH (see Chapter 2).23,148 The 
formation of 12-oxo-BAs reduces toxicity of BAs toward gut bacteria7, which is likely why a 
wide diversity of gut bacteria encode 12α-HSDH.18,23,143,149 However, substrate specificity of 
12α-HSDHs in 7α-dehydroxylating bacteria favors the reductive direction, converting 12-
oxoLCA to DCA (see Chapter 2).23 We, therefore, hypothesize that BA 7α-dehydroxylating 
bacteria express BA 12α-HSDH principally to “retoxify” 12-oxoLCA that was generated by 
bacteria less resistant to DCA. 
We recently demonstrated extensive oxidation of BAs by Eggerthella lenta.143 Indeed, E. 
lenta strains C592 and DSM 2243 encode 3α-, 3β-, 7α-, and 12α-HSDHs capable of converting 
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CA to trioxo-cholanoic acid under a nitrogen or carbon dioxide atmosphere. However, BA 
oxidation was inhibited under a hydrogen gas atmosphere (Figure 1.4). Genomic analysis 
revealed genes encoding energy conserving hydrogenase (echABCDEF) and Rnf complex 
(rnfABCDEG), as well as a complete Wood–Ljungdahl pathway, suggesting that E. lenta is an 
acetogen.143,150 The classical acetogen fixes CO2 or CO in the presence of H2
151; however, 
acetogens are known to utilize a wide range of electron donors. Under this scheme, E. lenta 
HSDH enzymes are hypothesized to generate NADH by oxidizing BAs, which provides reducing 
equivalents to fix CO2. In the presence of H2, E. lenta hydrogenases reduce NAD
+ via molecular 
hydrogen, and BA oxidation is prevented. Additional studies will be needed to confirm this 
hypothesis linking BA metabolism and H2 partial pressure in a novel acetogen. 
The role of microbial BA HSDHs in host physiology is also relatively unclear. While the 
involvement of oxo- and β-BAs in host signaling pathways has not been fully explored, there is 
evidence that products in the iso-BA pathway activate various host receptors. For example, along 
with LCA, 3-oxoLCA has been shown to activate the BA receptors FXR, VDR, and PXR.8,56 In 
contrast, 12-oxoLCA, 7-oxoLCA, and UDCA did not efficiently activate either FXR or VDR.8,50 
Recently, 3-oxoLCA and a planar iso-BA, isoalloLCA, were shown to be regulators of 
interleukin (IL)-17a expressing T helper cells (TH17) and regulatory T cells (Treg) in mice.
152 
Determining the full spectrum of both primary and secondary oxo- and β-derivatives against BA-








Host Glucocorticoid Synthesis 
Glucocorticoids are involved in diverse essential physiological processes throughout the 
body.153 Cortisol and corticosterone are the primary C21 glucocorticoids present in humans. 
However, cortisol concentrations are about 10 times greater than corticosterone.154 Cortisol plays 
a major role in the stress response and maintenance of blood glucose concentration, as well as in 
inhibition of protein synthesis in muscle, of lipogenesis in fat cells, and of the immune system.155 
Cortisol is synthesized in the adrenal gland from cholesterol and involves the action of 
both cytochrome P450 enzymes and hydroxysteroid dehydrogenases, much like BA biosynthesis 
(Figure 1.2). The first step is catalyzed by CYP11A1, which side-chain cleaves cholesterol and 
results in pregnenolone.9 This is the rate-limiting step and precursor to many other steroid 
hormones, including progesterone, corticosterone, aldosterone, testosterone, and estradiol.156 
17α-Hydroxyprogesterone is then produced by CYP17A1 (17-hydroxylase/17,20 lyase) and 
HSD3B2 (3β-HSD/Δ5/4-isomerase type 2). CYP21A2 converts 17α-hydroxyprogesterone to 11-
deoxycortisol. The last reaction results in the formation of cortisol through the action of 
CYP11B1.9,10 Cortisol circulates in serum at concentrations between 100 and 600 nM.9 Cortisol 
then acts in peripheral tissues by binding to the nuclear glucocorticoid receptor, resulting in 
regulation of numerous genes, including those involved in inflammation, immune function, and 
gluconeogenesis. Cortisol can also bind to mineralocorticoid receptor, which regulates 
electrolyte balance.157,158 Cortisol concentrations are tightly regulated by 11β-HSD isoforms 1 
and 2. 11β-HSD1/2 interconvert cortisol (C-11 hydroxyl) to its inactive form, cortisone (C-11 
ketone), which cannot bind the glucocorticoid receptor or mineralocorticoid receptor. 11β-HSD1 
functions primarily as a reductase to activate cortisol in the liver, muscle, and bone. In contrast, 
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11β-HSD2 acts as a dehydrogenase, inactivating cortisol to cortisone in the kidney, colon, and 
salivary glands.9 
Human tissues metabolize cortisol in various ways, leading to its excretion primarily in 
urine. However, low levels of cortisol and its derivatives are secreted in bile and enter the gut.159 
Cortisol undergoes 5α- or 5β-reduction in the liver, while cortisone is only 5β-reduced.160 After 
3α-reduction, 5α/β-tetrahydrocortisol and tetrahydrocortisone are produced, which are the main 
metabolites of cortisol and cortisone in urine, respectively.9 Cortisol can also be metabolized by 
20α- and 20β-HSDs, yielding either 20α- or 20β-dihydrocortisol.161 Carbonyl reductase-1 
(CBR1) has 20β-HSD activity producing 20β-dihydrocortisol, while a host 20α-HSD has been 
observed with specificity for progesterone, but not cortisol.9,162 20α/β-Reduction of 
tetrahydrocortisol and tetrahydrocortisone results in α/β-cortols or α/β-cortolones.163 
 
Host Androgen Synthesis 
Androgens are important for metabolic homeostasis and reproductive function in men, as 
well as women. Androgens are C19 steroids that are synthesized in the Leydig cells of the testes 
or adrenal glands.164 The primary active androgens in circulation are testosterone and 
dihydrotestosterone, although, in the adrenal glands, the major products are the androgen 
precursors dehydroepiandrosterone (and its sulfate ester), androstenedione, and 11β-
hydroxyandrostenedione (11β-OHAD).165 
Androgen biosynthesis in the adrenal cortex begins with side-chain cleavage of 
cholesterol to pregnenolone by CYP11A1. Then, CYP17A1 hydroxylase and 17,20-lyase 
activities produce dehydroepiandrosterone (DHEA). HSD3B2 (3β-HSD/Δ5/4-isomerase type 2) 
converts DHEA to androstenedione. Alternatively, AKR1C3 (17β-HSD) can produce 
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androstenediol from DHEA, and HSD3B2 then yields testosterone. Androstenedione can be 
further converted to 11β-OHAD by adrenal-specific CYP11B1 (11β-hydroxylase).166 
Even though 11β-OHAD makes up a large proportion of adrenal steroidogenesis, it has 
historically largely been ignored (except in fishes) due to its low androgenic activity.167 Storbeck 
et al. (2013) reported that 11β-OHAD leads to the formation of 11-ketotestosterone (11KT)168, a 
potent 11-oxygenated C19 androgen involved in castration-resistant prostate cancer
169,170 and 
polycystic ovary syndrome.170,171 This is important because, although 11β-OHAD is primarily 
produced in the adrenal glands by CYP11B1, peripheral side-chain cleavage of cortisol to 11β-
OHAD also occurs.172 Peripheral 11β-OHAD is not formed by CYP17A1.173 Thus, the enzyme 
responsible for cortisol-derived 11β-OHAD may be an unknown host enzyme and/or of 
microbial origin. Intriguingly, 11β-OHAD has been shown to be produced from side-chain 
cleavage of cortisol by human gut microbiota.14,174–176 
Androgens signal throughout the body by binding to androgen receptor (AR) expressed in 
various cell types, including B cells, T cells, neutrophils, and macrophages177, as well as colon 
cancer cell lines178. Nuclear AR is a ligand-dependent transcription factor that, when activated by 
an androgen, regulates expression of cell growth, differentiation, and even carcinogenesis in 
some cases.179 Intestinal cells express both nuclear AR and membrane AR.178–180 Importantly, the 
gut microbiome has evolved enzymes that catalyze many of the same reactions described for host 
glucocorticoid and androgen metabolism. This indicates that the host endocrine system has 






Microbial Cortisol Metabolism 
The earliest evidence of microbial biotransformation of cortisol was observed when rectal 
infusion of cortisol in ulcerative colitis patients led to an increase in urinary excretion of 17-
ketosteroids.181 This increase in urinary steroids was not detected when cortisol treatment 
coincided with oral neomycin182, suggesting microbial biotransformation of cortisol. Thereafter, 
side-chain cleavage of cortisol or steroid-17,20-desmolase activity was observed when human 
fecal samples produced C19 steroids after incubation with cortisol.
176 
In 1984, a bacterium was isolated from human fecal material exhibiting steroid-17,20-
desmolase activity producing 11β-OHAD from cortisol (Figure 1.2).174,175 This organism was 
named Clostridium scindens, formerly Clostridium strain 19, which also has BA 7α-
dehydroxylation activity.4 Additional organisms with steroid-17,20-desmolase activity were then 
isolated: Butyricicoccus desmolans ATCC 43058 (formerly Eubacterium desmolans), C. 
cadaveris AGR2141183, and the urinary microbe Propionimicrobium lymphophilum ACS-093-V-
SCH5.184,185 The operon encoding this activity (desABCD) has since been identified by 
performing RNA-Seq after inducing C. scindens ATCC 35704 with cortisol.14 The inducible 
desABCD operon consists of steroid-17,20-desmolase (DesAB) encoded by desAB, a 20α-HSDH 
(DesC), and a putative transporter (DesD) (Figure 1.5).14,186 C. scindens ATCC 35704 DesAB 
was determined to be a heterotetramer and recognized both cortisol and 11-deoxycortisol, which 
only differs from cortisol in the absence of an 11β-hydroxyl group.186 
C-20 reduced metabolites of cortisol have been observed in human urine, likely 
attributable to host enzymes that produce 20α- or 20β-dihydrocortisol and their derivatives 163,187. 
However, Winter et al. (1982) showed that gut microbiota can reduce cortisol to 20β-
dihydrocortisol, exhibiting 20β-HSDH (DesE) activity.188 B. desmolans and C cadaveris express 
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20β-HSDH 183, along with Bifidobacterium adolescentis.188 Additionally, the gut microbe 
Clostridium scindens ATCC 35704 can convert cortisol to 20α-dihydrocortisol.174 Thus, gut 
microbiota encode 20α- and 20β-HSDHs that biotransform cortisol (Figure 1.5). 
Human gut microbiota are also capable of 21-dehydroxylation of corticosteroids. 21-
Dehydroxylase activity was first detected in Eggerthella lenta (formerly Eubacterium 
lentum).189,190 E. lenta 21-dehydroxylase has substrate specificity for 11-deoxycorticosterone, 
deoxycortisol, dehydrocorticosterone, and corticosterone.191,192 The enzyme requires NAD(P)H 
and flavin or only reduced flavin mononucleotide for activity.192 Although this enzyme seems to 
be specific for corticosterone, 21-dehydroxylation of cortisol to 21-deoxycortisol also occurs.176 
Interestingly, 21-deoxycortisol is a substrate for 11β-HSD2193 while the 21-dehydroxylation 
product of corticosterone is a potent inhibitor.194 
 
Microbial Cortisol Hydroxysteroid Dehydrogenases 
Host hydroxysteroid dehydrogenases have been established as important for biosynthesis 
and modulation of steroid hormones such as androgens, estrogens, and glucocorticoids for 
years.5 Since the discovery of steroid hormone-converting HSDHs in the human gut microbiome, 
gut bacteria have been proposed to play an important role beyond that of the host in modification 
of steroids.14 Within the steroid-17,20-desmolase pathway, two HSDHs have been identified that 
convert cortisol to 20α- or 20β-dihydrocortisol and may act as enzymatic switches to control 
formation of 11β-OHAD (Figure 1.5). 
20β-Dihydrocortisol is excreted in urine at rates comparable to that of free cortisol in 
healthy individuals.161,187 Urinary excretion of 20α-dihydrocortisol occurs at rates of about 1.5 
times the excretion of cortisol.161,187 Although the physiologic role of 20α- and 20β-
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dihydrocortisol is not extensively studied, they are elevated in patients with Cushing’s 
syndrome187, as well as in patients with hypertension.195 
One of the first organisms studied expressing 20β-HSDH activity was the soil microbe 
Streptomyces hydrogenans.196 This enzyme reacted with not only cortisol, but also cortisone, 
cortexolone (lacks C-11 oxygen group), and their 21-aldehydes.196 More recently, the genes 
encoding 20β-HSDH in B. desmolans and C. cadaveris, organisms that were previously shown 
to have this activity in culture, have been identified.183,184 The gene is denoted desE due to its 
involvement in the DesAB pathway and because it forms an operon with the desAB genes.14,184 
Both B. desmolans and C. cadaveris are capable of cortisol side-chain cleavage, as well as 20β-
oxidoreduction.183,184 20β-HSDH has been characterized in detail from B. desmolans ATCC 
43058, which exhibits specificity for cortisol as substrate and is NAD(H)-dependent.184 
Bifidobacterium scardovii ATCC BAA-773 and the urinary tract microbe Propionimicrobium 
lymphophilum ACS-093-V-SCH5 also express 20β-HSDH according to HPLC184, and P. 
lymphophilum has also been shown to encode desAB.184,185 Additionally, the SDR family 
NAD(H)-dependent 20β-HSDH product of desE in B. adolescentis strain L2-32 has been 
characterized in this study. It is specific for cortisol and was crystallized in both the apo-form 
without any binding and the binary form with NADH bound at 2.2 and 2.0 Å, respectively (see 
Chapter 4).15 
Thus far, 20α-HSDH activity seems to be significantly less widespread than 20β-HSDH, 
with only one organism shown to exhibit the activity.14,197 Reduction of cortisol at the C-20 
position to 20α-dihydrocortisol was observed in pure cultures of C. scindens along with steroid-
17,20-desmolase activity.175 20α-HSDH from C. scindens ATCC 35704 was initially 
characterized from cell extracts and shown to be NAD(H)-dependent.198 The gene for 20α-
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HSDH was identified in 2013 after RNA-Seq analysis revealed a cortisol-inducible operon 
including desAB and desC, encoding steroid-17,20-desmolase and 20α-HSDH, respectively.14 In 
this study, the C. scindens ATCC 35704 20α-HSDH was crystallized for further characterization 
of the enzymatic mechanism. Hybrid quantum mechanical molecular modeling simulations 
revealed a reaction mechanism involving a multistep proton relay, which was validated by site-
directed mutagenesis experiments of active site and substrate binding residues (see Chapter 5).16 
An amino-acid homology search based on C. scindens ATCC 35704 20α-HSDH within the 
National Center for Biotechnology Information (NCBI) database uncovered two additional 
organisms, Denitratisoma oestradiolicum DSM 16959 and Intestinibacillus sp. Marseille-P4005, 
which may express 20α-HSDH, although activity has not yet been confirmed (see Chapter 3).24 
Microbial 20α- and 20β-HSDH may be important regulators of the steroid-17,20-
desmolase/DesAB pathway. By competing for cortisol as substrate with DesAB, they would 
decrease the potential for 11β-OHAD formation. Microbial steroid-17,20-desmolase activity may 
be one of the important missing enzymes contributing to peripheral 11β-OHAD production in the 
body.199 Recent work showed that Clostridium scindens ATCC 35704 and the urinary microbe 
Propionimicrobium lymphophilum ACS-093-V-SCH5 can side-chain cleave both cortisol and 
glucocorticoid drugs185, suggesting microbial production of 11β-OHAD may occur in both the 
gut and urinary tract. As mentioned above, 11β-OHAD can be further converted to highly 
androgenic 11KT.168 This has compelling implications for androgen-dependent diseases, such as 
castration-resistant prostate cancer, or diseases defined by androgen excess, such as polycystic 
ovary syndrome.170 Further studies are necessary to assess the efficacy of utilizing 20α- and/or 





Overall, both host and microbial HSDHs play pivotal roles in BA and glucocorticoid 
metabolism. Research on the importance of HSDH-derived BAs on host physiology is in its 
infancy. However, the immense diversity of these BA metabolites, due to combinations of 
HSDH activity, means that the gut harbors a multitude of potential candidates for host receptor 
signaling. Gut microbial cortisol HSDHs are likely important regulators of steroid-17,20-
desmolase activity, although additional research is needed to ascertain the physiological 
significance of 20α- and 20β-HSDH products. New microbial HSDHs are continually being 
discovered and characterized, which will allow mechanistic study of their impacts in disease 
models. 
Microbial HSDHs may have potential as therapeutic modulators in diseases such as 
colorectal cancer, liver cancer, castration-resistant prostate cancer, and polycystic ovary 
syndrome. However, to work toward therapeutics, we must first connect HSDH function to host 
phenotypes through mechanistic experiments, such as gnotobiotic animal studies.200,201 Such 
avenues include developing genetic knockouts of HSDHs in microbes naturally encoding them 
or, when genetic systems are unavailable, engineering genetically tractable microbes to encode 
HSDHs. Furthermore, crystal structures of microbial HSDHs will aid in any necessary 
mutagenesis to rationally design substrate specificity for these enzymes. Integrating functional 
studies, genetic manipulation, structural biology, and gnotobiotic animal experiments will be 
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Figure 1.1. Steroid structure. Steroids have a cyclopentanoperhydrophenanthrene ring 
structure. Cholesterol, the precursor to human steroid hormones, contains 27 carbons, while the 
major classes of steroid hormones contain the following: C24 bile acids, C19 androgens, C18 




Figure 1.2. Synthesis and microbial metabolism of bile acids and cortisol. (1) The bile acids 
(BAs) cholic acid (CA) and chenodeoxycholic acid (CDCA) are synthesized and conjugated to 
glycine (Gly) or taurine (Tau) in the liver. (2) They are then stored in the gallbladder until they 
are released in response to a meal. (3) Microbial deconjugation of amino acids, catalyzed by bile 
salt hydrolase (BSH), primarily occurs in the small intestine. (4) BAs are taken up in the terminal 
ileum and undergo enterohepatic circulation back to the liver indicated by green arrows. (5) 
About 5% of BAs are not recycled and proceed to the colon. (6) Gut microbiota residing in the 
colon can 7α-dehydroxylate CA or CDCA to secondary BAs in a pathway encoded by the BA-
inducible (bai) operon. Microbial hydroxysteroid dehydrogenases (HSDHs) interconvert BA  
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Figure 1.2 (cont.) 
hydroxyl groups between the α- and β-conformations through an oxo-intermediate. (A) Cortisol 
is synthesized in the adrenal glands. (B) Cortisol and its derivatives are principally excreted in 
urine; however, low levels are secreted in bile and enter the gut. (C) In the gut, cortisol can be 
side-chain cleaved by microbiota encoding steroid-17,20-desmolase (DesAB) or reduced to 20α- 




Figure 1.3. Microbial bile acid hydroxysteroid dehydrogenase metabolism. After 
deconjugation by bile salt hydrolase, the primary bile acids (BAs) chenodeoxycholic acid 
(CDCA) and cholic acid (CA) can be 7α-dehydroxylated or reversibly biotransformed by 
NAD(P)(H)-dependent hydroxysteroid dehydrogenases (HSDHs). CDCA is converted to the 
oxo-intermediate, 7-oxolithocholic acid (7-oxoLCA), and further to ursoDCA (UDCA) in the 
urso-BA pathway catalyzed by 7α- and 7β-HSDH. The secondary BAs lithocholic acid (LCA) 
and deoxycholic acid (DCA) are produced through the multi-step 7α-dehydroxylation of CDCA 
and CA, respectively. 3α-HSDH biotransforms DCA into 3-oxoDCA, and 3β-HSDH converts 3-
oxoDCA to isoDCA in the iso-BA pathway. DCA is converted to 12-oxoLCA by 12α-HSDH 
and from 12-oxoLCA to epiDCA by 12β-HSDH. HSDHs can recognize other BAs with the 




Figure 1.4. Proposed model for the role of Eggerthella lenta hydroxysteroid 
dehydrogenases: bile acid oxidation provides reductant for the Wood–Ljungdahl Pathway 
(WLP) of acetogenesis. This model is based on biochemical and genomic data demonstrating 
that E. lenta strains contain complete WLP genes, and that bile acid oxidation is inhibited by a 




Figure 1.5. Microbial cortisol hydroxysteroid dehydrogenase metabolism. Cortisol can be 
reversibly biotransformed by 20β-hydroxysteroid dehydrogenase (20β-HSDH; DesE) to 20β-
dihydrocortisol, or by 20α-HSDH (DesC) to 20α-dihydrocortisol. Steroid-17,20-desmolase 
(DesAB) converts cortisol to 11β-hydroxyandrostenedione (11β-OHAD). 21-Dehydroxylase 
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METABOLISM OF OXO-BILE ACIDS AND CHARACTERIZATION OF 
RECOMBINANT 12α-HYDROXYSTEROID DEHYDROGENASES FROM BILE ACID 
7α-DEHYDROXYLATING HUMAN GUT BACTERIA1 
 
ABSTRACT 
Bile acids are important cholesterol-derived nutrient signaling hormones, synthesized in 
the liver, that act as detergents to solubilize dietary lipids. Bile acid 7α-dehydroxylating gut 
bacteria generate the toxic bile acids deoxycholic acid and lithocholic acid from host bile acids. 
The ability of these bacteria to remove the 7-hydroxyl group is partially dependent on 7α-
hydroxysteroid dehydrogenase (HSDH) activity, which reduces 7-oxo-bile acids generated by 
other gut bacteria. 3α-HSDH has an important enzymatic activity in the bile acid 7α-
dehydroxylation pathway. 12α-HSDH activity has been reported for the low-activity bile acid 
7α-dehydroxylating bacterium Clostridium leptum; however, this activity has not been reported 
for high-activity bile acid 7α-dehydroxylating bacteria, such as Clostridium scindens, 
Clostridium hylemonae, and Peptacetobacter hiranonis. Here, we demonstrate that these strains 
express bile acid 12α-HSDH. The recombinant enzymes were characterized from each species 
 
1 Adapted with permission from Doden H, Sallam LA, Devendran S, Ly L, Doden G, Daniel SL, Alves JMP, Ridlon 
JM. Metabolism of oxo-bile acids and characterization of recombinant 12α-hydroxysteroid dehydrogenases from 
bile acid 7α-dehydroxylating human gut bacteria. Appl Environ Microbiol. 2018;84:e00235-18. © 2018 American 
Society for Microbiology. All rights reserved. 
2 H.D. and L.A.S. contributed equally to this work. 
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and shown to preferentially reduce 12-oxolithocholic acid to deoxycholic acid, with low activity 
against 12-oxochenodeoxycholic acid and reduced activity when bile acids were conjugated to 
taurine or glycine. Phylogenetic analysis suggests that 12α-HSDH is widespread among 
Firmicutes, Actinobacteria in the Coriobacteriaceae family, and human gut Archaea. 
 
IMPORTANCE 
12α-HSDH activity has been established in the medically important bile acid 7α-
dehydroxylating bacteria C. scindens, P. hiranonis, and C. hylemonae. Experiments with 
recombinant 12α-HSDHs from these strains are consistent with culture-based experiments that 
show a robust preference for 12-oxolithocholic acid over 12-oxochenodeoxycholic acid. 
Phylogenetic analysis identified novel members of the gut microbiome encoding 12α-HSDH. 
Future reengineering of 12α-HSDH enzymes to preferentially oxidize cholic acid may provide a 
means to industrially produce the therapeutic bile acid ursodeoxycholic acid. In addition, a cholic 
acid-specific 12α-HSDH expressed in the gut may be useful for the reduction in deoxycholic 
acid concentration, a bile acid implicated in cancers of the gastrointestinal (GI) tract. 
 
INTRODUCTION 
 Bile acids are synthesized from cholesterol in the liver, conjugated to the amino acid 
taurine or glycine, and secreted and stored in the gallbladder during the interdigestive period. 
During a meal, the gallbladder is hormonally stimulated to contract, releasing bile into the 
duodenum. In the small bowel, conjugated bile acids measure in the low-millimolar range and 
function to solubilize cholesterol, dietary lipids, and lipid-soluble vitamins.1 Conjugated bile 
acids are also directly antimicrobial, reducing the microbial load at the site of host nutrient 
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absorption. In the terminal ileum, ~95% of bile acids are returned to the liver after high-affinity 
transport by apical bile salt transporters into enterocytes and entrance into portal circulation after 
basolateral transport.2 However, roughly 400 to 800 mg per day of bile salts enters the large 
intestine, where anaerobic bacteria perform several important biotransformations. 
The “gateway reaction” is hydrolysis of the amino acid conjugate by bacterial bile salt 
hydrolases (BSH) which are found in all major bacterial phyla and in the two main species of 
human gut archaea.3 Gut microbes are also capable of removing the 7α-hydroxyl group from host 
cholic acid (CA; 5β-cholanic acid-3α,7α,12α-triol), forming deoxycholic acid (DCA; 5β-cholanic 
acid-3α,12α-diol), and from chenodeoxycholic acid (CDCA; 5β-cholanic acid-3α,7α-diol), 
forming lithocholic acid (LCA; 5β-cholanic acid-3α-ol).4,5 DCA and LCA are the main 
components of the bile acid profile of stool in healthy humans6 and have been associated 
causally with diseases of the gastrointestinal (GI) tract, including cancers of the colon7, liver8, 
and esophagus9, as well as cholesterol gallstone disease in a subset of patients10. 7α-Hydroxy bile 
acids, such as ursodeoxycholic acid (UDCA; 5β-cholanic acid-3α,7α-diol), are important in the 
therapy of the aforementioned GI diseases and function mainly to dilute and counteract the 
influence of microbe-derived DCA and LCA.11–13 UDCA synthesis from CA requires enzymatic 
oxidation of the 12α-hydroxyl group, followed by Wolff-Kishner reduction to remove the C-12 
carbonyl group.14 Therefore, understanding the role of bacterial 12α-dehydrogenation in 
microbial bile acid biotransformation and identifying genes encoding 12α-hydroxysteroid 
dehydrogenases (HSDH) in gut microbes are important in understanding host disease processes 




Strains of bile acid 7α-dehydroxylating bacteria (BA7) that have been isolated to date 
from human feces, or inferred by sequence, are within Clostridium clusters XIVa, IV, and XI.5 
Those strains in Clostridium cluster XIVa that express high BA7 activity and encode a 
polycistronic bile acid-inducible (bai) operon include strains of C. scindens, Peptacetobacter 
hiranonis (formerly Clostridium hiranonis), and C. hylemonae.5 HSDH enzymes play an 
important role in secondary bile acid formation by these gut bacterial species. Bile acids are 
pumped inside the cell by a proton-dependent transport protein (BaiG)15, ligated to coenzyme A 
(CoA) by the ATP-dependent CoA-ligase (BaiB)16 or ATP-independent CoA-transferases (BaiF 
and BaiK)17,18. Diverse gut microbiota express 7α-HSDHs, which convert host primary bile acids 
to 7-oxo-bile acids.4 An NADP-dependent 7α-HSDH gene has been identified and characterized 
in C. scindens VPI 1270819 and is inferred by sequence similarity in C. scindens ATCC 35704, 
C. hylemonae DSM 15053, and P. hiranonis DSM 132755. Additionally, after CoA ligation, two 
oxidation steps precede the rate-limiting 7α-dehydration step (BaiE)20,21, one of which, the baiA 
gene, encodes a 3α-HSDH22,23. The other, encoded by the baiCD and baiH genes, introduces a 
C-4=C-5 bond in 7α-hydroxyl and 7β-hydroxyl bile acid substrates, respectively.24 After 7α/β-
dehydration, a series of reductions (catalyzed by the baiN gene product) occur to convert 5β-
chol-4,6-dienoic acid-12α-ol-3-one to DCA or LCA.24,25 
Roughly half of the host primary bile acids synthesized in the liver contain a 12α-
hydroxyl group.1 Members of the gastrointestinal microbiota have evolved 12α-HSDHs capable 
of oxidizing and epimerizing the 12α-hydroxyl group from host CA and its microbial 
metabolites, including DCA.26 C. leptum, reported to express low BA7 activity27, has also been 
reported to express a 12α-HSDH28; however, the gene(s) encoding 12α-HSDH have not been 
identified. A previous bioinformatics analysis of bacterial HSDH enzymes identified a gene 
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encoding a putative 12α-HSDH (accession no. WP_006441568.1) in C. hylemonae29 based on a 
single deduced amino acid sequence from the only known gene encoding 12α-HSDH identified 
from Clostridium sp. strain ATCC 29733.30,31 This phylogeny also predicted that BA7 strains C. 
scindens ATCC 35704, C. hylemonae DSM 15053, and P. hiranonis DSM 13275 harbor 12α-
HSDHs; however, the genes predicted to encode this activity have yet to be reported. A major 
clue to the expression of 12α-HSDH in P. hiranonis (formerly strain HD-17) came from a study 
where resting cells of P. hiranonis produced significant levels of 12-oxoLCA when incubated 
aerobically with CA.32 We therefore sought to evaluate the potential of C. scindens ATCC 
35704, C. hylemonae DSM 15053, and P. hiranonis DSM 13275 to metabolize oxo-bile acids, 
and specifically to detect 12α-HSDH activity. Further, we sought to characterize purified 
recombinant 12α-HSDHs from these medically important gut microbes. 
 
RESULTS 
Transformation of 12-oxoLCA and other oxo-bile acids by C. scindens ATCC 35704, C. 
hylemonae DSM 15053, and P. hiranonis DSM 13275 in BHI cultures 
Studies to date have yet to examine the metabolism of 12-oxo-bile acid substrates in 
anaerobic cultures by BA7 strains. We therefore limited our screening of substrates to oxo-bile 
acids possessing a 12α-hydroxyl or 12-oxo group (i.e., CA derivatives) (Table 2.1). 12-oxoLCA 
was converted quantitatively to DCA in 24-h cultures of each strain (Table 2.1 and Figure 2.1). 
In contrast, all three converted 12-oxoCDCA to 7-oxoDCA rather than to DCA. We did not 
detect the formation of 12-oxoLCA when CA or its C-3– or C-7–oxo derivative was the 




All three strains reduced 3-oxoCA to CA, but only P. hiranonis DSM 13275 generated DCA 
(Table 2.1) 
7-oxoDCA was converted to DCA by C. scindens ATCC 35704 and P. hiranonis DSM 
13275 but not by C. hylemonae DSM 15053. DCA and 3-oxoDCA were not metabolized by 
these strains. Dioxo- and trioxo-bile acids were also evaluated for metabolism by BA7 bacteria. 
When 3,12-dioxoLCA was the substrate, all three strains reduced the 12-oxo-group and formed 
3-oxoDCA. Substrates 7,12-dioxoLCA and 3,7,12- trioxoLCA were converted to a mixture of 
CA, DCA, and 3-oxoDCA. Collectively, these results indicated that C. scindens ATCC 35704, 
C. hylemonae DSM 15053, and P. hiranonis DSM 13275 reduce oxo-bile acids, and each strain 
possesses 12α-HSDH activity. 
 
Cloning, overexpression, purification, and characterization of 12α-HSDH from C. scindens 
ATCC 35704, C. hylemonae DSM 15053, and P. hiranonis DSM 13275 
Recently, genes encoding 12α-HSDH were reported in Eggerthella lenta DSM 2243 
(Elen_2515)33 and Eggerthella CAG:298 (accession no. CDD59475)34. We aligned the amino 
acid sequences of the 12α-HSDHs from Eggerthella strains as well as 12α-HSDH reported in 
Clostridium sp. ATCC 29733 (accession no. ERJ00208.1), with putative 12α-HSDH from C. 
hylemonae DSM 15053 (CLOHYLEM_04236), C. scindens ATCC 35704 (CLOSCI_02455), 
and P. hiranonis DSM 13275 (CLOHIR_01081). Multiplesequence alignment is depicted in 
Figure 2.2. Each protein in the alignment is a member of the 3-ketoacyl-(acyl-carrier-protein) 
short-chain dehydrogenase/reductase (SDR) family, defined by a conserved N-terminal 
Rossmann-fold responsible for NAD(P)-binding (GGGX5GXG) and catalytic triad (SYK) 
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(Figure 2.2). The genomic context of the genes encoding putative 12α-HSDH in each 7α-
dehydroxylating bacterium is shown in Figure 2.3. 
To determine whether the genes CLOHYLEM_04236 (259 amino acids), 
CLOSCI_02455 (266 amino acids), and CLOHIR_01081 (266 amino acids) encode novel 12α-
HSDHs, we amplified the genes by PCR and cloned each gene into pET51(b)+ for 
overexpression in Escherichia coli. Each recombinant protein was overexpressed as an N-
terminal streptavidin fusion protein, which was purified by affinity chromatography using Strep-
Tactin resin and resolved by SDS-PAGE analysis (Figure 2.3). Recombinant 
CLOHYLEM_04236 (rCHYL) had a theoretical subunit mass of 28.0 kDa and yielded an 
observed subunit mass of 28.5 ± 0.3 kDa on SDS-PAGE (three independent protein gels). 
rCLOSCI_02455 (rCSCI) from C. scindens ATCC 35704 had a deduced subunit molecular mass 
of 28.2 kDa, with an observed subunit mass of 27.3 ± 0.9 kDa, and rCLOHIR_01081 (rCHIR) 
(theoretical subunit mass, 28.5 kDa) yielded an observed subunit mass of 28.5 ± 0.1 kDa. 
 
TLC and mass spectrometry of enzyme reaction products 
Next, we confirmed functional 12α-HSDH activity of purified rCSCI, rCHYL, and 
rCHIR in the presence of 12-oxoLCA substrate and reduced or oxidized pyridine nucleotide 
cofactors (Figure 2.4). DCA standard yielded a major mass ion of 391.2858 m/z in negative-ion 
mode, consistent with the molecular mass of DCA at 392.57 atomic mass units (amu). rCSCI 
was NADPH dependent, according to thin-layer chromatography (TLC) separation of bile acid 
metabolites. The single reaction product was eluted from TLC silica and yielded a major mass 
ion of 391.2856 m/z. Similarly, rCHYL showed specificity for NADPH, with no significant 
formation of product with NADH after 24 h, as determined by TLC. A product, whose migration 
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was identical to DCA, yielded a major mass ion in negative mode of 391.2856 m/z. When 
incubated with 12-oxoLCA in the presence of NADPH (but not NADH), purified rCHIR yielded 
a single product on TLC that comigrated with DCA, with a major mass ion of 391.2858 m/z. 
 
pH optimization of r12α-HSDHs 
In order to optimize the enzyme-catalyzed C-12 oxidoreduction, we monitored the 
conversion of pyridine nucleotides at 340 nm in various buffer systems adjusted to pH 
increments from pH 4.5 to 10.0 (Figure 2.5). The optimum pH for rCSCI in the oxidative 
direction with DCA as the substrate and NADP+ as the cosubstrate was 7.5, and the optimum in 
the reductive direction with 12-oxoLCA as the substrate and NADPH as the cosubstrate was 7.0. 
In the oxidative direction, the optimum pH for rCHYL with NADP+ as cofactor and DCA as the 
substrate was 8.0, while the optimum pH with NADPH and 12-oxoLCA was 7.0. The optimum 
pH for rCHIR in the oxidative direction was found to be 7.0 and was between 6.5 and 7.0 in the 
reductive direction. 
 
Kinetic analysis and substrate specificity of r12α-HSDHs 
Kinetic analysis was performed at the optimum pH for each enzyme and the particular 
reaction direction. In the oxidative direction, rCHYL, rCSCI, and rCHIR displayed comparable 
Km values for DCA at ~150 µM, a concentration approximating levels of DCA in fecal water 
obtained from Western individuals (Table 2.2; see also Supplementary Figure 2.1 in the 
supplemental material).35 The Km values for NADP+ were on the same order as those for DCA. 
The Km value for 12-oxoLCA in the reductive direction was an order of magnitude lower for 
rCHYL and ~4.5- and 5-fold lower for rCSCI and rCHIR, respectively (Table 2.2). Vmax and kcat 
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values were between 1.6- and 2.9-fold higher in the oxidative than the reductive direction. 
However, catalytic efficiencies (Km/kcat) were 2.8- to 3.5-fold greater in the reductive than 
oxidative direction. 
In the reductive direction, recombinant NADPH-dependent 12α-HSDH had between 9.55 
and 3.65% relative activity toward 12-oxoCDCA compared to 12-oxoLCA, suggesting hindrance 
by the 7α-hydroxyl group (Table 2.3). NADH was not a cosubstrate, as determined by 
spectrophotometric assay and overnight reaction mixtures separated by TLC (Figure 2.3). In the 
oxidative direction, the relative activity toward CA was between 54.44 and 82.32% that of the 
activity toward DCA. rCSCI had 16.5-fold lower activity toward taurine-conjugated DCA 
(TDCA) than did DCA, while rCHIR and rCHYL showed 2.4-fold and 2.2-fold lower activity 
toward TDCA than DCA, respectively. Glycine conjugation resulted in a relative activity similar 
to taurine conjugation with rCSCI, but rCHYL and rCHIR showed 4.1-fold and 3.9-fold 
decreases in activity relative to DCA, respectively (Table 2.3). 
 
Phylogenetic analysis of bacterial 12α-HSDH 
Next, we determined the phylogenetic positions of CSCI, CHIR, and CHYL relative to 
nearly 10,000 similar amino acid sequences in the NCBI NR database, by inferring a maximum 
likelihood tree, from which the subtree containing the sequences of interest was extracted for 
presentation (Figure 2.6). CHYL clustered with other Clostridiales sequences, including the first 
characterized 12α-HSDH from Clostridium sp. ATCC 29733.29 CHIR is a lone sequence which 
shares a common node with a larger set of clusters composed principally of Firmicutes and 
Actinobacteria. Within this larger cluster is CSCI, which is closely related to two metagenomic 
sequences, one sequence from Eubacterium sp. strain CAG:192 and one from Eggerthella sp. 
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strain CAG:298 (accession no. CDD59475.1). We recently reported that the protein with 
accession number CDD59475.1 has 12α-HSDH activity.34 
The Actinobacteria represented in the phylogeny, from the family Coriobacteriaceae, are 
of particular interest due to previous reports of 12α-HSDH activity. Wegner et al. demonstrated 
that mouse fecal isolate Enterorhabdus mucosicola DSM 19490T expresses bile salt hydrolase, 
as well as 3α-HSDH and 12α-HSDH activities.36 Our phylogenetic analysis suggests that the 
NAD(P)-dependent oxidoreductase (accession no. WP_028027349.1) is the 12α-HSDH encoded 
by E. mucosicola, and that closely related Enterorhabdus caecimuris protein (accession no. 
WP_016309125.1) is also a 12α-HSDH. Within this cluster are proteins from other 
Coriobacteriaceae members, such as an equol-producing strain of Adlercreutzia equolifaciens37 
and an asaccharolytic strain of Senegalemassilia anaerobia. Sharing a node (support value of 
0.946) with this cluster are additional Coriobacteriaceae family members in the genus 
Collinsella, including Collinsella aerofaciens (accession no. WP_006235414.1), which was 
recently reported to express 12α-HSDH activity.36 Another genus within the Coriobacteriaceae, 
Eggerthella, is represented at various points within the tree and deserves mention for two 
reasons. First, early reports establish E. lenta strains to be capable of oxidation and epimerization 
of bile acids, with clear 12α-HSDH activity.38–40 Second, in addition to the protein with 
accession number CDD59475.134, we recently characterized Elen_2515 from E. lenta DSM 
2243T, which was found to have bile acid 12α-HSDH activity33. 
While 12α-HSDH is well represented among Gram-positive members of the 
Actinobacteria and Firmicutes, the only taxa representing Gram-negative bacteria within this 
portion of the tree were strains of Bacteroides pectinophilus (Figure 2.6). There is a large cluster 
of Bacteroides sp. proteins, including several from Bacteroides fragilis, which were further 
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removed from the portion of the tree represented in Figure 2.6 (see also Supplementary Figure 
2.2). The B. fragilis proteins are members of the SDR family; however, they share only 31% 
amino acid identity with CSCI. Suspecting that the B. fragilis cluster represented in 
Supplementary Figure 2.2 might contain the 7α-HSDH reported for B. fragilis ATCC 25285, 
we compared the amino acid sequence of a 3-oxoacyl-[acyl-carrier-protein] reductase (accession 
no. WP_005799187.1) to that of 7α-HSDH (accession no. WP_005792012.1).41 However, the B. 
fragilis 7α-HSDH shared only 34% amino acid identity with the protein with accession number 
WP_005799187.1, despite both proteins being members of the FabG family of proteins. The 
sequence identity between WP_005799187.1 and the 12α-HSDH from C. scindens (CSCI) was 
only 31%. Multiple forms of 7α-HSDH were reported among strains of B. fragilis42, and further 
research will be needed to determine the functions of the proteins represented in this portion of 
the phylogeny. 
Archaea were also identified in an isolated cluster (Figure 2.6) populated by human gut 
isolates and metagenomic sequences of Methanobrevibacter smithii and Methanosphaera 
stadtmanae DSM 3091, consistent with a previous report.29 Our phylogeny suggests that 12α-
HSDH, like bile salt hydrolase3, was horizontally transferred from the Firmicutes to these 
Archaea. 
The low-activity BA7 bacteria C. leptum, Paraclostridium bifermentans, and 
Paeniclostridium sordellii were also represented in the larger phylogeny (Supplementary 
Figure 2.2). C. leptum was previously reported to express 12α-HSDH28; however, the gene 
encoding this enzyme has not been identified. C. leptum did not appear in a previous phylogeny 
based on the 12α-HSDH from Clostridium sp. ATCC 29733.30,31 However, we located a C. 
leptum protein (accession no. WP_003532012.1) that shares 61% identity with a deduced protein 
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from P. sordellii (accession no. WP_057547571.1), as well as C. perfringens (accession no. 
WP_096515955.1), an organism that has previously been shown to express 3α-, 7α-, and 12α-
HSDH activities.43 When the protein with accession number WP_057547571.1 was aligned with 
the amino acid sequence of a 7α-HSDH previously characterized from P. sordellii, it was 
determined that they shared only 36.29% identity. Paraclostridium bifermentans encodes a gene 
with deduced amino acid sequence (accession no. WP_021433828.1) sharing 86% identity with 
WP_057547571.1 from P. sordellii. Further work will be required to determine if these proteins 
identified in the phylogeny have 12α-HSDH activity. 
 
DISCUSSION 
It was shown in previous studies that C. scindens VPI 12708 generates a complex 
mixture of metabolites from the bile acid CA during anaerobic growth in culture medium 
(Figure 2.7).4,24 These studies identified 3α-HSDH and 7α-HSDH activities, and the genes 
encoding these enzymes have been reported in strains of C. scindens19,22, as well as P. 
hiranonis44 and C. hylemonae45. However, the formation of 12-oxointermediates has not been 
reported in anaerobic batch culture-based studies of these strains, but it was reported under 
aerobic conditions by resting cells of P. hiranonis.32 Oxidative conditions would be expected to 
funnel reductant toward detoxification of molecular oxygen, resulting in bile acid oxidation. C. 
leptum, which expresses BA7 activity but appears to lack several genes in the pathway harbored 
by C. scindens, P. hiranonis, and C. hylemonae5, also expresses 12α-HSDH28. Intriguingly, our 
extensive phylogenetic analysis may have identified the gene encoding 12α-HSDH in C. leptum; 
however, further work will be needed for confirmation. 
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The limitations of previous studies that cultured BA7 bacteria under low redox potential 
relate to their use of host-derived primary bile acids (CA, CDCA, and UDCA), rather than 
microbe-derived oxidized bile acid metabolites. Consistent with previous reports24,44,45, 12α-
HSDH activity was not observed when CA, 3-dehydro-CA, 7-oxoDCA, or DCA was added to 
anaerobic cultures of C. scindens, C. hylemonae, or P. hiranonis (Table 2.1). However, when we 
introduced 12-oxoLCA, 3,12-dioxoLCA, 7,12- dioxoLCA, and 3,7,12-trioxocholanic acid, we 
observed reduction of the 12-oxo-group, providing evidence for 12α-HSDH activity. 
Surprisingly, 12-oxoCDCA was not converted to DCA in batch cultures of C. scindens, P. 
hiranonis, and C. hylemonae. Instead, 12-oxoCDCA was converted quantitatively to 7-oxoDCA, 
whose formation could follow two metabolic routes, both depicted in Figure 2.7. Both reduction 
of bile acid oxo-groups and 7α-dehydroxylation result in a net 2-electron reduction.4 We 
therefore speculate that a reduction of oxo-bile acids fulfills the redox balance needs of the 
organisms in batch culture. It could also be that these oxo-derivatives do not induce the bile acid 
7α-dehydroxylation pathway. Future work will need to focus on understanding reductant flow 
and induction conditions in these gut bacteria when substrates are oxo-bile acids versus primary 
bile acids. 
The purified recombinant 12α-HSDH enzymes from these strains displayed an order of 
magnitude lower activity toward 12-oxoCDCA than 12-oxoLCA (Table 2.2). This is consistent 
with kinetic analysis of 12α-HSDH enzymes from gut bacteria that lack BA7 activity and the bai 
operon.30,33,34 Unlike C. scindens, P. hiranonis, and C. hylemonae, non-BA7 gut bacteria appear 
to oxidize the C-12 of DCA.26,33,44,45 
Our phylogenetic analysis updates and extends previous work on 12α-HSDH enzymes in 
gut bacteria.29 Indeed, we have recently verified that Eggerthella strains harbor distinct 12α-
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HSDH enzymes, both of which (Elen_2515 and the protein with accession no. CDD59475) are 
represented in our phylogeny (Figure 2.6). Furthermore, newly reported members of the gut 
microbiota recently obtained through culturomics approaches are represented in our phylogeny, 
expanding the potential for exploring bile acid metabolism by diverse gut microbes. The 
widespread distribution of 12α-HSDH among Firmicutes, Coriobacteriaceae family members of 
the Actinobacteria, and gut Archaea may represent an important detoxification mechanism to 
protect against the antimicrobial nature of DCA. DCA is roughly 10-fold more toxic to many gut 
bacteria than CA.45 12-oxoLCA is a commonly detected metabolite in human fecal samples; 
thus, the formation of this metabolite may have measurable effects on the microbial community 
and host physiology.46–48 Given their potential as redox-active centers, further research on oxo-
bile acids is warranted. 
The 12-oxo group of 12-oxoLCA would be expected to be an electron sink for bile acid 
7α-dehydroxylating gut bacteria, and reduction of this group would be favorable in an anaerobic 
environment. However, this may be a proximate cause, and a different evolutionary pressure may 
have evolved to respond to C-12 oxidation by other members of the gut microbiota. Oxidation of 
bile acid hydroxyl groups reduces the detergent nature of the bile acid and its toxicity to gut 
bacteria.49–52 Therefore, 12α-HSDH activity in bile acid 7α-dehydroxylating gut bacteria may 
have arisen to maintain toxic levels of DCA in fecal water, perhaps to reduce competitors for key 
nutrients. Furthermore, the observations of Masuda and Oda32 suggest that redox potential affects 
the direction of this reaction, and that oxidation of C-12 is more probable closer to the mucosa 
where oxygen partial pressures are increased.53 
At present, there are no structures for gut bacterial 12α-HSDHs. Such information would 
provide important insight into the key residues that might be altered to engineer an enzyme with 
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increased activity toward CA, a step toward improving Wolff-Kishner reduction in the synthesis 
of the therapeutic bile acid UDCA. Further, our data suggest that shifting CA metabolism toward 
the formation of 12-oxoCDCA may reduce the rate of formation of DCA, a bile acid implicated 
in cancers of the liver8 and colon7, as well as cholesterol gallstone formation10, and roles in 
cardiovascular disease are becoming apparent54. Theoretical studies also suggest that oxo-bile 
acids, including 12-oxo-derivatives, are potential enzyme inhibitors, effectors of host nuclear 
receptors, and substrates for particular P450 monooxygenases.55 Further studies are needed to 
determine the role of microbial bile acid oxidation on host physiology. 
 
MATERIALS AND METHODS 
Bacterial strains and culture conditions. 
C. scindens ATCC 35704, C. hylemonae DSM 15053, and P. hiranonis DSM 13275 were 
obtained from -80°C glycerol stocks from culture collections at the University of Illinois at 
Urbana-Champaign (UIUC) and Eastern Illinois University (EIU). Each strain was grown 
anaerobically at 37°C in butyl rubber-stoppered crimp-sealed culture tubes (18 by 150 mm, 
series 2048; Bellco Glass, Inc., Vineland, NJ, USA; 27.2 ml approximate stoppered volume at 1 
atm [101.29 kPa]) containing brain heart infusion (BHI) broth consisting of the following (grams 
per liter): BHI broth (BD Difco), 37; NaHCO3, 7.5; glucose, 2.0; yeast extract, 5.0; and 
resazurin, 0.001. The culture medium was prepared anaerobically by boiling and cooling the 
medium under 100% CO2, adding cysteine・HCI・H2O (0.5 g/liter) to the medium, and 
dispensing the medium under 100% CO2 into culture tubes (10 ml per tube). Tubes were 
subsequently crimp sealed and autoclaved. After autoclaving, the pH of the medium 
approximated 6.8. Stock solutions (10.6 mM) of bile acids were prepared in 100% methanol, 
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added to tubes, sealed with stoppers, and degassed by sparging and then flushing the headspace 
gas with argon. Bile acid solutions were added (0.1 ml) via sterile needles and syringes to tubes 
of sterile BHI broth to achieve an initial concentration of 0.1 mM after inoculation. In all 
experiments, growth was initiated by injecting 0.5 ml of inoculum per culture. The final 
concentration of methanol in cultures approximated 0.9% and did not influence the growth of the 
strains being tested; growth was also not observed following the addition of methanolic bile acid 
solutions to tubes of sterile BHI broth in the absence of inoculum. 
Escherichia coli DH5α (Turbo) competent cells were from New England BioLabs (NEB) 
(Ipswich, MA, USA) and E. coli BL21-CodonPlus(DE3)-RIPL cells were purchased from 
Stratagene (La Jolla, CA, USA) and grown in Luria-Bertani (LB) broth at 37°C. 
 
Chemicals 
5β-Cholanic acid-3α, 7α, 12α-triol (CA), 5β-cholanic acid-3α, 12α-diol (DCA), 5β-
cholanic acid-3α, 7α-diol (CDCA), 5β-cholanic acid-3α, 12α-diol N-(2-sulfoethyl)-amide 
(tauroDCA), glycoDCA, 5β-cholanic acid-3α, 7α, 12α-triol N-(2-sulfoethyl)-amide (tauroCA), 
5β-cholanic acid-3α, 7α, 12α-triol N-(carboxymethyl)-amide (glycoCA), 5β-cholanic acid-3α, 
7α-diol N-(2-sulfoethyl)-amide (tauroCDCA), and 5β-cholanic acid-3α, 7α-diol N-
(carboxymethyl)-amide (glycoCDCA) were purchased from Sigma- Aldrich (St. Louis, MO, 
USA). 5β-Cholanic acid-3α, 7α-diol-12-one (12-oxoCDCA), 5β-cholanic acid-3α-ol-12-one (12-
oxoLCA), 5β-cholanic acid-12α-ol-3-one (3-oxoDCA), 5β-cholanic acid-3α, 12α-diol-7-one (7-
oxoDCA), 5β-cholanic acid-3,7,12-trione (3,7,12-trioxoLCA), 5β-cholanic acid-3α-ol-7,12-dione 
(7,12-dioxoLCA), and 5β-cholanic acid-3,12-dione (3,12-dioxoLCA) were purchased from 
Steraloids, Inc. (Newport, RI, USA).56 Isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
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purchased from Gold Biotechnology (St. Louis, MO, USA). Strep-Tactin resin was purchased 
from IBA GmbH (Gottingen, Germany). All other reagents were of the highest possible purity 
and were purchased from Fisher Scientific (Pittsburgh, PA, USA). 
 
Detection of bile acids in cultures 
TLC was used for the detection of bile acids in BHI cultures and in standards prepared 
from sterile BHI broth supplemented with a bile acid.24,57,58 Briefly, a 1-ml sample of culture or 
sterile broth standard was transferred to duplicate 2-ml microcentrifuge tubes (0.5 ml of sample 
per tube). To each sample, 100 µl of 3 N HCl and 500 µl of ethyl acetate were added. The 
microcentrifuge tubes were capped, mixed by vortexing, and spun in a microcentrifuge for 1 min 
at 14,000 rpm. The organic phase (top layer) from both samples was removed and transferred to 
a 20-ml glass scintillation vial. The extraction step was repeated for each sample, and the 
combined ethyl acetate extracts (~2 ml) were dried at room temperature under a stream of 
nitrogen. Methanol (100 µl) was added to each vial, and the resuspended extracts were 
immediately spotted (50 µl) onto silica plates (Whatman AL SIL G, 250 µm thick, non-UV; 
Fisher Scientific). Individual and mixed methanolic standards (0.1 and 1.0 mM) were also 
prepared by dissolving pure bile acids directly in methanol and spotting (50 µl) onto silica plates. 
Unless indicated otherwise, TLC plates were developed in a tank containing 50 ml of solvent 
(cyclohexane, ethyl acetate, and glacial acetic acid, 12:12:1 [vol/vol/vol]). Once the solvent 
reached approximately 25 mm from the top of the plate, the plate was removed from the tank, 
sprayed with charring agent solution consisting of methanol (150 ml), water (150 ml), 
concentrated sulfuric acid (10 ml), and MnCl2・4H2O (1 g), heated to 115°C for 15 min, and 
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visualized with long-UV light (365 nm). Bile acids were identified by comparing Rf values of 
bile acid standards to those of bile acids detected in cultures. 
 
Isolation of genomic DNA 
Genomic DNA for PCR and molecular cloning applications was extracted from P. 
hiranonis DSM 13275, C. scindens ATCC 35704, and C. hylemonae DSM 15053 using the Fast 
DNA isolation kit from Mo Bio (Carlsbad, CA, USA), according to the manufacturer’s protocol.  
 
Heterologous expression of 12α-HSDH enzymes in E. coli and protein purification 
The pET- 51b(+) vector was obtained from Novagen (San Diego, CA, USA). Restriction 
enzymes were purchased from NEB (Ipswich, MA). Inserts were generated by PCR 
amplification using cloning primers obtained from Integrated DNA Technologies, Inc. 
(Coralville, IA, USA). The cloning primers used in this study are listed in Table 2.4. Inserts for 
directional cloning were amplified using the Phusion high-fidelity polymerase (Stratagene, La 
Jolla, CA, USA) and cloned into pET-51b(+) after the insert and vector were doubly digested 
with the appropriate restriction endonuclease and treated with DNA ligase. Recombinant plasmid 
was transformed into chemically competent E. coli DH5α cells via a heat shock method, plated, 
and grown for 16 h at 37°C on lysogeny broth (LB) agar plates supplemented with ampicillin 
(100 µg/ml). A single colony from each transformation was inoculated into LB broth (5 ml) 
containing ampicillin (100 µg/ml) and grown to saturation. The cells were subsequently 
centrifuged (3,220 x g, 15 min, 4°C), and plasmids were extracted from the resulting cell pellet 
using the QIAprep Spin miniprep kit (Qiagen, Valencia, CA, USA). The sequence of the insert 
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was determined by Sanger sequencing (W. M. Keck Center for Comparative and Functional 
Genomics at the University of Illinois at Urbana-Champaign). 
For protein expression, the correct recombinant plasmids extracted from the E. coli DH5α 
cells were transformed into E. coli BL21 CodonPlus (DE3)-RIPL chemically competent cells by 
heat shock method and cultured for 24 h at 37°C on LB agar plates supplemented with ampicillin 
(100 µg/ml) and chloramphenicol (50 µg/ml). Selected colonies were inoculated into LB broth 
(10 ml) supplemented with antibiotics and grown at 37°C for 6 h with vigorous aeration. The 
precultures were then added to fresh LB broth (1 liter), supplemented with ampicillin (100 
µg/ml), and aerated at 37°C until reaching an optical density at 600 nm (OD600) of 0.3. To 
induce recombinant protein expression, IPTG was added to each culture at a final concentration 
of 0.1 mM, and the temperature was decreased to 16°C. Following 16 h of incubation, cells were 
pelleted by centrifugation (4,000 x g, 30 min, 4°C) and resuspended in 30 ml of binding buffer 
(20 mM Tris-HCl, 150 mM NaCl, 10% glycerol, 10 mM 2-mercaptoethanol [pH 7.9]). The cell 
suspension was subjected to four passages through an EmulsiFlex C-3 cell homogenizer 
(Avestin, Ottawa, Canada), and the cell lysate was clarified by centrifugation at 20,000 x g for 30 
min at 4°C. 
The recombinant 12α-HSDHs were purified using Strep-Tactin resin (IBA GmbH), as per 
the manufacturing protocol. The protein was eluted with an elution buffer composed of 20 mM 
Tris-HCl, 150 mM NaCl, 10% glycerol, 10 mM 2-mercaptoethanol (pH 7.9), and 2.5 mM D-
desthiobiotin. The purity of the proteins was assessed by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE), and the protein bands were visualized by Coomassie brilliant 
blue G-250 staining. The concentrations of the proteins were calculated based on their extinction 
coefficients and molecular weights. The observed subunit weight for each was calculated by 
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The buffers used to investigate the optimal pHs of the recombinant 12α-HSDH enzymes 
(rCHYL, rCSCI, and rCHIR) contained 150 mM NaCl and varied contents of the following 
buffering agents: 50 mM sodium acetate (pH 4 to 6), 50 mM sodium phosphate (pH 6.5 to 7.5), 
and 50 mM Tris-Cl (pH 8 to 9). The linearity of the 12α-HSDH activity over time and the 
enzyme concentration were determined by monitoring the oxidation and reduction of NADP(H) 
aerobically at 340 nm (ε = 6,220 M-1・cm-1) continuously for 1.5 min in a reaction mixture with 
12α-HSDH and bile acid substrates. The reaction mixtures for rCHYL in the oxidative direction 
were composed of sodium phosphate buffer at pH 8.0, 18 nM enzyme with either 700 µM 
NADP+ and various concentrations of DCA or 900 µM DCA and differing NADP+ 
concentrations. The reductive direction consisted of pH 7.0 sodium phosphate buffer and 150 
µM NADPH and different 12-oxoLCA concentrations or 100 µM 12-oxoLCA and various 
NADPH concentrations, with 12.5 nM enzyme. rCSCI oxidative reaction mixtures included 10 
nM enzyme sodium phosphate buffer (pH 7.5), and 400 µM NADP+ with various concentrations 
of DCA or 1,500 µM DCA with different NADP+ concentrations. The reductive mixtures were 
sodium phosphate buffer at pH 7.0, 8 nM enzyme, and 150 µM NADPH with changing 12-
oxoLCA concentrations or 50 µM 12-oxoLCA with differing NADPH concentrations. The 
oxidative reaction mixtures for rCHIR were sodium phosphate buffer (pH 7), and 10 nM enzyme 
with either 900 µM NADP+ and various DCA concentrations or 1,600 µM DCA and different 
NADPµ concentrations. The reductive mixtures were composed of sodium phosphate buffer (pH 
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7), 200 µM NADPH with various 12-oxoLCA concentrations or 150 µM 12-oxoLCA with 
differing NADPH concentrations, and 8 nM enzyme. The kinetic parameters were estimated by 
fitting the data to the Michaelis-Menten equation by the nonlinear regression method using the 
enzyme kinetics module in GraphPad Prism (GraphPad Software, La Jolla, CA, USA). The 
substrate specificity analysis was performed according to the previously stated reaction mixtures, 
using saturating concentrations of substrate and pyridine nucleotide. 
 
TLC and mass spectrometry of bile acid metabolites 
Reaction mixtures were set up with 50 µM 12-oxoLCA substrate and NAD(P)(H) 
cofactor, either 12.5 nM rCHYL, 8 nM rCSCI, or 8 nM rCHIR, and the optimal pH 7.0 buffer up 
to 1 ml. The reaction mixtures were incubated overnight at room temperature and stopped with 
150 µl of 1 N HCl. The mixtures were extracted through vortexing with two volumes of ethyl 
acetate for 1 min and then two more volumes and another 1 min of vortexing. The organic phase 
was recovered and evaporated under nitrogen gas. The residue was dissolved in 30 µl ethyl 
acetate and spotted on the TLC plate (silica gel IB2-F flexible TLC sheet, 20 by 20 cm, with 
250-µm analytical layer; J.T. Baker, Avantor Performance Materials, LLC, PA, USA) with 8 µl 
of 10 mM DCA and 12-oxoLCA standards. The mobile phase consisted of 70:20:2 toluene–1,4-
dioxane–acetic acid. 
The bile acid metabolites separated on the TLC were visualized using a 10% 
phosphomolybdic acid in ethanol spray and heating for 15 min at 100°C. The bile acid 
metabolites were then extracted from TLC plates and sent for mass spectrometry (MS) analysis 
at the UIUC Mass Spectrometry Laboratory. The mass spectrometer (Thermo Scientific LTQ 
Orbitrap XL Hybrid Ion Trap-Orbitrap) was operated with an electrospray ionization (ESI) 
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source in negative-ion mode. The sample was introduced through syringe pump injection at a 
flow rate of 10 µl・min-1. The capillary voltage was -28 V, with a source temperature of 235°C. 
The mass spectrogram data were processed with the Thermo Xcalibur software.  
 
Phylogenetic analysis of bacterial 12α-HSDHs 
Sequences from the NCBI NR protein database were identified by BLASTP (limited to a 
maximum of 10,000 sequences, with an E value threshold of 1E-10) using as query protein with 
accession no. ERJ00208.1 (270 residues long) from Clostridium sp. ATCC 29733. Sequences 
shorter than 200 or longer than 350 amino acids were discarded to minimize fragments and other 
artifacts, as well as false positives (e.g., long sequences that have some similarity due to shared 
domains but are not likely to be homologues). The resulting 9,968 sequences were aligned using 
Muscle version 3.8.31.59 
Maximum likelihood phylogenetic analysis was performed using FastTree version 
2.1.860, with gamma-distributed heterogeneity rates and employing the WAG substitution model. 
The resulting tree was drawn and processed in Dendroscope version 3.5.961, and cosmetic 
adjustments were performed in Inkscape (http://inkscape.org). 
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Figure 2.1. Thin-layer chromatography (TLC) demonstrating the conversion of 12-
oxolithocholic acid (12-oxoLCA) to deoxycholic acid (DCA) by anaerobic cultures of C. 
scindens ATCC 35704, C. hylemonae DSM 15053, and P. hiranonis DSM 13275. DCA and 
12-oxoLCA standards were spotted in lanes 1 and 2, respectively. 12-oxoLCA was added to 
cultures of C. scindens ATCC 35704 (lane 3), C. hylemonae DSM 15053 (lane 4), and P. 




Figure 2.2. Boxshade representation of multiple-sequence alignment of 12α-hydroxysteroid 
dehydrogenases from Eggerthella lenta strains and Clostridium species. Depicted in the 
alignment are 12α-HSDH from Eggerthella lenta DSM 2243 (Elen_2515) (33), Eggerthella 
CAG:298 (accession no. CDD59475) (34), Clostridium sp. strain ATCC 29733 
(ClostATCC29733), Clostridium scindens ATCC 35704 (CSCI), Clostridium hylemonae DSM 
15053 (CHYL), and Peptacetobacter hiranonis DSM 13275 (CHIR). Asterisks mark amino 
acids predicted to bind pyridine nucleotide cofactor, and diamonds indicate conserved active-site 




Figure 2.3. Overexpression and purification of recombinant 12α-hydroxysteroid 
dehydrogenases from bile acid 7α-dehydroxylating bacteria. (a) Reaction catalyzed by 12α-
HSDH. (b) Genomic context of genes predicted to encode 12α-HSDH in BA7 bacteria. (c) SDS-
PAGE of 2 µg purified recombinant 12α-HSDHs overexpressed in E. coli and affinity purified 




Figure 2.4. TLC and mass spectrometry of 12α-hydroxysteroid dehydrogenase overnight 
reaction products. In lanes 1 and 2, DCA and 12-oxoLCA were spotted as standards, 
respectively. Purified recombinant protein (12.5 nM rCHYL, 8 nM rCSCI, 8 nM rCHIR) was 
incubated overnight under the following conditions: lane 3, 12-oxoLCA plus NADPH, no 
enzyme; lane 4, 12-oxoLCA plus NAD+ plus enzyme; lane 5, 12-oxoLCA plus NADP+ plus 
enzyme; lane 6, 12-oxoLCA plus NADH plus enzyme; lane 7, 12-oxoLCA plus NADPH plus  
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Figure 2.4. (cont.) 
enzyme. Arrow depicts spot analyzed by electrospray ionization mass spectrometry in negative 
mode, and compared to authentic DCA standard. Formula weight for DCA is 392.58. (a to c) 




Figure 2.5. Optimal pHs for purified recombinant 12α-hydroxysteroid dehydrogenases. 
Substrates were 12-oxoLCA with NADPH as cofactor (reductive direction, red) or DCA with 
NADP+ as cofactor (oxidative direction, blue). See Materials and Methods for buffer 
compositions. Experiments were repeated three or more times; values represent means ± 




Figure 2.6 (cont.) 
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Figure 2.6. Subtree of phylogenetic analysis of 12α-hydroxysteroid dehydrogenases. Branch 
colors reflect bacterial phylum and the domain Archaea. Descriptors for 12α-HSDHs 
characterized in the present study are boxed and in red font. Accession numbers are shown to the 




Figure 2.7. Schematic model of bile acid metabolism by bile acid 7α-dehydroxylating 
bacteria. (a) See introduction for information regarding the core bile acid 7α-dehydroxylation  
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Figure 2.7 (cont.) 
pathway catalyzed by bile acid-inducible (Bai) enzymes. Transport of oxo-bile acid derivatives 
hypothesized to import via sodium dependent-bile acid transporter (BaiG). See Table 2.1 for 
anaerobic culture-based bile acid conversion studies. (b) Alternative routes for conversion of 12-
oxochenodeoxycholic acid (12-oxoCDCA) to 7-oxodeoxycholic acid (7-oxoDCA), observed in 




Table 2.1. Effect of structure on bile acid transformation by C. scindens ATCC 35704, C. hylemonae DSM 15053, and P. hiranonis DSM 13275. 




Bile acid detected after growth (24 h) 
CA 3-oxoCA 7-oxoDCA 
12-














P. hiranonis - - - - 
 










P. hiranonis - - - - 
 






P. hiranonis - - - - 









           
3-oxocholic acid (3-oxoCA) 
12-oxochenodeoxycholic 
acid (12-oxoCDCA) 





Table 2.1 (cont.) 
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0.22 ± 0.02d C. scindens C. hylemonae - - 
C. scindens 
P. hiranonis 
- - - - - 
            











Table 2.1 (cont.) 
 





- - C. hylemonae - - - -  
a Final concentration of bile acid added to BHI culture was 0.1 mM.   
b Values determined from TLC analysis represent the means ± standard deviation (SD) of three or more replications. TLC solvent (cyclohexane, ethyl acetate, and glacial acetic acid; 12:12:1 [v/v/v]) was 
used for detection.  Detection limits approximated ≤10 µM. 
c -, not detected. 
d The presence or absence of the added bile acid following growth in BHI broth was determined with an additional TLC solvent (toluene, 1-4 dioxane, and glacial acetic acid; 70:20:2 [v/v/v]).  Detection 







Table 2.2. Steady-state kinetic parameters of 12α-HSDH homologs. 
  Substrate or coenzymea 
Homolog Kinetic Parameters 12-oxoLCA NADPH DCA NADP+ 
rCSCI Km (µM) 17.52 (0.32) 34.01 (0.32) 178.61 (0.66) 79.88 (0.37) 
Kcat (sec
-1) 31.13 (1.56) 26.71 (1.22) 90.93 (4.46) 90.74 (4.35) 
Vmax (µmole•min
-1•mg-1) 66.15 (3.31) 56.74 (2.59) 193.19 (9.47) 192.79 (9.24) 
Kcat/Km (µM
-1•sec-1) 1.77 (0.109) 0.79 (0.042) 0.51 (0.029) 1.14 (0.063) 
rCHYL Km (µM) 32.70 (0.55) 48.31 (0.37) 147.80 (0.38) 110.53 (0.38) 
Kcat (sec
-1) 45.09 (2.19) 44.52 (2.30) 72.52 (3.55) 66.72 (3.18) 
Vmax (µmole•min
-1•mg-1) 96.76 (4.70) 95.53 (4.94) 155.63 (7.64) 143.18 (6.82) 
Kcat/Km (µM
-1•sec-1) 1.38 (0.08) 0.92 (0.056) 0.49 (0.028) 0.60 (0.033) 
rCHIR Km (µM) 34.29 (0.34) 40.37 (0.38) 175.44 (0.50) 127.94 (0.42) 
Kcat (sec
-1) 72.09 (3.50) 76.24 (3.88) 130.62 (7.88) 129.75 (6.68) 
Vmax (µmole•min
-1•mg-1) 151.82 (7.37) 160.57 (8.16) 275.08 (16.60) 273.26 (14.07) 
Kcat/Km (µM
-1•sec-1) 2.10 (0.12) 1.89 (0.11) 0.74 (0.052) 1.01 (0.060) 




Table 2.3. Substrate specificity of purified 12α-HSDHs. 
  rCSCIb  rCHYLb  rCHIRb 









12-oxoLCA NADPH 38.59 ± 2.38 100  79.42 ± 3.58 100  133.56 ± 4.91 100 
12-oxoLCA NADH -c -  - -  - - 
12-oxoCDCA NADPH 3.69 ± 0.12 9.55  3.31 ± 0.11 4.16  4.88 ± 0.16 3.65 
DCA NADP+ 153.42 ± 6.2 100  127.68 ± 3.50 100  239.16 ± 2.89 100 
CA NADP+ 83.55 ± 1.55 54.44  102.79 ± 2.85 80.51  196.87 ± 4.36 82.32 
TDCA NADP+ 9.28 ± 0.57 6.05  57.56 ± 1.78 45.08  96.45 ± 6.48 40.33 
GDCA NADP+ 9.76 ± 1.56 6.36  30.86 ± 0.67 24.17  61.81 ± 3.61 25.85 
CDCA NADP+ - -  - -  - - 
DCA NAD+ - -  - -  - - 
a 12-oxolithocholic acid (12-oxoLCA), 12-oxochenodeoxycholic acid (12-oxoCDCA), deoxycholic acid (DCA), cholic acid (CA), 
taurodeoxycholic acid (TDCA), glycodeoxycholic acid (GDCA), chenodeoxycholic acid (CDCA). For both the reductive and oxidative 
directions, the highest activity was set to 100%. The concentrations used in the assays were based on Km values (refer to Materials and Methods). 
b Values represent the means ± SD based on three or more replications. 
c-, no activity detected. 
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Table 2.4. Sequence of oligonucleotide cloning primers.  






CLOSCI_02455 ATATAGGATCCTATGGGATTTTTAACAGGTAAGACAGCC (5’-Forward Primer-3’) 28.24 32,110 
ATATAAAGCTTTTATGGCCTAAGCCCCATTCC (5’-Reverse Primer-3’) 
    
CLOHYLEM_04236 ATATATGGTACCGATGGGTATATTTGACGGAAAAACAGCTA 27.96 24,995 
ATATATAAGCTTTTATGGGCGCTGTCCCATGC 
    
CLOHIR_01081 ATATAGGATCCTATGGGATTTTTAAATGGAAAAACAG 28.49 29,130 
ATATAGAGCTCTTAAGGTCTTAATCCCATTCCA 






























              
Supplementary Figure 2.1. Kinetic Analysis of rCHYL, rCSCI, rCHIR. Michaelis-Menten 
and Lineweaver-Burk plot of enzyme initial velocity with varying concentration of substrate (left 
panel) and co-substrate (right panel) in both the reductive (top panels) and oxidative (bottom 
panels). Enzyme reaction conditions are described in Materials and Methods. The 
oxidation/reduction of NAD(H) was measured by continuous spectrophotometry at 340 nm for 5 
min and the initial velocities were used calculated to calculate kinetic constants (Table 2.1). 
































Supplementary Figure 2.2 (cont.) 
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Supplementary Figure 2.2. Sub-tree of phylogenetic analysis, displaying a large cluster 
dominated by Bacteroidetes. Numbers on nodes represent clade support, from zero to one, as 
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COMPLETION OF THE GUT MICROBIAL EPI-BILE ACID PATHWAY1 
 
ABSTRACT 
Bile acids are detergent molecules that solubilize dietary lipids and lipid-soluble 
vitamins. Humans synthesize bile acids with α-orientation hydroxyl groups which can be 
biotransformed by gut microbiota to toxic, hydrophobic bile acids, such as deoxycholic acid 
(DCA). Gut microbiota can also convert hydroxyl groups from the α-orientation through an oxo-
intermediate to the β-orientation, resulting in more hydrophilic, less toxic bile acids. This 
interconversion is catalyzed by regio- (C-3 vs. C-7) and stereospecific (α vs. β) hydroxysteroid 
dehydrogenases (HSDHs). So far, genes encoding the urso- (7α-HSDH & 7β-HSDH) and iso- 
(3α-HSDH & 3β-HSDH) bile acid pathways have been described. Recently, multiple human gut 
clostridia were reported to encode 12α-HSDH, which interconverts DCA and 12-oxolithocholic 
acid (12-oxoLCA). 12β-HSDH completes the epi-bile acid pathway by converting 12-oxoLCA to 
the 12β-bile acid denoted epiDCA; however, gene(s) encoding this enzyme have yet to be 
identified. We confirmed 12β-HSDH activity in cultures of Clostridium paraputrificum ATCC 
25780. From six candidate C. paraputrificum ATCC 25780 oxidoreductase genes, we discovered 
the first gene (DR024_RS09610) encoding bile acid 12β-HSDH.  Phylogenetic analysis revealed 
unforeseen diversity for 12β-HSDH, leading to validation of two additional bile acid 12β-
HSDHs through a synthetic biology approach. By comparison to a previous phylogenetic 
1 Reprinted with permission from Doden HL, Wolf PG, Gaskins HR, Anantharaman K, Alves JMP, Ridlon JM. 
Completion of the gut microbial epi-bile acid pathway. Gut Microbes. 2021, in press. © 2021 The Authors. 
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analysis of 12α-HSDH, we identified the first potential C-12 epimerizing strains: Collinsella 
tanakaei YIT 12063 and Collinsella stercoris DSM 13279. A Hidden Markov Model search 
against human gut metagenomes located putative 12β-HSDH genes in about 30% of subjects 
within the cohorts analyzed, indicating this gene is relevant in the human gut microbiome. 
 
INTRODUCTION 
The human liver produces all 14 enzymes necessary to convert cholesterol into the 
dihydroxy bile acid chenodeoxycholic acid (3α,7α-dihydroxy-5β-cholan-24-oic acid; CDCA) 
and the trihydroxy bile acid cholic acid (3α,7α,12α-trihydroxy-5β-cholan-24-oic acid; CA).1 
These bile acids are conjugated to taurine or glycine in the liver helping to lower the pKa and 
maintain solubility, impermeability to cell membranes, and lower the critical micellar 
concentration, allowing for efficient emulsification of dietary lipids and lipid-soluble vitamins.2 
Bile acids are effective detergents owing to the α-orientation of the hydroxyl groups which 
produce a hydrophilic-face above the plane of the cyclopentanephenanthrene steroid nucleus, and 
a hydrophobic-face below the plane of the hydrocarbon rings.1 Conjugated bile acids emulsify 
lipids throughout the duodenum, jejunum, and ileum. Once bile acids reach the terminal ileum, 
high affinity transporters (intestinal bile acid transporter, IBAT) actively transport both 
conjugated and unconjugated bile acids from the intestinal lumen into ileocytes where they are 
bound to ileal bile acid binding protein (IBABP) and exported across the basolateral membrane 
into portal circulation and returned to the liver.3 This process of recycling of bile acids is known 
as the enterohepatic circulation (EHC), responsible for recirculating the ~2 g bile acid pool 8-10 
times daily. While ~95% efficient, roughly 600-800 mg bile acids escape active transport and 
enter the large intestine.2  
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         Anaerobic bacteria adapted to inhabiting the large intestine have evolved enzymes to 
modify the structure of host bile acids.2 Conjugated bile acids are hydrolyzed, releasing the 
amino acids, by bile salt hydrolases (BSH) in diverse gut bacteria representing the major phyla, 
including Bacteroidetes, Firmicutes, and Actinobacteria as well as the domain Archaea.4 By 
contrast, the unconjugated primary bile acids CA and CDCA are 7α-dehydroxylated by a select 
few species of gram-positive Firmicutes mostly in the genus Clostridium, forming deoxycholic 
acid (3α,12α-dihydroxy-5β-cholan-24-oic acid; DCA) and lithocholic acid (3α-hydroxy-5β-
cholan-24-oic acid; LCA), respectively.1,5 The secondary bile acids DCA and LCA have 
increased hydrophobicity relative to their primary counterparts, which is associated with elevated 
toxicity.6 DCA and LCA have been causally linked to cancers of the colon7, liver8, and 
esophagus9. Importantly, gut microbiota can produce less toxic oxo-bile acids and β-hydroxy bile 
acids as well.6 
Bile acid 3α-, 7α-, and 12α-hydroxyl groups can be reversibly oxidized and epimerized to 
the β-orientation by pyridine nucleotide-dependent hydroxysteroid dehydrogenases (HSDHs) 
distributed across the major phyla including Firmicutes, Bacteroidetes, Actinobacteria, 
Proteobacteria, as well as methanogenic archaea.1,10 HSDH enzymes that recognize bile acids are 
regio- (C-3 vs. C-7) and stereospecific (α vs. β) for hydroxyl groups decorating the steroid 
nucleus. Thus, bile acid 12α-HSDH reversibly converts the C-12 position of bile acids from the 
α-orientation, such as on DCA, to 12-oxo bile acids, such as 12-oxolithocholic acid (12-
oxoLCA).11–14 Bile acid 12β-HSDH completes the epimerization by interconverting 12-oxo bile 
acids to the 12β-configuration, forming epi-bile acids. We recently identified and characterized 
NAD(H)- and NADP(H)-dependent 12α-HSDHs from Eggerthella sp. CAG:29815, Clostridium 
scindens, C. hylemonae, and Peptacetobacter hiranonis (formerly Clostridium hiranonis)10. In 
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addition to these recently reported 12ɑ-HSDHs, multiple genes encoding enzymes in the urso- 
(7α- & 7β-HSDH) and iso- (3α- & 3β-HSDH) bile acid pathways have been described to date 
(Figure 3.1).5 However, a gene encoding 12β-HSDH to complete the epi-bile acid pathway has 
not yet been reported. 
         The first indication that gut bacteria may encode 12β-HSDH was suggested by the 
detection of 12β-hydroxy bile acids in human feces.16–18 Edenharder and Schneider (1985) 
reported 12β-dehydrogenation of bile acids by Clostridium paraputrificum, and epimerization of 
DCA by co-culture with E. lenta and C. paraputrificum.19 Thereafter, Edenharder and Pfützner 
(1988) characterized crude NADP(H)-dependent 12β-HSDH activity from C. paraputrificum D 
762-06.20 However, little is known about the potential diversity of gut bacteria capable of 
forming 12β-hydroxy bile acids that molecular analysis is predicted to yield. Here, we report the 
identification of a gene encoding NADP(H)-dependent 12β-HSDH from C. paraputrificum 
ATCC 25780 and characterization of the recombinant gene products purified after heterologous 
expression in E. coli from C. paraputrificum. We also identify novel taxa encoding bile acid 12β-
HSDH by phylogenetic analysis, confirmed by a synthetic biology approach.   
 
RESULTS 
C. paraputrificum ATCC 25780 possesses bile acid 12β-HSDH activity 
We first investigated the bile acid metabolizing capability of C. paraputrificum ATCC 
25780 because previous studies reported bile acid 12β-HSDH activity in other C. paraputrificum 
strains, but did not identify the gene(s) responsible.20 The epi-bile acid pathway of DCA involves 
the reversible conversion of DCA (3α,12α) to 12-oxoLCA (3α,12-oxo) through the action of 
12α-HSDH, and 12-oxoLCA to epiDCA (3α,12β) by 12β-HSDH (Figure 3.1). C. paraputrificum 
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ATCC 25780 was incubated with two potential substrates of 12β-HSDH, 12-oxoLCA and 
epiDCA, along with DCA as a control. In order to contrast the product formed by bile acid 12β-
HSDH with that formed by bile acid 12α-HSDH activity, Clostridium scindens ATCC 35704, 
which is known to express 12α-HSDH, was incubated with the same substrates. When 12-
oxoLCA was incubated in cultures of C. paraputrificum ATCC 25780, the primary product 
eluted at 13.97 min with 391.28 m/z in negative ion mode (Figure 3.2). This is consistent with 
the elution time of epiDCA standard and its 392.57 amu formula weight. With epiDCA as 
substrate, the culture produced a major peak of 391.28 at 13.96 min and a minor peak of 389.27 
m/z at 14.34 min, which suggests epiDCA was not converted in large quantities to 12-oxoLCA 
(390.56 amu). C. paraputrificum incubation with DCA did not result in detectable formation of 
12-oxoLCA or epiDCA products. Taken together, these data demonstrate C. paraputrificum 
ATCC 25780 expresses bile acid 12β-HSDH activity, but not bile acid 12α-HSDH. C. scindens 
ATCC 35704 incubation with 12-oxoLCA resulted in a main product (15.57 min and 391.28 
m/z) consistent with DCA (392.57 amu), demonstrating bile acid 12α-HSDH activity. In 
addition, reaction with DCA resulted in a peak at 15.57 min and 391.28 m/z along with a peak 
agreeing with 12-oxoLCA at 14.34 min and 389.27 m/z. When epiDCA was incubated with 
cultures of C. scindens ATCC 35704, we did not observe formation of 12-oxoLCA. 
 
Identification of a gene encoding bile acid 12β-HSDH 
After bile acid 12β-HSDH activity was confirmed in C. paraputrificum ATCC 25780, its 
genome was searched for genes encoding proteins annotated as oxidoreductases within the NCBI 
database. HSDHs are NAD(P)-dependent and often members of the large and diverse SDR 
(short-chain dehydrogenase/reductase) family.21 Five SDR family oxidoreductase proteins and 
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one aldo/keto reductase were identified as 12β-HSDH candidates in the C. paraputrificum ATCC 
25780 genome and pursued for further study. These six genes were amplified from genomic 
DNA of C. paraputrificum ATCC 25780, cloned into the pET-28a(+) vector, and overexpressed 
in E. coli (Supplementary Table 3.1). The N-terminal His6-tagged recombinant proteins were 
purified by metal-affinity chromatography and resolved by SDS-PAGE (Figure 3.3A). 
Two out of the six recombinant proteins (WP_027096909.1, WP_027099631.1) were not 
soluble and bands at the expected molecular masses were apparent in the membrane fraction by 
SDS-PAGE. These proteins were not explored further. The other four 12β-HSDH candidates 
(WP_027099077.1, WP_027098355.1, WP_027097937.1, WP_027098604.1) were soluble and 
visualized by SDS-PAGE. The four soluble recombinant proteins were then screened for 
pyridine nucleotide-dependent bile acid 12β-HSDH activity by TLC and spectrophotometric 
assay. Screening reactions were prepared with 12-oxoLCA and NADPH, or epiDCA and NADP+ 
in pH 7.0 phosphate buffer. 
Only WP_027099077.1 exhibited 12β-HSDH activity by TLC and spectrophotometric 
assay, which was also confirmed by LC-MS (Figure 3.3B). Reaction products of 
WP_027099077.1 with 12-oxoLCA and NADPH, epiDCA and NADP+, DCA and NADP+, and 
no substrate control were subjected to LC-MS. In the presence of purified recombinant 
WP_027099077.1 and NADPH, 12-oxoLCA was reduced quantitatively (2 hydrogen addition) to 
a product that eluted at 13.12 min with 391.28 m/z in negative ion mode. This is consistent with 
the 392.57 amu formula weight and elution time for epiDCA based on the substrate standard. 
Additionally, epiDCA was oxidized to a product with an elution time of 13.40 min at 389.27 
m/z, agreeing with the retention time and formula weight of 390.56 amu for authentic 12-
oxoLCA. DCA (392.57 amu) was not converted by WP_027099077.1 as the sole peak observed 
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matched DCA standard at 14.60 min and 391.29 m/z. The interconversion of 12-oxoLCA and 
epiDCA, but no activity with DCA, indicates stereospecificity for the 12β-hydroxy position. 
Thus, DR024_RS09610 has been identified as the first gene reported that encodes bile acid 12β-
HSDH (WP_027099077.1). 
Recombinant C. paraputrificum WP_027099077.1, hereafter referred to as Cp12β-
HSDH, had a theoretical subunit molecular mass of 27.4 kDa. The observed subunit molecular 
mass was 26.4 ± 0.5 kDa by SDS-PAGE, calculated from three independent protein gels. 
WP_027099077.1 is predicted to be a cytosolic protein that is not membrane-associated by 
TMHMM v. 2.0.22 
 
Biochemical characterization of recombinant Cp12β-HSDH 
The approximate native molecular mass of Cp12β-HSDH was determined by size-
exclusion chromatography. Cp12β-HSDH exhibited an elution volume of 15.04 ± 0.02 mL, 
corresponding to a 54.67 ± 0.79 kDa molecular mass relative to protein standards (Figure 3.4A). 
The size-exclusion data along with the theoretical subunit molecular mass of 27.4 kDa suggests 
Cp12β-HSDH assembles a homodimeric quaternary structure in solution. In order to optimize 
the enzymatic activity of Cp12β-HSDH, the conversion of pyridine nucleotides at 340 nm was 
measured in buffers between pH 6.0 and 8.0 by spectrophotometric assay (Figure 3.4B). The 
optimum pH for Cp12β-HSDH in the oxidative direction with epiDCA as the substrate and 
NADP+ as co-substrate was pH 7.5. In the reductive direction where 12-oxoLCA was the 
substrate and NADPH the co-substrate, the optimum pH was 7.0. 
Michaelis-Menten kinetics were performed at the pH optimum for each direction. In the 
reductive direction, Cp12β-HSDH displayed a Km value for 12-oxoLCA at 18.76 ± 0.40 µM 
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which was similar to that of NADPH (Table 3.1; Supplementary Figure 3.1). The Km value in 
the oxidative direction with epiDCA as substrate was about twice the Km determined for 12-
oxoLCA. The Km for NADP
+ was 36.84 ± 0.55 µM. The Vmax and kcat were greater in the 
oxidative than the reductive direction. However, the catalytic efficiency (kcat/Km) of 12-oxoLCA 
as substrate was greater than the oxidative direction with epiDCA as substrate. 
Pyridine nucleotide cofactor and bile acid substrate-specificity of Cp12β-HSDH were 
determined by relative activity compared to either 12-oxoLCA or epiDCA through 
spectrophotometric assay (Table 3.2). NAD+ and NADH were not co-substrates for Cp12β-
HSDH. DCA (3α,12α) as well as CA (3α,7α,12α) were not substrates, which is expected because 
they are 12α-hydroxy bile acids not 12β-hydroxy bile acids. CDCA (chenodeoxycholic acid; 
3α,7α) lacks a 12-hydroxyl group, and as expected was not a substrate. The CA derivatives 12-
oxoCDCA (3α,7α,12-oxo) and epiCA (3α,7α,12β) had ~12% and 27% activity, respectively, 
relative to bile acids lacking a 7α-hydroxyl group. The activity of 3,12-dioxoLCA was ~19% 
compared to 12-oxoLCA. Altogether, the results suggest Cp12β-HSDH is specific for NADP(H) 
and favors 12-oxoLCA and epiDCA over their 7α-hydroxy counterparts. 
 
Phylogenetic analysis of Cp12β-HSDH 
The Cp12β-HSDH sequence from C. paraputrificum ATCC 25780 (WP_027099077.1) 
was used in a BLASTP search against the NCBI non-redundant protein database in order to 
determine its prevalence across bacteria. A maximum likelihood phylogeny of 5,000 sequences 
was constructed, revealing that many sequences most similar to Cp12β-HSDH are found in 
Firmicutes and Actinobacteria (Supplementary Figure 3.2). Within the 5,000-member 
phylogeny, a subtree (highlighted grey) of the most closely related proteins to Cp12β-HSDH was 
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selected for closer inspection (Figure 3.5). Cp12β-HSDH clustered most closely with other C. 
paraputrificum sequences (WP_099327725, WP_049179624, WP_111937163). These sequences 
are encoded by C. paraputrificum strains isolated from preterm infants, namely strain LH025, 
LH141, and LH05823, or isolated from feces (Gcol.A11).24 
Firmicutes harbor the majority of sequences within the 12β-HSDH subtree, spanning 
genera including Eisenbergiella, Ruminococcus, and Coprococcus. To determine if other 
organisms within the tree have bile acid 12β-HSDH activity, the gene encoding 
WP_118677302.1 from Eisenbergiella sp. OF01-20 was synthesized by IDT in the codon-usage 
of E. coli (Supplementary Table 3.1), cloned into pET-28a(+), overexpressed in E. coli, and 
purified by affinity chromatography (Figure 3.5). Recombinant WP_118677302.1 was screened 
by spectrophotometric assay with NAD(P)(H) against 12-oxoLCA, epiDCA, and DCA. Relative 
to Cp12β-HSDH, WP_118677302.1 exhibited 88% activity with 12-oxoLCA, and 83% activity 
with epiDCA. WP_118677302.1 did not show conversion of DCA, confirming that this enzyme 
has bile acid 12β-HSDH activity (Table 3.2). 
The subtree also contains many sequences from Actinobacteria, the genera Collinsella 
and Olsenella among them. Collinsella species are of interest because C. aerofaciens expresses 
BSH and various HSDHs recognizing sterols25, including bile acid 12α-HSDH.26 To determine if 
a member of the Actinobacteria encodes a bile acid 12β-HSDH, a sequence more distantly 
related to Cp12β-HSDH, Olsenella sp. GAM18 WP_120179297.1, was chosen for gene 
synthesis and protein overexpression because it had not been shown previously to metabolize 
bile acids (Figure 3.5). 12-oxoLCA, epiDCA and DCA were tested as substrates and conversion 
was measured by spectrophotometric assay. Recombinant WP_120179297.1 displayed activity 
with 12-oxoLCA at 128% relative to Cp12β-HSDH, 69% relative activity with epiDCA, and 
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showed no reaction with DCA (Table 3.2). These data confirm that the more distantly related 
WP_120179297.1 has bile acid 12β-HSDH activity.  
Within the extended subtree are various Novosphingobium species. These 
Alphaproteobacteria deserve mention due to their ability to biodegrade aromatic compounds, 
such as phenanthrene27 and estrogen.28 To test if this cluster has bile acid 12β-HSDH activity, 
WP_007678535.1 from Novosphingobium sp. AP12 was synthesized, cloned, overexpressed, and 
purified (Figure 3.5). The potential 12β-HSDH activity of WP_007678535.1 was screened using 
12-oxoLCA, epiDCA, and DCA as substrates. WP_007678535.1 exhibited no activity with these 
bile acid substrates (Table 3.2). Because Novosphingobium strains are frequently plant-
associated or isolated from aquatic environments29, this enzyme may be specific for other 
substrates. 
The genomic context of 12β-HSDH genes from C. paraputrificum ATCC 25780, 
Eisenbergiella sp. OF01-20, and Olsenella sp. GAM18 was explored (Supplementary Figure 
3.3). The three 12β-HSDH genes did not appear to be organized within an operon nor was the 
genomic context conserved across these organisms. 
Two organisms present in the 12β-HSDH subtree, Collinsella tanakaei and Collinsella 
stercoris (Figure 3.5, asterisks), were also found in a phylogenetic analysis of putative 12α-
HSDHs (see Chapter 2).10 Due to strain variation within species, we inspected the sequences 
further and determined that the pairs of HSDHs are encoded by the same strain within each 
species. Collinsella tanakaei YIT 12063 12α-HSDH (WP_009141301.1) and 12β-HSDH 
(WP_009140706.1) are encoded by the genes HMPREF9452_RS06335 and 
HMPREF9452_RS03390, respectively. Collinsella stercoris DSM 13279 also contains both 
putative 12α-HSDH (WP_040360544.1; COLSTE_RS02900) and 12β-HSDH 
110 
 
(WP_006720039.1; COLSTE_RS01465).10 While the paired activity of 12α/12β-HSDH has not 
been tested in culture, these organisms may be novel epi-epimerizing strains that convert bile 
acid 12α-hydroxyl groups to the epi-configuration. To our knowledge, these are the first strains 
identified with C-12 epimerizing ability. 
 
Hidden Markov Model search of putative 12β-HSDH genes in human gut metagenomes 
To understand the distribution of potential 12β-HSDH genes in the human colonic 
microbiome, a Hidden Markov Model (HMM) search was performed against metagenome 
assembled genomes (MAGs) from four publicly available cohorts30–33 using reference sequences 
from the 12β-HSDHs characterized in this paper (Figure 3.5). Putative 12β-HSDH genes 
inferred by HMM search were found in ~30% of the subjects (198/666) (Figure 3.6A). Twenty-
two subjects exhibited two different organisms containing the gene. This gene was found in 
healthy subjects as well as subjects with the following disease states: colorectal cancer, 
colorectal adenoma, fatty liver, hypertension, and type 2 diabetes. 
Two hundred twenty microbial genomes contained putative 12β-HSDH genes among 
16,936 total available genomes. Putative 12β-HSDH genes were most often identified in the 
phylum Firmicutes, which was dominated by genes in Lachnospira eligens (formerly 
Eubacterium eligens) (Figure 3.6B). The gene from L. eligens was widespread across subjects in 
each of the four cohorts. This large proportion of hits from L. eligens may reflect its higher 
relative abundance allowing it to be assembled better into genomes. Sequences from this 
organism also appeared multiple times in the 12β-HSDH subtree (Figure 3.5). Lachnospira 
eligens is a pectin degrader capable of promoting anti-inflammatory cytokine IL-10 production 
in vitro34 and has been proposed as a probiotic for atherosclerosis35. The gene was also present in 
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C. paraputrificum along with other unidentified Clostridium sp. and Eubacterium sp. 
Actinobacteria had few members with the gene, represented by Collinsella intestinalis, 
Collinsella tanakaei, and Olsenella sp. Phocaeicola coprocola (formerly Bacteroides coprocola) 
was the only member of phylum Bacteroidetes with the gene. 
 
Phylogenetic analysis of regio- and stereospecific HSDHs 
Next, the phylogenetic relationship between Cp12β-HSDH (WP_027099077.1) and other 
regio- and stereospecific HSDHs was explored. To accomplish this, we updated the HSDH 
phylogeny presented by Mythen et al. (2018) by including additional bacterial or archaeal HSDH 
sequences of known or putative function along with representative eukaryotic sequences (Figure 
3.7; Supplementary Table 3.2).15 The sequences included span the known HSDH functional 
capacities, with some recognizing bile acids and others recognizing steroids like cortisol or 
progesterone. Most members of each HSDH class are clustered together, which is apparent by 
each highlight color encompassing more than one HSDH of the same known function. 
Furthermore, most bacterial HSDHs grouped separately from their eukaryotic counterparts. 
Prokaryotic sequences were interspersed among the eukaryotic with some exceptions in 
grouping by HSDH function. Cp12β-HSDH, the two other confirmed bile acid 12β-HSDHs 
(WP-118677302.1, WP_120179297.1), and additional similar sequences from across our bile 
acid 12β-HSDH subtree formed their own cluster. These sequences shared a branch with 
bacterial bile acid 12α-HSDHs as well as eukaryotic 3β-HSD/Δ5→Δ4/isomerases. Bile acid 12α-
HSDH sequences included various clostridia (EDS06338.1, EEG75500.1, EEA85268.1, 
ERJ00208.1)10,36 and Eggerthella (CDD59475.1).15 Collinsella aerofaciens (EBA39192.1), 
which has been reported to express bile acid 12α-HSDH activity26, grouped with the known bile 
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acid 12α-HSDHs along with two human gut archaeal sequences from Methanosphaera 
stadtmanae and Methanobrevibacter smithii. 
Clostridial (gram-positive) bile acid 7α-HSDHs (AAB61151.1 etc.)37 clustered separately 
from those expressed by E. coli (BAA01384.1)38 and those predicted in Bacteroides (gram-
negative), similarly to the Mythen et. al. (2018) phylogeny. Bile acid 7β-HSDHs did not closely 
cluster with other classes of bacterial HSDHs. Instead, the nearest neighbours to the three known 
bile acid 7β-HSDHs (WP_006236005.1, WP_004843516.1, AET80684.1)25,39,40 included in this 
tree were eukaryotic steroid 11β- and 17β-HSDs. 
Bacterial 3α-HSDHs clustered together, excluding one outlier from Eggerthella lenta 
(ACV54671.1).41 Within the bile acid 3α-HSDH group, four enzymes predicted with this 
function formed a separate branch apart from the confirmed bile acid 3α-HSDHs. Likewise, three 
known bile acid 3β-HSDHs grouped together (ACV55294.1, ACV54192.1, EDN78833.1)41, 
while one Eggerthella sequence was most closely related to putative bile acid 3β-HSDHs from 
Lactobacillus spp. identified by BLAST search in Mythen et. al (2018). 
Bacterial steroid 20β-HSDHs convert the glucocorticoid cortisol to 20β-dihydrocortisol. 
Two experimentally confirmed 20β-HSDHs (WP_003810233.1, WP_051643274.1) (see Chapter 
4)42,43 grouped with putative sequences from both gut and urinary tract isolates. To date, only 
one steroid 20α-HSDH sequence, which interconverts cortisol and 20α-dihydrocortisol, has been 
reported (C. scindens EDS07887.1) (see Chapter 5).44,45 Therefore, we performed a BLASTP 
search and found two sequences with high similarity, WP_145772308.1 from Denitratisoma 
oestradiolicum DSM 16959 and WP_107631222.1 from Intestinibacillus sp. Marseille-P4005. 
D. oestradiolicum DSM 16959 was isolated from sludge in a municipal wastewater treatment 
plant and can use 17β-estradiol as a sole carbon and energy source.46 Intestinibacillus 
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massiliensis strain Marseille-P3216, a close relative to Intestinibacillus sp. Marseille-P4005 
found in our tree, was isolated from the human colon and is most closely related to the species 
Butyricicoccus desmolans (formerly Eubacterium desmolans) by 16S rRNA gene sequence.47 
Interestingly, B. desmolans ATCC 43058 encodes a 20β-HSDH (WP_051643274.1).43 
Eukaryotic HSDH sequences, typically denoted HSD, were spread throughout the 
phylogeny, but generally grouped with like sequences. The 17β- and 11β-HSD sequences did not 
form a group, instead clustering by type. For example, Homo sapiens 11β-HSD type 1 
(NP_861420.1) was closely related to Rattus norvegicus 11β-HSD type 1 (NP_058776.2) and 
more distantly related to Homo sapiens 11β-HSD type 2 (NP_000187.3). 11β-HSD type 1 and 
type 2 both interconvert steroids between active and inactive forms, such as cortisol and 
cortisone.48 However, 11β-HSD type 1 primarily acts as a reductase in many tissues while 11β-
HSD type 2 functions as a dehydrogenase.48 
 
DISCUSSION 
Microbial bile acid HSDHs have been studied since the early 1970s, with much of the 
original work focusing on 3α- and 7α-HSDHs.14,49 Thereafter, 3β-, 7β- and 12α-HSDH activity 
was observed in cultures of various microbiota1, including Eggerthella lenta (formerly 
Eubacterium lentum) which is capable of oxidizing CA and DCA at C-12 and epimerizing bile 
acids at C-3.50 In the mid-1980s, C. paraputrificum, C. tertium, and Clostridioides difficile each 
in binary cultures with E. lenta were shown to epimerize DCA via a 12-oxo-intermediate to 
epiDCA.19 Since then, HSDH genes encoding the iso- and urso-bile acid pathways and 12α-
HSDH were identified, but not 12β-HSDH.5 In this work, we identified the first bile acid 12β-
HSDH gene, completing the microbial epi-bile acid pathway.  
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Edenharder & Pfützner (1988) initially characterized NADP(H)-dependent 12β-HSDH 
from crude extracts of the fecal isolate C. paraputrificum strain D 762-06, with differing results 
from our findings.20 Gel filtration analysis of crude extract from C. paraputrificum strain D 762-
06 suggested a molecular mass of 126 kDa; whereas our current work with Cp12β-HSDH from 
ATCC 25780 is estimated at 54.6 KDa by gel filtration chromatography. The strain used in this 
study, C. paraputrificum ATCC 25780, was also isolated from feces.51 It is possible that these 
are the same NADP(H)-dependent enzymes by sequence from two different strains of C. 
paraputrificum and that the recombinant protein quaternary structure is unstable, resulting in a 
dimeric form in our study. Alternatively, these bacterial strains may have distinct versions of 
12β-HSDH with different amino acid sequences, as we have shown previously for 12α-HSDH 
from Eggerthella lenta.15,52 Indeed, the 12β-HSDH from C. paraputrificum strain D 762-06 was 
reported to be partially membrane associated, whereas hydropathy prediction by TMHMM v. 2.0 
found no evidence of transmembrane domains in Cp12β-HSDH. In addition, pH optima for the 
conversion of 12-oxoLCA between Cp12β-HSDH (7.0) and the native 12β-HSDH (10.0) from 
strain D 762-06 differed. Oxidation of epiDCA was optimal at pH 7.5 for Cp12β-HSDH, and 
reported as pH 7.8 for the crude native enzyme from strain D 762-06.20 Further work will be 
needed to determine if distinct bile acid 12β-HSDHs are present in C. paraputrificum strains. 
Cp12β-HSDH exhibited a dimeric quaternary structure by size-exclusion chromatography 
under our experimental conditions. Although future crystallization of Cp12β-HSDH would better 
illustrate its true polymeric state, HSDHs are often either tetrameric42,53 or dimeric.54,55 Cp12β-
HSDH was more specific for bile acids lacking a position 7-hydroxyl group: epiDCA and 12-
oxoLCA, over epiCA and 12-oxoCDCA. Cp12β-HSDH also had lower activity with 3,12-
dioxoLCA versus 12-oxoLCA. This indicates that both the 7-hydroxyl and 3-oxo groups hinder 
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the ability of Cp12β-HSDH to convert the substrate. An x-ray crystal structure of Cp12β-HSDH 
may shed light on why this apparent steric hindrance occurs. 
Phylogenetic analysis of Cp12β-HSDH coupled with synthetic biological “sampling” and 
validation at different points along the branches revealed shared 12β-HSDH function among 
Eisenbergiella sp. OF01-20 and Olsenella sp. GAM18, lending functional credibility to 
sequences throughout the subtree (Figure 3.5; Table 3.2). Eisenbergiella sp. OF01-20 was 
originally sequenced from a human gut microbiota cultivation project (Integrated Microbial 
Genomes [IMG] Genome ID: 2840324701). Eisenbergiella spp. are often present at relative 
abundances of less than 0.1% in human fecal samples.56,57 Olsenella sp. GAM18 was initially 
isolated from humans (IMG Genome ID: 2841219092). The relative abundance of Olsenella was 
shown to be about 2% within the gut microbiome of some individuals.58 Our subtree includes 
more abundant gut taxa such as Ruminococcus (relative abundance ~5%)59,60 and Collinsella 
(relative abundance ~8%)59, as well. Due to limitations in 16S rDNA sequencing depth, it is 
difficult to conclude if the species in our subtree are found at relevant levels in the human gut or 
if 12β-HSDH genes are present. Therefore, we performed a HMM search to assess the relative 
prevalence of 12β-HSDH genes. About 30% of subjects had putative 12β-HSDH genes, 
indicating the relevance of this gene in the human gut microbiome. The HMM search revealed 
that 220 microbial genomes out of 16,936 total contained putative 12β-HSDH genes. While 
concrete prevalence is difficult to establish, putative 12β-HSDH genes are less widespread than 
the ubiquitous bile-acid metabolizing gene, bile salt hydrolase4, which was present in 
2,456/16,936 total genomes in these cohorts. These data expand the limited metagenomic work 
that has focused on bile acid HSDH genes in the human gut.61 
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Two organisms from our 12β-HSDH subtree were also identified in a 12α-HSDH 
phylogeny from Doden et al. (2018) (see Chapter 2). Putative proteins WP_009140706.1 (12β-
HSDH) and WP_009141301.1 (12α-HSDH) are both present in Collinsella tanakaei YIT 12063 
and are encoded by the genes HMPREF9452_RS03390 and HMPREF9452_RS06335, 
respectively. Similarly, Collinsella stercoris DSM 13279 encodes both putative 12β-HSDH 
(WP_006720039.1; COLSTE_RS01465) and 12α-HSDH (WP_040360544.1; 
COLSTE_RS02900).10 Although the dual 12α/12β-HSDH activity is untested in culture, we 
predict these strains are novel C-12 epimerizers. Epimerizing strains have been identified for the 
C-319,41 and C-7 hydroxyl1,62 positions, however, this is the first indication of bacteria capable of 
C-12 epimerization. 
The sequence WP_007678535.1 from Novosphingobium sp. AP12, whose recombinant 
enzyme product did not exhibit bile acid 12β-HSDH activity with the substrates tested, may be 
specific for aerobic bile acid degradation products. Environmental microorganisms, such as 
Comamonas testosteroni TA441 and Pseudomonas sp. strain Chol1, encode a CA degradation 
pathway involving conversion of a 12-oxo-intermediate to 7α,12β-dihydroxy-androsta-1,4-diene-
3,17-dione (12β-DHADD).63,64 Thus, sequences in the extension of the subtree may have 12β-
HSDH activity, but with specificity for side-chain cleaved steroids rather than bile acids. 
Indeed, this function joins the vast repertoire of HSDHs already studied in many 
Firmicutes and Actinobacteria.1 Bile acid 12α-HSDH activity has been detected in Eggerthella 
species15,52 in the phylum Actinobacteria and various clostridia10–12,36 in the phylum Firmicutes. 
Similarly, 3α- and 3β-HSDH are widespread among Firmicutes1,65, and 3α-HSDH has also been 
reported in Eggerthella species.13,15,41 7α- and 7β-HSDH were shown in numerous 
Firmicutes14,37,65 and the Actinobacteria Collinsella aerofaciens.25 Along with these bile acid-
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specific HSDHs, the glucocorticoid 20α- and 20β-HSDHs are evident in both Firmicutes43,45 and 
Actinobacteria such as Bifidobacterium adolescentis42. Until this study, there were no reports of 
genes encoding 12β-HSDH and the activity had only been shown in C. paraputrificum, C. 
tertium and C. difficile.19 Thus, our phylogenetic analysis revealed hitherto unknown diversity 
for bile acid 12β-HSDHs within the Firmicutes and Actinobacteria. Bacteroidetes sequences 
were notably absent within our 12β-HSDH subtree and only one sequence was identified in our 
HMM search, although Bacteroidetes have been shown to encode multiple other HSDHs.1,49 
Interestingly, C. tertium and C. difficile enzymes were also not present in our phylogenetic 
analysis even though this activity has been reported for strains of these clostridia19, indicating 
that genes encoding other forms of bile acid 12β-HSDH are present in the gut microbiome. 
The distribution pattern of microbial HSDHs is becoming increasingly clear (Figures 3.5 
& 3.7), although in many cases the evolutionary pressures on gut microbes for encoding 
particular regio- and stereospecific HSDH enzymes is not clear. As observed with BSH enzymes, 
the functional importance of HSDHs may be strain-dependent. In some strains, the mere ability 
to acquire or dispose of reducing equivalents may be important, and the class of enzyme 
unimportant. Bile acid hydroxylation patterns affect the binding and activation/inhibition of host 
nuclear receptors.67 HSDH enzymes may thus act in interkingdom-signaling, a hypothesis that 
has recent support based on the effect of oxidized and epimerized bile acids on the function of 
regulatory T cells.68,69  
The concerted action of pairs of HSDHs result in bile acid products with reduced toxicity 
for microbes expressing the HSDH(s) or for an important inter-species partner, which was likely 
a factor in the evolution of these enzymes. Examples of strains of species capable of epimerizing 
bile acid hydroxyl groups are found in the literature, and the physicochemical properties and 
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reduced toxicity of β-hydroxy bile acids are known, providing hypotheses for physiological 
function. Clostridium limosum (now Hathewaya limosa) expresses both bile acid-inducible 
NADP-dependent 7α- and 7β-HSDH capable of converting CDCA to UDCA.70 CDCA is more 
hydrophilic and more toxic to bacteria than UDCA.6,71 Indeed, treatment with UDCA increases 
the hydrophilicity of the biliary pool, reducing cellular toxicity and improving biliary disorders.72 
Similarly, strains of Eggerthella lenta15,41 and Ruminococcus gnavus41 express both NADPH-
dependent 3α- and 3β-HSDHs capable of forming 3β-bile acids (iso-bile acids). Iso-bile acids are 
also more hydrophilic and less toxic to bacteria than the α-hydroxy isomers.41 At least some 
strains of R. gnavus also express NADPH-dependent 7β-HSDH, contributing to the 
epimerization of CDCA to UDCA.39 It may be speculated that R. gnavus HSDHs function in 
detoxification of hydrophobic bile acids such as CDCA and DCA; however, further work is 
needed. Analogous to E. lenta and R. gnavus, C. paraputrificum is another example of a strain 
encoding multiple HSDHs that favor formation of β-hydroxy bile acids.19 C. paraputrificum 
strains encode the iso-bile acid pathway as well as NADPH-dependent 12β-HSDH.19,20 While 
little is known about the biological effects of 12β-bile acids (epi-bile acids), the physicochemical 
properties relative to 12α-hydroxy bile acids should approximate that of iso- and urso-
derivatives.6,41,71 An important question emerging from these observations is whether one 
particular epimeric product rather than another has important consequences on the fitness of the 
bacterium generating them, or if the increased hydrophilicity and reduced toxicity are the key 
factors. 
Since the initial detection of epi-bile acids by Eneroth et. al. and Ali et. al.16–18, the 
measurement of bile acid metabolomes in clinical samples has become commonplace73, yet few 
studies measure or report epi-bile acids. Recently, 12β-hydroxy and 12-oxo-bile acids have been 
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quantified in human feces by Franco et. al. (2019). 12-oxoLCA was the most abundant oxo-bile 
acid in feces at concentrations of about one half that of DCA in stool. While epiDCA itself was 
not measured, 3-oxo-12β-hydroxy-CDCA was shown at 12 ± 4 µg/g wet feces.74 Additionally, 
epiDCA has been reported in biliary bile of angelfish, likely produced from bacterial origin, so 
the 12β-HSDH gene may be widespread among resident microbiota of diverse vertebrate taxa.75 
A critical limitation to the study of epi-bile acids is the absence of commercially available 
standards, although there are methods available for chemical synthesis.76,77 The newly identified 
bile acid 12β-HSDHs could be employed for the enzymatic production of epi-bile acid standards 
from oxo-intermediates. 
The physiological effects of epi-bile acids are poorly characterized, particularly in the GI 
tract. Borgstrӧm and colleagues compared infusion of CA, ursoCA, and epiCA on bile flow, lipid 
secretion, bile acid synthesis, and bile micellar formation. In contrast to ursoCA and CA, epiCA 
was secreted into bile in an unconjugated form. The 12β-hydroxyl group may hinder the enzyme 
responsible for conjugation. Additionally, epiCA infusion increased the rate of secretion of 
newly synthesized bile salts.78 Another study reported increased 12-oxoLCA levels in rats with 
high tumor incidence when they were fed a high safflower oil or corn oil diet.(Reddy 1984) 
While the toxicity of epi-bile acids has not yet been tested relative to the secondary bile acids 
DCA or LCA, both 12-oxoLCA and epiDCA are less hydrophobic than DCA by LC-MS 
(Figures 3.2 & 3.3). Due to the involvement of DCA in cancers of the liver and colon7,8, bile 
acid 12β-HSDH may be of therapeutic importance in modulating the bile acid pool in favor of 
epiDCA over toxic DCA. Future studies with animal models will be imperative to determine the 




MATERIALS AND METHODS 
Bacterial strains and chemicals 
Clostridium paraputrificum ATCC 25780 and Clostridium scindens ATCC 35704 were 
obtained from 80°C glycerol stocks from culture collections at the University of Illinois Urbana-
Champaign (UIUC). E. coli DH5α (Turbo) competent cells from New England Biolabs (Ipswich, 
MA) and NovaBlue GigaSingles™ Competent cells from Novagen (San Diego, CA, USA) were 
used for cloning, and E. coli BL21-Codon-Plus (DE3) RIPL was purchased from Stratagene (La 
Jolla, CA, USA) and used for protein overexpression. 5β-Cholanic acid-3α, 7α, 12α-triol (CA), 
5β-cholanic acid-3α,12α-diol (DCA), and 5β-cholanic acid-3α,7α-diol (CDCA) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Authentic 5β-cholanic acid-3α,12β-diol (epiDCA) 
and 5β-cholanic acid-3α,7α,12β-diol (epiCA) were generously obtained from Lee R. Hagey 
(University of California, San Diego). Other bile acids were purchased from Steraloids 
(Newport, RI, USA). All other reagents were of the highest possible purity and purchased from 
Fisher Scientific (Pittsburgh, PA, USA). 
 
Whole cell bile acid conversion assay 
C. paraputrificum ATCC 25780 and C. scindens ATCC 35704 were cultivated in 
anaerobic brain heart infusion (BHI) broth for 24 hrs. Two mL anaerobic BHI was inoculated 
with 1:10 dilution of either organism along with 50 μM bile acid substrate and incubated at 37°C 
for 24 hours. The bacterial cultures were centrifuged at 10,000 ⨉ g for 5 min to remove bacterial 
cells and the conditioned medium was adjusted to pH 3.0. Solid phase extraction was used to 
extract bile acid products from bacterial culture. Waters tC18 vacuum cartridges (3 cc) (Milford, 
MA, USA) were preconditioned with 6 mL 100% hexanes, 3 mL 100% acetone, 6 mL 100% 
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methanol, and 6 mL water (pH 3.0). The conditioned medium was added to the cartridges and 
vacuum was applied to pull media through dropwise. Cartridges were washed with 6 mL water 
(pH 3.0) and 40% methanol. Bile acid products were eluted with 3 mL 100% methanol. Eluates 
were then evaporated under nitrogen gas and the residues dissolved in 200 μL 100% methanol 
for LC-MS analysis. 
 
Liquid chromatography-mass spectrometry 
LC-MS analysis for all samples was performed using a Waters Acquity UPLC system 
coupled to a Waters SYNAPT G2-Si ESI mass spectrometer (Milford, MA, USA). LC was 
performed with a Waters Acquity UPLC HSS T3 C18 column (1.8 m particle size, 2.1 mm x 
100 mm) at a column temperature of 40°C. Samples were injected at 1 L. Mobile phase A was 
water and B was acetonitrile. The mobile phase gradient was as follows: 0 min 100% mobile 
phase A, 0.5 min 100% A, 25 min 0% A, 25.1 min 100% A, 28 min 100% A. The flow rate was 
0.5 mL/min. MS was carried out in negative ion mode with a desolvation temperature of 300°C 
and desolvation gas flow of 700 L/hr. The capillary voltage was 3,000 V. Source temperature 
was 100°C and cone voltage was 30 V. Chromatographs and mass spectrometry data were 
analyzed using Waters MassLynx software (Milford, MA, USA). 
 
Isolation of genomic DNA  
Genomic DNA was extracted from C. paraputrificum ATCC 25780 using the Fast DNA 
isolation kit from Mo-Bio (Carlsbad, CA, USA) according to the manufacturer's protocol for 




Heterologous expression of potential 12β-HSDH proteins 
The pET-28a(+) and pET-46 Ek/LIC vectors were obtained from Novagen (San Diego, 
CA, USA). Restriction enzymes were purchased from NEB (Ipswich, MA, USA). Inserts were 
generated by PCR amplification with cloning primers from Integrative DNA Technologies 
(Coralville, IA, USA) of C. paraputrificum ATCC 25780 genomic DNA or genes synthesized in 
E. coli K12 codon usage (IDT, Coralville, IA, USA). Cloning primers and genes created by gene 
synthesis are listed in Supplementary Table 3.1. Inserts were amplified using the Phusion High 
Fidelity Polymerase (Stratagene, La Jolla, CA, USA) and cloned into pET-28a(+) after insert and 
vector were double digested with the appropriate restriction endonuclease and treated with DNA 
Ligase, or annealed into pET-46 Ek/LIC after treatment with T4 DNA Polymerase. Recombinant 
plasmids were transformed via heat shock method, plated, and grown overnight at 37°C on 
lysogeny broth (LB) agar plates supplemented with antibiotic (50 µg/mL kanamycin or 100 
µg/mL ampicillin). Vectors were either transformed into chemically competent E. coli DH5α 
cells and grown with kanamycin (pET-28a(+)) or transformed into NovaBlue GigaSingles™ 
Competent cells and grown with ampicillin (pET-46 Ek/LIC). A single colony from each 
transformation was inoculated into LB medium (5 mL) containing the corresponding antibiotic 
and grown to saturation. Recombinant plasmids were extracted from cell pellets using the 
QIAprep Spin Miniprep kit (Qiagen, Valencia, CA, USA). The sequence of the inserts was 
confirmed by Sanger sequencing (W. M. Keck Center for Comparative and Functional Genomics 
at the University of Illinois at Urbana-Champaign). 
For protein expression, the extracted recombinant plasmids were transformed into E. coli 
BL-21 CodonPlus (DE3) RIPL chemically competent cells by heat shock method and cultured 
overnight at 37°C on LB agar plates supplemented with ampicillin or kanamycin (100 µg/ml; 50 
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µg/mL) and chloramphenicol (50 µg/ml). Selected colonies were inoculated into 10 mL of LB 
medium supplemented with antibiotics and grown at 37°C for 6 hours with vigorous aeration. 
The pre-cultures were added to fresh LB medium (1 L), supplemented with antibiotics, and 
aerated at 37°C until reaching an OD600nm of 0.3. IPTG was added to each culture at a final 
concentration of 0.1 mM to induce and the temperature was decreased to 16°C for a 16-hour 
incubation. Cells were pelleted and resuspended in binding buffer (20 mM Tris-HCl, 300 mM 
NaCl, 10 mM 2-mercaptoethanol, pH 7.9). The cells were subjected to five passages through an 
EmulsiFlex C-3 cell homogenizer (Avestin, Ottawa, Canada), and the cell debris was separated 
by centrifugation. 
The recombinant protein in the soluble fraction was then purified using TALON® Metal 
Affinity Resin (Clontech Laboratories, Mountain View, CA, USA) per the manufacturer’s 
protocol. The recombinant protein was eluted using an elution buffer composed of 20 mM Tris-
HCl, 300 mM NaCl, 10 mM 2-mercaptoethanol, and 250 mM imidazole at pH 7.9. The resulting 
purified protein was analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). The observed subunit mass for each was calculated by migration distance of 
purified protein to standard proteins in ImageJ (https://imagej.nih.gov/ij/docs/faqs.html). 
TMHMM v. 2.0 was used to predict transmembrane helices.22 
 
Enzyme Assays 
Pure recombinant 12β-HSDH reaction mixtures were made using 50 μM substrate, 150 
μM cofactor and 10 nM enzyme in 150 mM NaCl, 50 mM sodium phosphate buffer at the pH 
optima 7.0 or 7.5. Reactions were monitored by spectrophotometric assay measuring the 
oxidation or reduction of NADP(H) aerobically at 340 nm (6,220 M-1.cm-1) continuously for 1.5 
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min on a NanoDrop 2000c UV-Vis spectrophotometer (Fisher Scientific, Pittsburgh, PA, USA) 
using a 10 mm quartz cuvette (Starna Cells, Atascadera, CA, USA). Additional reactions were 
incubated overnight at room temperature and extracted by vortexing with two volumes ethyl 
acetate twice. The organic layer was recovered and evaporated under nitrogen gas. The products 
were dissolved in 50 μL methanol and LC-MS was performed as described above or used for 
thin layer chromatography. 
The buffers for investigation of the optimal pH of recombinant 12β-HSDH contained 150 
mM NaCl and one of the following buffering agents: 50 mM sodium acetate (pH 6.0), 50 mM 
sodium phosphate (pH 6.5 to 7.5), and 50 mM Tris-Cl (pH 8.0). Substrate specificity was 
performed according to the above reaction conditions at the optimal pH. 
The reaction mixtures for kinetic analysis were 10 nM enzyme, sodium phosphate buffer 
(pH 7.0), and 150 µM NADPH for varying concentrations of 12-oxoLCA or 80 µM 12-oxoLCA 
for varying NADPH concentrations in the reductive direction. The oxidative reaction mixture 
contained 10 nM enzyme, sodium phosphate buffer (pH 7.5), and 300 µM NADP+ when epiDCA 
concentrations were changed or 100 µM epiDCA when NADP+ was varied. Kinetic parameters 
were estimated with GraphPad Prism (GraphPad Prism, La Jolla, CA, USA) to fit the data using 
nonlinear regression to the Michaelis-Menten equation. 
 
Thin layer chromatography 
Reaction mixtures were made using 50 μM substrate, 150 μM cofactor and 10 nM 
enzyme in 150 mM NaCl, 50 mM sodium phosphate buffer at pH 7.0. Reactions were incubated 
overnight at room temperature and extracted by vortexing with two volumes ethyl acetate twice. 
The organic layer was recovered and evaporated under nitrogen gas. The products were 
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dissolved in 50 μL methanol and spotted on a TLC plate (silica gel IB2-F flexible TLC sheet, 20 
x 20 cm, 250 μm analytical layer; J. T. Baker, Avantor Performance Materials, LLC, PA, USA). 
The steroids were separated with a 70:20:2 toluene–1,4-dioxane–acetic acid mobile phase and 
visualized using a 10% phosphomolybdic acid in ethanol spray and heating for 15 min at 
100°C.79 
 
Native molecular weight determination 
Size-exclusion chromatography was performed using a Superose 6 10/300 GL analytical 
column (GE Healthcare, Piscataway, NJ, USA) connected to an ÄKTAxpress chromatography 
system (GE Healthcare, Piscataway, NJ, USA) at 4°C. The column was equilibrated with 50 mM 
Tris-Cl and 150 mM NaCl at a pH of 7.5. The purified protein was loaded onto the analytical 
column at a concentration of 10 mg/mL and eluted at a flow rate of 0.3 ml/min. The native 
molecular mass of 12β-HSDH was determined by comparing its elution volume to that of Gel 
Filtration Standard proteins (Bio-Rad, Hercules, CA, USA): thyroglobulin, γ-globulin, 
ovalbumin, myoglobin, vitamin B12. 
 
Phylogenetic Analysis 
The sequence of the C. paraputrificum 12β-HSDH protein (accession number 
WP_027099077.1) was used as query for a similarity search against the NCBI non-redundant 
protein database by BLASTP80, with a maximum E-value threshold of 1e-10 and a limit of 5,000 
results. Retrieved sequences were aligned with Muscle v. 3.8.155181 and analyzed by maximum 
likelihood with RAxML v. 8.2.11.82 Selection of the best-fitting amino acid substitution model 
and number of bootstrap pseudoreplicates were performed automatically, and substitution rate 
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heterogeneity was modeled with gamma distributed rate categories. The resulting phylogenetic 
tree was formatted by Dendroscope v. 3.5.1083 and further cosmetic modifications were 
performed with the vector editor Inkscape, v. 0.92.4 (https://inkscape.org). 
For closer analysis of the phylogenetic affiliation of C. paraputrificum ATCC 25780 12β-
HSDH, sequences from the well-supported subtree where this sequence is located in the 5,000-
sequence tree, plus an outgroup, were reanalyzed for confirming the relative placement of all 
sequences nearest to Cp12β-HSDH. The methods used were the same as described above for the 
full tree. 
A maximum-likelihood tree of representative HSDH sequences was inferred by selecting 
sequences from each HSDH subfamily, based on the tree from Mythen et al. (2018)15, with the 
addition of eukaryotic, archaeal, and other bacterial sequences deposited in the public databases. 
Phylogenetic inference methods were the same as described above. 
 
Hidden Markov Model Search 
A Hidden Markov Model (HMM) search was performed using a custom HMM profile 
against a concatenated file of metagenome assembled genomes (MAGs) from four publicly 
available cohorts.30–33 MAGs were filtered for genome completeness, quality, and contamination 
as described.84 For generation of the custom 12β-HSDH profile, reference sequences from the 
12β-HSDHs characterized in this paper were aligned with MAFFT, manually trimmed, and 
constructed using hmmscan.85 The MAG database was searched using HMMSearch version 
3.3.085, using an individually identified cut-off of 350.00. Resulting hits were then filtered to 
remove results less than 70% completeness and closest matched species were recorded. The 
127 
 




We gratefully acknowledge support to J.M.R. for this work by the National Cancer 
Institute grant 1RO1 CA204808-01, as well as USDA Hatch ILLU-538-916 and Illinois Campus 
Research Board RB18068. H.L.D. is supported by the David H. and Norraine A. Baker Graduate 
Fellowship in Animal Sciences. We would like to express our very great appreciation to Dr. Lee 







Figure 3.1. A gene encoding 12β-HSDH completes the gut microbial epi-bile acid pathway. 
Cholic acid (CA) is converted to the oxo-intermediate, 7-oxodeoxycholic acid (7-oxoDCA), and 
further to ursoCA through the urso-bile acid pathway catalyzed by NAD(P)-dependent 7α- and 
7β-HSDH. The secondary bile acid deoxycholic acid (DCA) is formed through the multi-step 7α-
dehydroxylation of CA. DCA is biotransformed to 3-oxoDCA by 3α-HSDH and to isoDCA by 
3β-HSDH in the iso-bile acid pathway. DCA can be converted to 12-oxolithocholic acid (12-
oxoLCA) by 12α-HSDH and from 12-oxoLCA to epiDCA by 12β-HSDH. Examples of bacteria 
expressing each HSDH are shown below the reaction followed by corresponding gene 





Figure 3.2. Clostridium paraputrificum ATCC 25780 expresses 12β-HSDH while C. scindens 
ATCC 35704 expresses 12α-HSDH by whole-cell LC-MS. (A) Representative negative ion 
mode LC-MS chromatograms in single ion monitoring mode overlaid with linked vertical axes 
of C. paraputrificum reaction products from 50 M substrate compared to deoxycholic acid 
(DCA), 12-oxolithocholic acid (12-oxoLCA) and epiDCA standards. (B) As a control, 
representative negative ion mode LC-MS chromatograms in single ion monitoring mode overlaid 
with linked vertical axes of C. scindens products from 50 M substrate was used to demonstrate 
12α-HSDH activity. Standards are shown in A and B for ease of comparison to products.  
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Figure 3.2 (cont.) 
Formula weight for DCA is 392.57 atomic mass units (amu), 12-oxoLCA is 390.56 amu, 




Figure 3.3. Identification of a gene encoding 12β-HSDH. (A) SDS-PAGE of candidate 
Clostridium paraputrificum 12β-HSDH proteins that were heterologously expressed in E. coli 
and purified with TALON® metal affinity resin. Lanes are as follows: S, molecular weight 
protein standard; 077, WP_027099077.1; 355, WP_027098355.1; 937, WP_027097937.1; 604, 
WP_027098604.1; 909, WP_027096909.1; 631, WP_027099631.1. (B) Representative negative 
ion mode LC-MS chromatograms in single ion monitoring mode overlaid with linked vertical 
axes of WP_027099077.1 reaction products compared to deoxycholic acid (DCA), 12-
oxolithocholic acid (12-oxoLCA) and epiDCA standards. Standards were run on a separate day 
and show a slight offset in elution time. Reactions consisted of 10 nM WP_027099077.1 with 50 
M (or no) substrate, 150 M pyridine nucleotide in 50 mM sodium phosphate, 150 mM sodium 
chloride buffer at pH 7.0. Formula weight for DCA is 392.57 atomic mass units (amu), 12-





Figure 3.4. Biochemical characterization of recombinant C. paraputrificum 12β-HSDH. (A) 
Native molecular size analysis of 10 mg/mL purified 12β-HSDH via size-exclusion 
chromatography. (B) Effect of pH on 12β-HSDH activity. The reaction in the reductive direction 
(blue) consisted of 12-oxoLCA as substrate with NADPH as cofactor. The oxidative reaction 





Figure 3.5. Maximum-likelihood tree based on a subset of the taxa present in the full 
phylogenetic analysis of 12β-HSDH and SDS-PAGE of proteins explored further. Sequences 
selected for this analysis were those nearest to the C. paraputrificum 12β-HSDH (highlighted), 
plus an outgroup. For the full tree with about 5,000 sequences, see Supplementary Figure 3.2. 
Taxonomic affiliations are indicated by branch colors as specified in the legend. Bolded 
sequences were chosen for further study. Asterisks indicate novel C-12 epimerizing organisms. 
(Inset) SDS-PAGE of purified recombinant Eisenbergiella WP_118677302.1, Olsenella 
WP_120179297.1, and Novosphingobium WP_007678535.1 heterologously expressed in E. coli 





Figure 3.6. 12β-HSDH Hidden-Markov Model search. (A) Number of subjects identified with 
putative 12β-HSDH genes present in their gut metagenomes. The metagenomes analyzed were 
from 4 distinct cohorts. (B) Distribution of microbial genomes with putative 12β-HSDH genes 





Figure 3.7. Maximum-likelihood phylogenetic analysis of regio- and stereospecific HSDHs. 
Clusters are shaded by function or marked as eukaryotic, as displayed in the legend. Sequences 
with experimentally determined activities are labeled with their function followed by organism 







Table 3.1. Steady-state kinetic parameters of purified recombinant 12β-HSDH. 
  Substrate or cofactora 
Enzyme Kinetic parameter 12-oxoLCAb NADPH epiDCA NADP+ 
Cp12β-HSDH Km (µM) 18.76 ± 0.40
c 29.16 ± 0.42 44.43 ± 1.13 36.84 ± 0.55 
 kcat (s
-1) 26.62 ± 1.62 28.15 ± 1.74 59.32 ± 5.47 44.61 ± 3.77 
 Vmax (µmol • min
-1 • mg-1) 58.41 ± 3.56 61.75 ± 3.82 130.13 ± 12.01 97.87 ± 8.27 
 kcat/Km (µM
-1 • s-1) 1.42 ± 0.11 0.97 ± 0.07 1.34 ± 0.15 1.21 ± 0.12 
aAssays were performed at saturating concentrations of components not being tested (refer to Materials and Methods). 
b12-oxolithocholic acid (12-oxoLCA), epideoxycholic acid (epiDCA). 




Table 3.2. Substrate and pyridine nucleotide specificity of purified recombinant C. 
paraputrificum 12β-HSDH, Eisenbergiella WP_118677302.1, Olsenella WP_120179297.1, 
and Novosphingobium WP_007678535.1. 
Enzyme Substratea,b Cofactor 
Activity 
(µmol·min-1·mg-1) Relative activity (%) 
Cp12β-HSDH 
12-oxoLCA NADPH 18.26 ± 1.01c 100 
12-oxoLCA NADH -d - 
12-oxoCDCA NADPH 2.21 ± 0.82 12.08 
3,12-dioxoLCA NADPH 3.49 ± 0.34 19.09 
WP_118677302.1 12-oxoLCA NADPH 16.04 ± 1.23 87.85 
WP_120179297.1 12-oxoLCA NADPH 23.29 ± 2.57 127.57 
WP_007678535.1 12-oxoLCA NADPH - - 
Cp12β-HSDH 
epiDCA NADP+ 33.42 ± 0.81 100 
epiDCA NAD+ - - 
epiCA NADP+ 8.99 ± 0.90 26.88 
DCA NADP+ - - 
CA NADP+ - - 
CDCA NADP+ - - 
WP_118677302.1 epiDCA NADP+ 27.85 ± 1.12 83.32 
WP_120179297.1 epiDCA NADP+ 23.02 ± 2.57 68.86 
WP_007678535.1 epiDCA NADP+ - - 
a12-oxolithocholic acid (12-oxoLCA), 12-oxochenodeoxycholic acid (12-oxoCDCA), deoxycholic acid (DCA), cholic acid (CA). 
bAssays were performed with 10 nM enzyme, 50 uM substrate and 150 uM cofactor at optimum pH. 
cValues represent the mean ± SD of three or more replicates. 






 Supplementary Figure 3.1. Kinetic analysis of Cp12β-HSDH activity. Michaelis-Menten and 
Lineweaver-Burk plots of initial enzyme velocity with varying concentration of substrate (top 
panels) and cofactor (bottom panels) in both the reductive (left panels) and oxidative (right 
panels) directions. See Materials and Methods for enzyme reactions. Oxidation/reduction of 
NAD(H) was measured by continuous spectrophotometry at 340 nm for 1.5 min and the initial 
velocities were used to calculate kinetic constants (Table 1). Each point represents the mean ± 
SD of three or more replicates.  
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 Supplementary Figure 3.2. 12β-HSDH 5,000-member tree. Maximum likelihood phylogeny 
for the five thousand sequences from the NR database that are most similar to C. paraputrificum 
12β-HSDH (WP_027099077.1). Taxonomic affiliations are indicated by branch colors as 
specified in the legend. The region highlighted in gray shows the sequences that were reanalyzed 





Supplementary Figure 3.3. Genomic context of 12β-HSDH genes from Clostridium 
paraputrificum ATCC 25780, Eisenbergiella sp. OF01-20, and Olsenella sp. GAM18. 







Supplementary Table 3.1. Cloning primers for putative 12β-HSDHs and synthesized genes. 
Gene ID 










pET-28a(+) 27.35 31,775 
ATATATCTCGAGTTAAGGAGCTATTGAGTATCCACCATCC (5’-Reverse 
Primer-3’) 











pET-28a(+) 26.26 14,565 
ATATATCTCGAGTTAAATATACCCTCCATCCACTCTAAGTATCTG 













pET-28a(+) 34.68 31,650 
ATATATCTCGAGTTAAGGAAGTGTATTTCCTGCTGCCTTA 




pET-28a(+) 32.86 34,060 
ATATATCTCGAGTTAGCTATCTACCATAGTTCCACCATTAACA 




































     
142 
 


















aDeduced recombinant protein molecular weight. 




Supplementary Table 3.2. Sequences used in HSDH phylogenetic analysis. 
Accession No. Function Organism Reference 
WP_027099077.1 12β-HSDH Clostridium paraputrificum ATCC 
25780 
Current study 
WP_007678535.1 putative 12β-HSDH Novoshingobium sp. AP12 Current study 
WP_120179297.1 12β-HSDH Olsenella sp. GAM18 Current study 
WP_009140706.1 putative 12β-HSDH Collinsella tanakaei Current study 
WP_117888595.1 putative 12β-HSDH Ruminococcus sp. AF14-10 Current study 
WP_005612898.1 putative 12β-HSDH Ruminococcus lactaris Current study 
WP_118677302.1 12β-HSDH Eisenbergiella sp. OF01-20 Current study 
EDS06338.1 12α-HSDH  Clostridium scindens ATCC 35704  Doden Appl. Environ. Microbiol. 2018  
EEG75500.1 12α-HSDH  Clostridium hylemonae DSM 15053  Doden Appl. Environ. Microbiol. 2018 
EEA85268.1 12α-HSDH  Peptacetobacter hiranonis/Clostridium 
hiranonis DSM 13275 
Doden Appl. Environ. Microbiol. 2018 
CDD59475.1 12α-HSDH  Eggerthella sp. CAG:298  Mythen Appl. Environ. Microbiol. 2018 
ERJ00208.1 12α-HSDH  Clostridium sp. strain ATCC 29733  Macdonald J. Lipid Res. 1979; Aigner 
US patent 2011  
WP_096515955.1 putative 12α-HSDH Clostridium perfringens Doden Appl. Environ. Microbiol. 2018 
WP_011406312.1 putative 12α-HSDH Methanosphaera stadtmanae DSM 
3091 
Kisiela J. Steroid Biochem. Mol. Biol. 
2012 
ABQ87936.1 putative 12α-HSDH Methanobrevibacter smithii ATCC 
35061 
Kisiela J. Steroid Biochem. Mol. Biol.  
2012 
EBA39192.1 putative 12α-HSDH  Collinsella aerofaciens ATCC 25986  Kisiela J. Steroid Biochem. Mol. Biol. 
2012 
WP_006235414.1 putative 12α-HSDH  Collinsella aerofaciens ATCC 25986  Kisiela J. Steroid Biochem. Mol. Biol. 
2012 
EEG90138.1 putative 12α-HSDH  Coprococcus comes ATCC 27758  Kisiela J. Ster. Biochem. Mol. Biol. 2012 
CDD59474.1 3α-HSDH Eggerthella sp. CAG:298  Mythen Appl. Environ. Microbiol.  2018 
ACV54671.1/ 
WP_009306474.1 
3α-HSDH  Eggerthella lenta DSM 2243  Devlin Nat. Chem. Biol. 2015 
EDN77529.1 3α-HSDH  Ruminococcus gnavus ATCC 29149  Devlin Nat. Chem. Biol.2015 
P19337.1 3α-HSDH  Clostridium scindens ATCC 35704  Mallonee Curr. Microbiol. 1995; 
Bhowmik Proteins 2014  
ACF20977.1 3α-HSDH  Clostridium hylemonae DSM 15053  Ridlon Anaerobe 2010  
EEA86309.1 3α-HSDH  Clostridium hiranonis DSM 13275  Wells Appl. Environ. Microbiol. 2000  
EEG48917.1 putative 3α-HSDH  Blautia hydrogenotrophica DSM 10507  Kisiela J. Steroid Biochem. Mol. Biol. 
2012 
EDR48431.1 putative 3α-HSDH  Dorea formicigenerans ATCC 27755  Kisiela J. Steroid Biochem. Mol. Biol. 
2012 
EDK24466.1 putative 3α-HSDH  Ruminococcus torques ATCC 27756  Kisiela J. Steroid Biochem. Mol. Biol. 
2012 
EDM85978.1 putative 3α-HSDH  Ruminococcus obeum ATCC 29174  Kisiela J. Steroid Biochem. Mol. Biol. 
2012 
EDT24590.1 putative 3α-HSDH  Clostridium perfringens B str. ATCC 
3626  
Macdonald Biochim. Biophys. Acta 
1976; Hirano Appl. Environ. Microbiol. 
1981  
CDD59473.1 3β-HSDH  Eggerthella sp. CAG:298  Mythen Appl. Environ. Microbiol. 2018  
ACV55294.1 3β-HSDH Eggerthella lenta DSM 2243  Devlin Nat. Chem. Biol. 2015 
ACV54192.1 3β-HSDH Eggerthella lenta DSM 2243  Devlin Nat. Chem. Biol. 2015 
EDN78833.1 3β-HSDH Ruminococcus gnavus ATCC 29149  Devlin Nat. Chem. Biol. 2015 
BAA01384.1 7α-HSDH  Escherichia coli  Yoshimoto J. Bacteriol. 1991  
AAA53556.1 7α-HSDH  Clostridium sordellii ATCC 9714  Coleman J. Bacteriol. 1994  
AAB61151.1 7α-HSDH  Clostridium scindens VPI 12708  Baron J. Bacteriol. 1991 
WP_005792012.1 3-oxoacyl-[acyl-carrier-
protein] reductase 
Bacteroides fragilis ATCC 25285 Doden Appl. Environ. Microbiol. 2018 
WP_006440226.1 putative 7α-HSDH  Clostridium hiranonis DSM 
13275/Peptacetobacter hiranonis  
Kisiela J. Steroid Biochem. Mol. Biol. 
2012 
WP_007751324.1 putative 7α-HSDH  Bacteroides finegoldii DSM 17565  Kisiela J. Steroid Biochem. Mol. Biol. 
2012 
WP_011860631.1 putative 7α-HSDH  Clostridioides difficile 630  Kisiela J. Steroid Biochem. Mol. Biol. 
2012 
NP_810824.1 putative 7α-HSDH  Bacteroides thetaiotaomicron VPI-5482  Ferrandi Appl. Microbiol. Biotechnol. 
2012; Kisiela J. Steroid Biochem. Mol. 
Biol. 2012; Sherrod Biochim. Biophys. 
Acta 1977  
WP_006236005.1 7β-HSDH Collinsella aerofaciens ATCC 25986  Liu Appl. Microbiol. Biotechnol. 2011  
WP_004843516.1 7β-HSDH Ruminococcus gnavus ATCC 29149  Lee J. Lipid Res. 2013  
AET80684.1 7β-HSDH Clostridium absonum/Clostridium 
sardiniense  




Supplementary Table 3.2 (cont.) 
EDS07887.1 20α-HSDH Clostridium scindens ATCC35704 Ridlon J. Lipid Res. 2013 
WP_107631222.1 putative 20α-HSDH Intestinibacillus sp. Marseille-P4005 Current study 
WP_145772380.1 putative 20α-HSDH Denitratisoma oestradiolicum Current study 
WP_003810233.1 20β-HSDH Bifidobacterium adolescentis L2-32 Doden J. Biol. Chem. 2019 
WP_051643274.1 20β-HSDH Butyricicoccus desmolans ATCC 43058  Devendran J. Lipid Res. 2017  
WP_051196374.1 putative 20β-HSDH Clostridium cadaveris AGR2141  Devendran J. Lipid Res. 2017  
WP_027640050.1 putative 20β-HSDH Clostridium cadaveris AGR2141  Devendran J. Lipid Res. 2017  
BAQ31198.1 putative 20β-HSDH Bifidobacterium scardovii DSM 13734  Devendran J. Lipid Res. 2017  
WP_024111275.1 putative 20β-HSDH Propionimicrobium sp. BV2F7  Devendran J. Lipid Res. 2017  
AMB99905.1 putative 20β-HSDH Aerococcus urinaehominis Devendran J. Lipid Res. 2017 
WP_040693668.1 putative 20β-HSDH Propionimicrobium lymphophilum 
ACS-093-V-SCH5 
Ly J. Steroid Biochem. Mol. Biol. 2020 
WP_073996553.1 putative 20β-HSDH Arcanobacterium urinimassiliense Ly J. Steroid Biochem. Mol. Biol. 2020 
WP_025022266.1 aldo/keto reductase  Lactobacillus hayakitensis  Mythen Appl. Environ. Microbiol. 2018  
KRM19149.1 oxidoreductase  Lactobacillus hayakitensis DSM 18933  Mythen Appl. Environ. Microbiol. 2018  
KRM65245.1 oxidoreductase  Lactobacillus agilis DSM 20509  Mythen Appl. Environ. Microbiol. 2018 
WP_050611824.1 aldo/keto reductase  Lactobacillus agilis  Mythen Appl. Environ. Microbiol. 2018  
WP_019206370.1 aldo/keto reductase  Lactobacillus ingluviei  Mythen Appl. Environ. Microbiol. 2018  
KRL88436.1 organophosphate reductase  Lactobacillus ingluviei DSM 15946  Mythen Appl. Environ. Microbiol. 2018  
ASN60792.1 aldo/keto reductase  Lactobacillus curvatus  Mythen Appl. Environ. Microbiol. 2018  
WP_085844664.1 aldo/keto reductase  Lactobacillus curvatus  Mythen Appl. Environ. Microbiol. 2018  
WP_054778020.1 aldo/keto reductase  Lactobacillus saniviri  Mythen Appl. Environ. Microbiol. 2018  
BAN77682.1 conserved hypothetical protein  Adlercreutzia equolifaciens DSM 19450  Mythen Appl. Environ. Microbiol. 2018  
WP_041715350.1 SDR family oxidoreductase  Adlercreutzia equolifaciens  Mythen Appl. Environ. Microbiol. 2018  
CDD77593.1 putative uncharacterized 
protein  
Cryptobacterium sp. CAG:338  Mythen Appl. Environ. Microbiol. 2018  
CDD68244.1 putative uncharacterized 
protein  
Eggerthella sp. CAG:368  Mythen Appl. Environ. Microbiol. 2018  
CDB33831.1 putative uncharacterized 
protein  
Eggerthella sp. CAG:209  Mythen Appl. Environ. Microbiol. 2018  
CCY06514.1 putative uncharacterized 
protein  
Eggerthella sp. CAG:1427  Mythen Appl. Environ. Microbiol. 2018  
CDD56334.1 putative uncharacterized 
protein  
Bacteroides pectinophilus CAG:437  Mythen Appl. Environ. Microbiol. 2018  
WP_044925038.1 short-chain dehydrogenase Anaerostipes hadrus  Mythen Appl. Environ. Microbiol. 2018 
WP_008116638.1 NAD(P)-dependent 
oxidoreductase  
Bacteroides pectinophilus  Mythen Appl. Environ. Microbiol. 2018 
WP_077326212.1 short-chain dehydrogenase  Anaerostipes hadrus  Mythen Appl. Environ. Microbiol. 2018 
 short-chain dehydrogenase  Clostridiales bacterium Nov_37_41  Mythen Appl. Environ. Microbiol. 2018 
WP_055161728.1 short-chain dehydrogenase  Anaerostipes hadrus  Mythen Appl. Environ. Microbiol. 2018 
WP_055258939.1 short-chain dehydrogenase  Anaerostipes hadrus  Mythen Appl. Environ. Microbiol. 2018 
CCX88977.1 dehydrogenases with different 
specificities  
Clostridium sp. CAG:590  Mythen Appl. Environ. Microbiol. 2018 
WP_009265642.1 short-chain dehydrogenase  Lachnospiraceae bacterium 5_1_63FAA  Mythen Appl. Environ. Microbiol. 2018 
    
AAB41916.1 3α-HSD Homo sapiens Khanna J. Biol. Chem. 1995 
NP_612556.1 3α-HSD Rattus norvegicus Cheng Mol. Endocrinol. 1991 
NP_001315544.1 3β-HSD/Δ5→ Δ4/isomerase 
type 1 
Homo sapiens Thomas J. Steroid Biochem. 1989 
NP_001007720.3 3β-HSD/Δ5→ Δ4/isomerase 
type 1 
Rattus norvegicus de Launoit J. Biol. Chem. 1992 
NP_001159592.1 3β-HSD/Δ5→ Δ4/isomerase 
type 2 
Homo sapiens Rheaume Mol. Endocrinol. 1991 
Q04828.1 AKR1C1 (20α-HSDH) Homo sapiens Zhang J. Mol. Endocrinol. 2000 
NP_001748.1 Carbonyl reductase 1 (20β-
HSDH) 
Homo sapiens Morgan Sci. Rep. 2017 
AAA30980.1 20β-HSDH Sus scrofa Tanaka J. Biol. Chem. 1992 
NP_861420.1 11β-HSD type 1 Homo sapiens Tannin J. Biol. Chem. 1991 
NP_058776.2 11β-HSD type 1 Rattus norvegicus Agarwal J. Biol. Chem. 1989 
NP_000187.3 11β-HSD type 2 Homo sapiens Wilson J. Clin. Endocrinol. Metab. 1995 
NP_000404.2 17β-HSD type 1 Homo sapiens Winqvist Hum. Genet. 1990 
NP_002144.1 17β-HSD type 2 Homo sapiens Labrie DNA Cell Biol. 1995 
AAC50066.1 17β-HSD type 3 Homo sapiens Geissler Nat. Genet. 1994 
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STRUCTURAL AND BIOCHEMICAL CHARACTERIZATION OF 20β-
HYDROXYSTEROID DEHYDROGENASE FROM BIFIDOBACTERIUM 
ADOLESCENTIS STRAIN L2-321 
 
ABSTRACT 
Anaerobic bacteria inhabiting the human gastrointestinal tract have evolved various 
enzymes that modify host-derived steroids. The bacterial steroid-17,20-desmolase pathway 
cleaves the cortisol side chain, forming pro-androgens predicted to impact host physiology. 
Bacterial 20β-hydroxysteroid dehydrogenase (20β-HSDH) regulates cortisol side-chain cleavage 
by reducing the C-20 carboxyl group on cortisol, yielding 20β-dihydrocortisol. Recently, the 
gene encoding 20β-HSDH in Butyricicoccus desmolans ATCC 43058 was reported, and a 
nonredundant protein search yielded a candidate 20β-HSDH gene in Bifidobacterium 
adolescentis strain L2-32. B. adolescentis 20β-HSDH could regulate cortisol side-chain cleavage 
by limiting pro-androgen formation in bacteria such as Clostridium scindens and 21-
dehydroxylation by Eggerthella lenta. Here, the putative B. adolescentis 20β-HSDH was cloned, 
overexpressed, and purified. 20β-HSDH activity was confirmed through whole-cell and pure 
enzymatic assays, and it is specific for cortisol. Next, we solved the structures of recombinant 
20β-HSDH in both the apo- and holo-forms at 2.0–2.2Å resolutions, revealing close overlap 
 
1 Reprinted with permission from Doden HL, Pollet RM, Mythen SM, Wawrzak Z, Devendran S, Cann I, 
Koropatkin NM, Ridlon JM. Structural and biochemical characterization of 20β-hydroxysteroid dehydrogenase from 
Bifidobacterium adolescentis strain L2-32. J Biol Chem. 2019;294(32):12040-12053. © 2019 Doden et al.  
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except for rearrangements near the active site. Interestingly, the structures contain a large, 
flexible N-terminal region that was investigated by gel-filtration chromatography and CD 
spectroscopy. This extended N terminus is important for protein stability because deletions of 
varying lengths caused structural changes and reduced enzymatic activity. A nonconserved 
extended N terminus was also observed in several short-chain dehydrogenase/reductase family 
members. B. adolescentis strains capable of 20β-HSDH activity could alter glucocorticoid 
metabolism in the gut and thereby serve as potential probiotics for the management of androgen-
dependent diseases.  
 
INTRODUCTION 
 Hydroxysteroid dehydrogenases (HSDH) are pyridine nucleotide-dependent enzymes 
classified into three superfamilies, including aldo-keto reductase (AKR), long/medium-chain 
dehydrogenase/reductase (MDR), and short-chain dehydrogenase/ reductase (SDR), which 
interconvert between enol and keto forms of hydroxyl groups on diverse small molecules.1,2 The 
gut microbiome is exposed to a mixture of glucocorticoids and bile acids. Recent investigations 
identified bacterial strains of diverse taxa expressing stereo- and regio-specific HSDHs in the 
SDR and AKR families capable of oxidation and epimerization of bile acid hydroxyl groups at 
C-3, C-7, and C-12.3–5 Cortisol and corticosterone are human steroid hormone glucocorticoids 
that can be metabolized by both host and bacterial enzymes.6 Cortisol is the major glucocorticoid 
in humans and is present in concentrations ranging from 5 to 20 µg/dl throughout the day.7 The 
various bacterial reactions altering steroid structure impact the host by generating potent 
signaling molecules capable of modulating host physiology. 
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Recent attention has been focused on the bacterial steroid- 17,20-desmolase pathway 
(desABCD) converting cortisol to 11β-hydroxyandrostenedione (11β-OHAD) in Clostridium 
scindens and the zinc-dependent MDR family 20α-HSDH (desC), a predicted enzymatic 
regulator of the pathway (Figure 4.1).2,8,9 11β- OHAD is a pro-androgen whose formation by gut 
bacteria10 as well as urinary tract bacteria9 may contribute to castration-resistant prostate cancer11 
and polycystic ovary syndrome12. The bacterial steroid-17,20-desmolase pathway has also been 
reported in Clostridium cadavaris and Butyricicoccus desmolans (formerly Eubacterium 
desmolans) and is associated with NADH-dependent cortisol 20β-HSDH (desE) activity.9,13 
Previous studies also identified strains of Bifidobacterium adolescentis isolated from human and 
rat fecal dilutions expressing cortisol 20β- HSDH activity alone.14 Recently, the gene encoding 
gut bacterial NADH-dependent 20β-HSDH activity was reported in B. desmolans.9 Phylogenetic 
analysis identified numerous Bifidobacterium spp. strains, including strains of B. adolescentis, 
encoding putative cortisol 20β-HSDH.9 
Gut bacterial 20β-HSDH is a member of the SDR family of proteins.9 The SDR family 
constitutes one of the largest protein superfamilies distributed across all three domains of life15, 
comprising functionally diverse members.16 SDR family enzymes include several Enzyme 
Commission (EC) classifications, including lyases and isomerases, along with pyridine 
nucleotide-dependent oxidoreductases, which constitute the majority of enzymes. Currently, in 
Uniprot there are 266,639 SDR entries, and members typically share only ~20–30% amino acid 
residue identity in pairwise comparisons. Most SDR family members are 250–350 amino acids in 
length, with secondary structures consisting of a Rossmann fold domain containing 6–7 β-strands 
flanked by three α-helices.17 Members usually contain a conserved Gly-rich sequence critical in 
NAD(P)(H) binding, as well as a catalytic tetrad composed of Ser, Tyr, Lys, and Asn residues.15 
154 
 
The SDR family enzymes vary in substrate recognition, including sugars, dyes, prostaglandins, 
porphyrins, alcohols, and steroids.16 Consequently, substrate-binding residues are not highly 
conserved. Differentiating HSDHs from other functional classes of SDR family enzymes is 
important for identifying steroid biochemical pathways in gut metagenomes. At present, this task 
is impeded by a lack of primary amino acid sequences for several HSDHs whose activities have 
been reported in bacterial isolates18, but also the need to determine residues important in 
differentiating HSDHs into functional categories (i.e. 7α-HSDH from 7β-HSDH and both from 
20β-HSDH). 
The first SDR family enzyme with HSDH activity crystallized was 3α,20β-HSDH from 
the soil bacterium Streptomyces hydrogenans.19 The 3α,20β-HSDH reversibly oxidizes the 3β-
hydroxyl and 20β-hydroxyl groups of androgens and progestins. The S. hydrogenans 3α,20β-
HSDH shares 31% amino acid sequence identity with the 20β-HSDH from B. adolescentis, 
which does not appear to function as a dual 3β-HSDH.9 Humans express glucocorticoid 20β-
HSDH activity as well via carbonyl reductase 1 (CBR1).20 20β-Dihydrocortisol is detected in the 
urine of patients with Cushing’s disease21 and the plasma of hypertensive individuals22. It is thus 
important to obtain a mechanistic understanding of gut bacterial 20β- HSDH because this 
enzyme is capable of generating 20β-dihydrocortisol and regulating both major microbial side-
chain cleavages of cortisol: steroid-17,20-desmolase activity resulting in pro-androgens6, and 
cortisol 21-dehydroxylation producing 21-deoxycortisol, a hypertensive compound (Figure 
4.1).6,23 By understanding the structure and function of 20β-HSDH, the ability of B. adolescentis 
strain L2-32 to shift glucocorticoid metabolism in the gut may be improved. 20β-HSDH activity 
could reduce formation and absorption of 11β-hydroxyandrogens and 21-deoxycortisol, which 
are implicated in chronic human disease. 
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Herein, we report the structures of NADH-dependent 20β- HSDH from B. adolescentis 
strain L2-32 at 2.2 Å for the apo-form and 2.0 Å for the binary complex with NADH. Through 
site-directed mutagenesis and binding-affinity studies, we have identified residues comprising 
the substrate-binding pocket and propose a catalytic mechanism for NADH-dependent C-20 
reduction. Along, flexible N-terminal domain involved in overall 20β-HSDH stability was 
discovered, having widespread implications for other members of the diverse SDR family.  
 
RESULTS 
B. adolescentis expresses 20β-HSDH activity 
 The 20β-HSDH sequence from B. desmolans ATCC 43058 was used to query the 
nonredundant protein sequences database (BLASTP).9 An annotated SDR family oxidoreductase 
(WP_003810233.1) from B. adolescentis was found with a sequence identity of 59%. This 
protein was selected for further study because it has the potential to be of great pharmaceutical 
interest, as strains of B. adolescentis have potential probiotic function, i.e. capable of conferring 
beneficial effects on the host. 20β-HSDH catalyzes the conversion of cortisol to 20β-
dihydrocortisol in the boxed reaction depicted in Figure 4.1, and to determine whether B. 
adolescentis strain L2-32 possesses 20β- HSDH activity, whole-cell extracts were screened for 
the activity at 48 h. The result, as shown in Figure 4.2, was net conversion of cortisol to 20β-
dihydrocortisol. As controls, B. desmolans ATCC 43058 and C. scindens ATCC 35704 were 
both shown to metabolize cortisol, as well as 20β-dihydrocortisol and 20α-dihydrocortisol, 
respectively. 20α-Dihydrocortisol is not metabolized by B. adolescentis strain L2-32 or B. 
desmolans ATCC 43058, both of which possess desE, a gene previously shown to encode 
NAD(H)-dependent 20β-HSDH in B. desmolans and Bifidobacterium scardovii.9 20β-
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Dihydrocortisol is not a metabolite for C. scindens ATCC 35704, which was previously shown to 
harbor the desC gene, expressing NAD(H)-dependent 20α-HSDH.8 The desAB genes, encoding 
steroid- 17,20-desmolase, are present in both C. scindens ATCC 35704 and B. 
desmolansATCC43058. As expected, net conversions of 20α-dihydrocortisol to 11β-OHAD and 
20β-dihydrocortisol to 11β-OHAD were observed in cultures of C. scindens ATCC 35704 and B. 
desmolans ATCC 43058, respectively. In contrast, B. adolescentis strain L2-32 lacks the desAB 
genes, and incubation with cortisol resulted in net conversion to 20β-dihydrocortisol under 
anaerobic conditions. 
 
Biochemical characterization of recombinant 20β-HSDH 
To determine whether the SDR family oxidoreductase identified in B. adolescentis 
(WP_003810233.1) encodes a 20β- HSDH (DesE), the gene was cloned into the pET-28a(+) 
expression vector. The N-terminal His6-tagged recombinant protein was overexpressed in 
Escherichia coli BL21(DE3)-RIPL and purified via metal-affinity chromatography as a single 
band on SDS-PAGE, and the molecular mass was similar to the theoretical calculated subunit 
molecular mass of 31.7 kDa (Figure 4.3A). The native molecular mass of the recombinant 20β-
HSDH (r20β-HSDH) protein was determined by gel-filtration chromatography with reference to 
protein standards. r20β-HSDH displayed an elution volume of 13.9 ml, corresponding to a 
molecular mass of 130.5 β 2.8 kDa (Figure 4.3B). Thus, the gel filtration data, together with the 
subunit molecular mass determined by SDS-PAGE, suggest that r20β-HSDH forms a 
homotetrameric quaternary structure in solution. A tetrameric structure was also seen in the 
structural data, and the proposed tetramer is shown in Figure 4.5B. The purified r20β-HSDH 
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exhibited a pH optimum of 5.0 in the reductive direction, and in the oxidative direction the 
optimum was pH 5.5 (Figure 4.4A). 
The Michaelis-Menten saturation curve was determined from the primary reaction of 
cortisol reduction performed by r20β-HSDH (Figure 4.4B). The saturation curve was used to 
estimate the kinetic constants that are reported in Table 4.1. The purified r20β-HSDH has a Km 
of 24.07 µM when cortisol is the substrate. The Vmax, kcat, and kcat/Km values for cortisol were 
determined to be 21.08 µmol•min-1•µmg-1, 668.3 min-1, and 27.77 µM-1•min-1, respectively. 
Substrate-specificity studies revealed that cortisol was the primary substrate utilized by 20β-
HSDH (Table 4.2). Hydroxyl groups on rings C and D are important for substrate specificity by 
r20β-HSDH. We observed an ~34% reduction in relative activity with 11-deoxycortisol and an 
~61% reduction in activity with corticosterone, which lacks a 17-hydroxyl group. Reduction of 
the 3-oxo-Δ4 to 3α-, 5β-H (tetrahydrocortisol) results in an ~56% reduction in activity relative to 
cortisol. It was previously determined that recombinant steroid-17,20-desmolase from C. 
scindens ATCC 35704 also showed significant reduction in side-chain cleavage activity with 
tetrahydrocortisol8 but not allotetrahydrocortisol (3α-,5α-H). Consistent with the whole-cell 
conversion data from B. adolescentis strain L2-32 (Figure 4.2A), the oxidative direction with 
20β-dihydrocortisol and NAD+ has only 0.23% of the relative activity compared with cortisol 
and NADH. As expected, 20α- dihydrocortisol did not serve as a substrate, nor did we detect 
formation of 20α-derivatives with purified recombinant r20β-HSDH in the presence of NADH. 






Overall crystallographic structure of 20β-HSDH 
 The apo crystal structure of r20β-HSDH was solved using molecular replacement with 
the structure of an SDR from Mycobacterium marinum (PDB code 3R1I) and refined at a 
resolution of 2.2 Å (Rw = 0.1960 and Rf = 0.2310) (Table 4.3). The tertiary structure contains 
motifs characteristic of the SDR superfamily, including a Rossmann fold consisting of seven 
central β-strands (β3–β2–β1–β4–β5–β6–β7) flanked by six α-helices (Figure 4.5A, left). The 
structure shows two monomers in the asymmetric unit that align with an RMSD of 0.339 Å. The 
largest differences between the monomers are the 2 Å shift in the α4 helix near the β4–α4 loop, 
the length of the β4, β5, and β6 strands, and the α6 helix. These differences are likely due to the 
flexibility of the adjacent loops that could not be modeled in either monomer and may play a role 
in substrate binding. The monomer with the most unambiguous density in this region is shown in 
Figure 4.5A. In addition to the Rossman fold, r20β-HSDH contains a partial α-helical N 
terminus of ~40 residues that extends outward from the core protein structure and interacts with 
other monomers when the protein is in its tetramer formation (Figure 4.5, A, right, and B). 
We attempted to crystallize the ternary complex of NADH and cortisol bound to the 
inactive S181A mutant of r20β-HSDH (Table 4.1 and Supplementary Figure 4.1). Crystals 
diffracted to 2.0 Å (Rw = 0.187 and Rf = 0.238) and show NADH clearly bound in the active site, 
but no density for cortisol is seen (Supplementary Figure 4.2, A and B). These crystals were of 
the C121 space group, with eight monomers in the asymmetric unit (Table 4.3). The monomers 
showed little variation and aligned with RMSD values ranging from 0.14 to 0.24 Å. The largest 
difference between monomers is the helical character of the N-terminal extension anda1Åshift in 
a flexible loop (residues 235–245) close to where cortisol is predicted to bind (Supplementary 
Figure 4.2C). This loop is near the α6helix and was not resolved in the apo structure. The 
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inability to fully resolve this loop in all monomers suggests flexibility when cortisol is not 
bound. 
The NADH was bound within a deep pocket and makes five side-chain and three peptidyl 
backbone hydrogen-bonding or electrostatic interactions (Figure 4.5, B–D). The carboxylic acid 
of Asp-101 is positioned 2.9 Å away from the adenine nucleotide, whereas the carboxylic acid of 
Asp-72 is positioned 2.5 and 2.8 Å from the O2 and O3 hydroxyls of the adenine ribose, 
respectively. The side-chain hydroxyl of Ser-235 is 2.5 Å from the α-phosphate group as well as 
within 3.3 Å of the carboxamide N of the nicotinamide. The Nϵ of Lys-204 coordinates the O2 
and O3 (3.3 and 3.1 Å) of the nicotinamide ribose, and Tyr-200, part of the catalytic tetrad, is 
directed toward the N of the pyridine ring and the adjacent ribose (3.4 and 2.6 Å). Additionally, 
the O3 of the nicotinamide ribose interacts with the peptidic N of Gly-130 (3.5 Å) and peptidic O 
of Asn-128 (2.7 Å), whereas the nicotinamide carboxamide is positioned 2.9 and 3.0 Å from 
Val-233 (Figure 4.5C). van der Waals interactions are seen between NADH and Cys-100, Val-
102, the Asn-128 side chain, Val-131, Thr-179, Gly-231, Ile-237, and Phe-238 (yellow in Figure 
4.5D) and, most notably, Gly-48, -51, and -52, which fall within the Gly-rich region 
characteristic of SDR family enzymes (pink in Figure 4.5D). 
The overall structure and NADH-binding pocket of r20β-HSDH are similar to the 
NADH-bound structure of 3α,20β-HSDH from S. hydrogenans, which is the only structure of an 
SDR enzyme with known 20β-HSDH activity (Supplementary Figure 4.2D). The two 
structures align with an RMSD ~1 Å for 975 atoms. Significant differences are seen in the 
nicotinamide position and the enzyme’s predicted substrate-binding site, especially around the 
20β-HSDH α6-helix, likely allowing for the 3α-HSDH activity seen in the S. hydrogenans 
enzyme (Supplementary Figure 4.2D). Despite these changes, most of the protein–cofactor 
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interactions are conserved. Notable differences are Arg-16 that interacts with the bis-phosphate 
in the 3α,20β-HSDH is replaced by a glycine in our structure. In addition, Thr-187 in 3α,20β-
HSDH is replaced by Ser-235 in our structure and is too far (>3.5 Å) from the cofactor to make a 
meaningful interaction. Except for Arg-16 in 3α,20β-HSDH, the Gly-rich region characteristic of 
SDR enzymes provides a similar docking site for the adenine side of NADH (GAAGGLG in 
20β-HSDH and GGARGLG in 3α,20β-HSDH), and the catalytic tetrad is completely conserved 
(Supplementary Figure 4.2D). 
Although the apo structure aligns well with the NADH-bound form (RMSD 0.49–0.56 Å 
across the NADH-bound monomers), significant rearrangements occur near the active site to 
accommodate NADH binding (Supplementary Figure 4.2E). The β3 to α3 loop shifts up to 1.4 
Å, allowing Asp-101 to interact with the adenine ring. Most striking is the loss of the discrete 
secondary structure toward the end of β4 and β5 allowing the nicotinamide ribose to sit in the 
space occupied by the 5th β-sheet in the apo structure. Along with the shortening of β4 and β5, 
the α4 and α5 helices shift ~2 and 3 Å, respectively. Movement of α5 allows a 3.8 Å shift of Tyr-
200, which then interacts with the nicotinamide and the adjacent ribose. Neither the loops 
between β4 and α4 nor between β5 and α5 were resolved in the apo structure; however, these 
loops were well-defined in the NADH-bound structure and may help form the binding site for 
cortisol. Most significantly, the shortening of β4 allows the loop connecting to α5 to swing 
toward the α6 helix and C terminus of the protein. This movement elongates the binding cleft 






Catalytic residues and predicted binding of NADH and cortisol 
The conserved catalytic tetrad (NSYK), characteristic of the SDR superfamily, is 
conserved in 20β-HSDH (green in Supplementary Figure 4.3). Mutation of the putative 
catalytic serine (Ser-181) and tyrosine (Tyr-200) to an alanine completely abolished activity 
based on both spectrophotometric assay and TLC separation of overnight reaction products 
(Table 4.1 and Supplementary Figure 4.1A). Wildtype (WT) r20β-HSDH was incubated with 
cortisol, forming 20β-dihydrocortisol. 11β-OHAD showed no observable conversion, confirming 
B. adolescentis 20β-HSDH does not have 3α-HSDH activity (Supplementary Figure 4.1A). To 
determine whether cortisol binds to the S181A mutant, we performed isothermal titration 
calorimetry (ITC) in the presence of NADH (2 mM) or a combination of NADH + cortisol 
(1mM) (Supplementary Figure 4.1B). NADH bound tightly, with a Kd of 28.97 µM. However, 
cortisol was shown to bind with much less affinity, suggesting that Ser-181 is important for 
cortisol binding and explaining the absence of cortisol binding in attempts to obtain the ternary 
complex. The S183A mutant retained 56% activity relative to the WT. The Y200A mutant 
showed no activity, and ITC experiments with 2 mM NADH suggest loss of binding, confirming 
the importance of Tyr-200 in hydrogen bonding to the nicotinamide nitrogen. Comparison of 
circular dichroism (CD) spectra between WT and 20β-HSDH mutants indicate these alanine 
substitutions did not significantly affect secondary structural elements (Supplementary Figure 
4.1C).  
 
Extended N terminus is important for secondary and quaternary structures 
In both the apo and holo structures of r20_-HSDH, we were not able to fully resolve the 
N terminus (Figure 4.5A, right). In the most complete monomers found in the NADH-bound 
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structure, there was no electron density for the first 10 residues, suggesting a flexible N terminus. 
Other SDR family proteins whose structures have been solved, and which contain a large, 
extended N-terminal region, include a quinuclidinone reductase (RrQR) from Rhodotorula 
rubra24 and an S-specific carbonyl reductase from Candida parapsilosis25. There was no electron 
density for the first six amino acid residues of RrQR, indicating a flexible region. An extended 
structure was observed from residues 7–19 and observed hydrophobic stacking between Pro-10 
and Tyr-229 of the protomer indicating possible quaternary stability.24 The S-specific carbonyl 
reductase from C. parapsilosis is another example of a pyridine nucleotide-dependent SDR 
member that contains an extended N-terminal peptide. Comparison between WT and the N-
terminally truncated mutant form (Asp-31) showed no observable change in catalytic activity, 
and only a marginal decrease in tetrameric stability in the truncated form.25 To assess the 
magnitude of the extended N-terminal abundance throughout the SDR family, a representative 
full-sequence alignment was produced (Supplementary Figure 4.4). The B. adolescentis 20β-
HSDH sequence and 555 sequences annotated as SDR family with predicted HSDH function and 
bacterial in origin were obtained from the UniProt database. Within these predicted bacterial 
HSDHs, about 10% (39/556) have an extended N terminus of greater than or equal to 10 amino 
acid residues. The extended N-terminal regions were not conserved throughout the alignment. 
Based on this subset of SDR sequences along with the functionally different quinuclidinone 
reductase and carbonyl reductase, a significant portion of SDR family members likely have an 
extended N terminus. 
The functional role, if any, of this N-terminal region of 20β- HSDH and the nearest 
homologs are understudied. We generated the N-terminal truncations of varying lengths (r20β- 
HSDHΔ1–17, r20β-HSDHΔ1–21, and r20β-HSDHΔ1–38) to determine the effect of truncation on 
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oligomerization, monomeric secondary structure, and enzymatic activity. The locations of these 
truncations are indicated on the structure in Figure 4.5A, right, although there is no density for 
any residues before 17 in the structure. The purified r20β-HSDH and mutants were separated by 
gel-filtration chromatography, resulting in a calculated mass of 130.5 ± 2.8 kDa (subunit 31.69 
kDa) for r20β-HSDH–WT, 123.2 ± 5.8 (subunit 29.9 kDa) for r20β-HSDHΔ1–17, 95.1 ± 8.6 
(subunit 29.4 kDa) for r20β-HSDHΔ1–21, and 43.4 ± 5.4 (subunit 28.7 kDa) for r20β-HSDHΔ1–38 
(Supplementary Figure 4.5). r20β-HSDHβ1–17 is predicted to be tetrameric much like r20β-
HSDH–WT, which was supported by the crystal structure (Figure 4.5B). However, r20β-
HSDHΔ1–21 and r20β- HSDHΔ1–38 were estimated to be trimeric and a mix of dimeric or 
monomeric forms, respectively. 
We next determined the effect of extended N-terminal truncation on enzyme activity and 
thermal stability. Enzymatic activities of truncated derivatives were compared relative to the WT 
(Figure 4.6A). r20β-HSDHΔ1–17 retained 62% activity when cortisol was the substrate and 
NADH co-substrate relative to r20β-HSDH–WT. Temperature-dependent CD of r20β-HSDHΔ1–
17 resulted in a transition temperature (ΔTm) of 55.70 ± 0.099 °C (Figure 4.6B). r20β-HSDHΔ1–21 
retained only 2.9% activity relative to r20β-HSDH–WT with a ΔTm of 54.7 ± 0.052 °C. r20β-
HSDHΔ1–38 lost complete enzyme activity, and the CD of r20β-HSDH–WT versus r20β-
HSDHΔ1–38 resulted in a shift in transition temperature from 56.16 ± 0.10 to 43.3 ± 0.11 °C. 
These results indicate an important role of the 38-residue extended N terminus in protein stability 
as deletion of the first 21 residues effectively abolished enzyme activity with a 1.45 °C shift in 
Tm. 
CD in the far-UV region was performed to assess the impact of N-terminal truncation on 
secondary protein structure (Figure 4.6, C and D). CD spectra were analyzed using DichroWeb, 
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producing relative composition of α-helices, β-sheets, β-turns, and unordered regions. The 
relative amount of α-helix was reduced in each of the truncated proteins compared with r20β-
HSDH–WT. r20β-HSDHΔ1–21 composition was most different with ~10% increase in β-sheet and 
β-turn, and 30% decrease in α-helix compared with WT. The percent of unordered regions was 
largely stable across all truncated proteins (21.3–28.3%). These results indicate an important role 
of the extended N terminus in overall protein stability illustrated by changes in secondary 




Bacterial 20β-HSDH is an NADH-dependent oxidoreductase belonging to the SDR 
family and is expressed by some strains of B. adolescentis.9 The gene encoding NAD(H)-de- 
pendent 20β-HSDH from B. adolescentis strain L2-32 was cloned, overexpressed, and 
structurally characterized in the apo and NADH-bound forms. The 20β-HSDH crystal structure 
had a tetrameric configuration with the catalytic tetrad and coenzyme-binding domains 
characteristic of the SDR family (Figure 4.5).15 Ser-181 is predicted to stabilize cortisol, and 
mutation to an alanine results in loss of substrate binding. The enzymatic reaction is proposed to 
initiate as a proton transfer from Ser-181 to the C-20 carbonyl of cortisol. Next, a hydride is 
predicted to be transferred to C-20 from NADH. From there, a subsequent proton relay likely 
occurs that follows the order: NADH → Ser-181, Tyr-200 → 2’OH ribose, and bulk solvent → 
Tyr-200. Determination of the structure of the ternary complex will be critical to confirm the 
catalytic mechanism and cortisol binding. Multiple attempts to crystallize with both NADH and 
cortisol bound at varying concentrations were unsuccessful. A possible avenue for future 
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experiments is to use NAD+ and 20β-dihydrocortisol rather than NADH and cortisol. 
Alternatively, a cortisol derivative such as carbenoxolone could be utilized. Carbenoxolone was 
bound in the S. hydrogenans 3α,20β-HSDH structure, although this substrate seemed to inhibit 
NADH binding as well.26 
Short-chain dehydrogenase/reductase family enzymes are extremely diverse, currently 
spanning 266,639 entries in the Uniprot database. SDR family proteins recognize diverse 
substrates, from steroids to sugars, alcohols, and xenobiotics.16 At present, there are 475 SDR 
family structure entries in PDB and about 216 of those are HSDHs. To determine how 
widespread this extended N terminus may be, a full sequence alignment was created composed 
of bacterial HSDHs in the SDR family from the UniProt database (Supplementary Figure 4.4). 
A total of 555 predicted HSDH sequences were compiled, along with the B. adolescentis 20β-
HSDH sequence, and 39 of them exhibited an extended N terminus with an unconserved amino 
acid sequence. Many of these 39 sequences were only annotated based on inferred homology, 
except for 053547_MYCTU and 3BHDP_RUMGV. The probable SDR 
dehydrogenase/reductase and the possible 17β-hydroxysteroid dehydrogenase, 053547_MYCTU, 
were first identified from the complete genome sequence of Mycobacterium tuberculosis strain 
H37Rv, although the function has not been experimentally determined.27 Notably, 
3BHDP_RUMGV in Ruminococcus gnavus ATCC 29149 was functionally studied and shown to 
have bile acid 3β-HSDH activity by TLC and GC coupled to MS.5 Unfortunately, neither of 
these proteins have been crystallized and can corroborate the extended N termini demonstrated 
by sequence alignment. Nonetheless, extended N-terminal regions seem to be frequent (~10%) 
across putative bacterial HSDHs and are likely prevalent throughout the entire SDR family, as 
well. Takeshita et al.24 noted the flexible N terminus in a quinuclidinone reductase, but it was not 
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studied in depth (PDB code 4O0L, Supplementary Figure 4.3). Zhang et al.35 investigated a 
carbonyl reductase extended N terminus in more detail and concluded that it conferred some 
stability to the oligomer; however it did not impact enzymatic activity (PDB code 3CTM, 
Supplementary Figure 4.3). This contrasts the extensive analysis performed in this study on the 
B. adolescentis 20β-HSDH N terminus, which displays complete abolition of activity when fully 
truncated, as well as marked changes in oligomerization and secondary structure. 
Supplementary Figure 4.6 represents a potential model for the effect of N-terminal truncation 
on r20β-HSDH structure/function where truncation of the first 17 amino acid residues resulted in 
40% loss of activity relative to WT while retaining a tetrameric structure. Truncation of the next 
four residues (r20β- HSDHΔ1–21) resulted in a precipitous drop in enzymatic activity to 2% of 
WT and exhibited a trimeric configuration. Finally, the full truncation of the 38-residue extended 
N terminus resulted in complete loss of activity and a mixed dimeric and monomeric form. 
Future studies could utilize targeted site-directed mutagenesis to determine which residues along 
the flexible N terminus, specifically between residues 17 and 21, are essential for stability. The 
role of the N-terminal region in 20β-HSDH stability and activity could have broad impacts 
across proteins of diverse functional classes within the vast SDR family. 
The corticosteroids β-cortol and β-cortolone have been identified in human urine 
samples.28,29 β-Cortol is formed from tetrahydrocortisol, and β-cortolone is produced from 
tetrahydrocortisone, both by the proposed action of a human 20β-HSDH.28 Recent work 
identified at least one enzyme, CBR1, with NADPH-dependent 20β-HSDH activity.20 It was 
determined that 20β-dihydrocortisol displayed weak glucocorticoid receptor agonism, indicating 
that 20β-dihydrocortisol formation by gut bacteria may have important physiological effects on 
the host. In zebrafish, Danio rerio, the gene encoding 20β-HSDH is distinct from that in 
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mammals.30 Zebrafish 20β-HSDH type 2 catalyzes the conversion of cortisone to 20β-
hydroxycortisone, which is important in zebrafish stress response through inactivation and 
excretion of both endogenous and exogenous cortisol.30 Importantly, bacterial 20β-HSDH 
enzymes are becoming more well-studied, as evidenced by previous work in B. desmolans9 and 
the current study in B. adolescentis. Further work will be needed to determine the contribution of 
gut bacteria to formation of 20β-derivatives of human glucocorticoids. 
B. adolescentis is among the first bacteria to colonize the gastrointestinal tract of breast-
fed infants; the species was first isolated from the stool of a healthy 2-year-old infant in 
1996.31,32 The presence of B. adolescentis has been associated with numerous health benefits; 
however, the mechanisms by which this species and other bifidobacteria confer these benefits on 
the host have yet to be fully understood. There are currently 31 known species of bifidobacteria33 
with few among a limited selection of commonly used probiotic organisms.34 B. adolescentis 
strain L2-32 encoding a 20β-HSDH has the potential to be a novel therapeutic probiotic based on 
the important regulatory role of 20β-HSDH in the steroid-17,20-desmolase pathway.9 
Bacterial steroid-17,20-desmolase (DesAB) converts cortisol into 11β-OHAD (Figure 
4.1).8 This compound is pro-androgenic due to the ability of both host35 and microbial6 enzymes 
to biotransform it into 11-ketotestosterone (11-KT). The androgen 11-KT has been shown 
previously to activate androgen receptor (AR) with similar effectiveness to testosterone itself.11 
AR is a ligand-dependent transcription factor that regulates genes for cell proliferation and 
death.36 This recently discovered pro-androgenic microbe-mediated cortisol metabolism could 
directly impact androgen-dependent diseases, such as castration-resistant prostate cancer and 
polycystic ovary syndrome.12 
168 
 
Bacterial 20β-HSDH can be thought of as acting as an enzymatic “switch” by converting 
cortisol to 20β-dihydrocortisol, either regulating bacterial cortisol 21-dehydroxylation or 
effectively blocking the steroid-17,20-desmolase pathway (Figure 4.1).9 B. desmolans and a 
urinary isolate, Propionimicrobium lymphophilum, have both 20β-HSDH and steroid-17,20-
desmolase activity9, whereas C. scindens expresses steroid-17,20- desmolase and 20α-HSDH8. B. 
adolescentis encodes only 20β-HSDH; therefore, B. adolescentis could be a potential inter-
species modulator in gut environments with steroid-17, 20-desmolase and 20α-HSDH activities. 
Another competing cortisol biotransformation is 21-dehydroxylase activity in Eggerthella.37 E. 
lenta lacks both 20α-HSDH and 20β-HSDH, and modification of the cortisol/corticosterone side 
chain blocks 21-dehydroxylation.38 21-Dehydroxylation of cortisol produces 21-deoxycortisol, a 
potent inhibitor of the host kidney 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2) enzyme.23 
Inhibition of 11β-HSD2 was shown to cause severe hypertension in humans with an inactivating 
mutation in this gene.6 Thus, a B. adolescentis probiotic with the 20β-HSDH “switch” could 
alleviate the inhibitory effects of 21-deoxycortisol by shifting cortisol metabolism toward 20β-
dihydrocortisol. The B. adolescentis 20β-HSDH is about 400 times more active in the reductive 
direction with cortisol as substrate, the preferred direction for a probiotic that seeks to reduce 
androgen excess or concentrations of 21-deoxycortisol. However, the solved crystal structure 
supports targeted mutagenesis of binding residues to optimize activity in either direction. Future 
in vivo investigations are needed to assess the efficacy and safety of 20β-HSDH–encoding B. 






MATERIALS AND METHODS 
Bacterial strains, enzymes, reagents, and materials 
B. adolescentis, strain L2-32, was purchased through BEI Resources (catalog no. HM-
633). Turbo Competent E. coli DH5α (high efficiency) cells were purchased from New England 
Biolabs (Ipswich, MA). BL21-CodonPlus (DE3)-RIPL–competent E. coli cells were purchased 
from Agilent Technologies (catalog no. 230280). Phusion High-Fidelity DNA polymerases, 
restriction endonucleases, and T4 DNA ligase were purchased from New England Biolabs. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased from Gold Biotechnology. 
TALON His-tag purification resin was purchased from Takara Bio USA, Inc. Corning Spin-X 
UF concentrators with a 10-kDaMWCOwere purchased from MilliporeSigma. Steroids were 
purchased from Steraloids. All other materials were purchased from Thermo Fisher Scientific 
and MilliporeSigma. 
 
Whole-cell steroid conversion assay 
B. adolescentis strain L2-32, B. desmolans ATCC 43058, and C. scindens ATCC 35704 
were cultivated in anaerobic brain heart infusion (BHI) broth. Steroids were dissolved in 
methanol and added to sterile anaerobic BHI medium at a concentration of 50 µM. The samples 
were then seeded separately with 0.1 ml of each bacterial culture and incubated at 37 °C for 48 h. 
After incubation, the products were extracted by vortexing the samples with 2 volumes of ethyl 
acetate for 3 min followed by recovery of the organic phase. The organic phase was then 
evaporated under nitrogen gas. The remaining residues were dissolved in 100µl of methanol and 
analyzed using a high-performance LC (HPLC) system (Shimadzu, Japan) equipped with a C18 
analytical column (Capcell Pak c18, Shiseido, Japan). The mobile phase contained acetonitrile/ 
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water with 0.01% formic acid, and the flow rate was maintained at 0.2 ml.min-1. A DAD detector 
was used at a wavelength of 254 nm. Peak retention times and peak areas of samples were 
compared with standard steroid molecules. 
 
Cloning and formation of the 20β-HSDH expression vector 
Genomic DNA was extracted and purified from B. adolescentis, strain L2-32, using the 
FastDNA spin kit fromMPBiomedicals. The gene encoding 20β-HSDH (WP_003810233.1) was 
amplified using Phusion High-Fidelity DNA polymerase and the following primers: 5’-
ATATATcatatgATGGCAGTGAATCATCGCAGATTCCA-3’ and 5’-
ATATATctcgagTTAGAAGACGCTTAGCCGCCATCTAC-3’. The restriction endonuclease 
sites for NdeI and XhoI are shown in lowercase, respectively. The PCR product was purified and 
double-digested with NdeI and XhoI restriction endonucleases. The digested PCR product was 
purified and cloned into the pET-28a(+) (Novagen, Madison, WI) vector using T4 DNA ligase to 
create the expression construct. The pET-28a(+) vector used had previously been re-engineered 
by replacing the kanamycin resistance gene with the ampicillin resistance gene. The resulting 
construct was transformed into Turbo Competent E. coli DH5α (high efficiency) cells by heat-
shock at 43 °C for 35 s and outgrown for 1 h in Super Optimal Broth with Catabolite Repression 
(SOC) (Ipswich, MA) before growing on LB agar plates supplemented with ampicillin (100 
µg/ml) for 16 h at 37 °C. Single colonies from the LB agar plates were inoculated into 5 ml of 
LB medium containing ampicillin (100 µg/ml) and grown overnight at 37 °C at 220 rpm. The 
cells were then centrifuged at 4000 x g for 10 min at 4 °C, and plasmids were extracted and 
purified from the pellets using the QIAprep Spin miniprep kit. Both strands of the plasmid DNA 
were sequenced for confirmation of the insert and absence of mutations using T7 promoter and 
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T7 terminator primers (W. M. Keck Center for Comparative and Functional Genomics at the 
University of Illinois at Urbana-Champaign). Once overexpressed, the expected protein should 
include an N-terminus His6-tag and a thrombin cleavage site. 
 
Site-directed mutagenesis 
Plasmids containing the 20β-HSDH gene construct were mutated using the QuikChange 
Lightning site-directed mutagenesis kit. Primers containing the desired mutations were designed 
as follows: 5’-CTGATCTTCACAGCCgcgCTGTCCGACACAA-3’ and 5’-
TTGTGTCCGGACAGcgcGGCTGTGAAGATCAG-3’ for serine 181 to alanine (S181A); and 
5’-TCTTCACAGCCTCCCTGgcgGGACACAACGCGAACTA-3’ and 5’-
TATTCGCGTGTGTCCcgcCAGGGAGGCTGTGAAGA-3’ for serine 183 to alanine (S183A). 
Mutated bases are shown in lowercase. The resulting mutated constructs were transformed into 
Turbo Competent E. coli DH5α (high efficiency) cells by heat shock at 43 °C for 35 s and 
outgrown for 1 h in Super Optimal Broth with Catabolite Repression (SOC) (New England 
Biolabs, Ipswich, MA) before growing on LB agar plates supplemented with ampicillin (100 
µg/ml) for 16 h at 37 °C. Single colonies from the LB agar plates were inoculated into 5 ml of 
LB medium containing ampicillin (100 µg/ml) and grown overnight at 37 °C at 220 rpm. The 
cells were then centrifuged at 4000 x g for 10 min at 4 °C, and plasmids were extracted and 
purified from the pellets using the QIAprep Spin miniprep kit. Mutations were confirmed by 
sequencing of the mutated plasmid using T7 promoter and T7 terminator primers (W. M. Keck 





Overexpression and purification of WT and mutant 20β-HSDH proteins 
For protein expression, recombinant plasmids extracted from the E. coli DH5α cells were 
transformed into BL21- CodonPlus (DE3)-RIPL Competent E. coli cells by heat shock at 43 °C 
for 35 s and outgrown for 1 h in Super Optimal Broth with Catabolite Repression (SOC) (New 
England Biolabs, Ipswich, MA) before growing on LB agar plates supplemented with ampicillin 
(100 µg/ml) and chloramphenicol (50 µg/ml). After 16 h of growth at 37 °C, five colonies were 
picked to inoculate 10 ml of LB medium containing ampicillin (100 µg/ml) and chloramphenicol 
(50 µg/ml) and were grown for 6 h at 37 °C with shaking at 220 rpm. The turbid pre-culture was 
then added to 1 liter of LB medium containing the same antibiotics and shaken at 37 °C at 220 
rpm. At an A600 of 0.6, the culture was induced with 0.25 mM IPTG, after which the culture was 
incubated at 16 °C at 220 rpm for 16 h. Cells were pelleted by centrifugation at 4000 x g for 30 
min at 4 °C. The pellets were resuspended in 25 ml of buffer containing 50mM Tris-Cl and 
300mM NaCl at pH 7.9. The resuspended cells were homogenized using an EmulsiFlex C-3 
homogenizer by passing the samples through the homogenizer four times, and the cell debris was 
removed by centrifugation at 20,000 x g for 30 min at 4 °C. The recombinant protein in the 
soluble lysate was then purified using metal chelate chromatography followed by removal of the 
His6 tag by use of thrombin. The recombinant protein was further purified using anion-exchange 
chromatography to remove the excess thrombin. The resulting purified protein was analyzed 
using SDS-PAGE.  
TLC 
Reaction mixtures were made using 50 µM substrate, 150 µM cofactor, and 5 nM 
enzyme in 150 mM NaCl, 50 mM Tris-Cl buffer at pH 7.8. They were incubated overnight at 
room temperature and extracted by vortexing 2 volumes of ethyl acetate twice. The organic layer 
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was recovered and evaporated under nitrogen gas. The products were dissolved in 30 µl of 
methanol and spotted on a TLC plate (silica gel IB2-F flexible TLC sheet, 20 x 20 cm, 250-µm 
analytical layer; Avantor Performance Materials, LLC, PA). The steroids were separated with an 
isooctane/ethyl acetate/acetic acid (5:25:0.2, v/v) mobile phase and visualized by spraying with 
50% sulfuric acid in ethanol and heating for 10 min at 100 °C. 
 
Gel-filtration chromatography 
Gel-filtration chromatography was performed on a Superose 6 10/300 GL analytical 
column (GE Healthcare) attached to an ÄKTAxpress chromatography system (GE Healthcare) at 
4 °C. The purified protein was concentrated to 10 mg/ml and loaded onto the analytical column 
equilibrated with 50mMTris-Cl and 150 mM NaCl at pH 7.5 and was eluted at a flow rate of 0.3 
ml/min. The native molecular mass of the 20β-HSDH proteins were determined by comparing 
elution volume with that of Gel Filtration Standard proteins (Bio-Rad): thyroglobulin, γ-globulin, 
ovalbumin, myoglobin, vitamin B12. 
 
Optimal pH determination 
The 20β-HSDH pH optimum was measured spectrophotometrically by monitoring the 
reductive biotransformation of cortisol to 20β-dihydrocortisol as well as the reverse oxidative 
biotransformation of 20β-dihydrocortisol to cortisol. For the reductive direction, measurements 
were taken by analyzing the decrease of NADH at 340 nm. For the oxidative direction, 
measurements were taken by analyzing the increase of NADH at 340 nm. The buffers used in the 
pH profiling contained 50 mM buffering agent and 150 mM NaCl. Buffering agents used were as 
follows: sodium acetate trihydrate (pH 3.5–5.5), sodium phosphate monobasic monohydrate (pH 
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6.5–7.5), Tris (pH 8.0–9.0), glycine (pH 10–11). For the reductive reaction, 50 nM enzyme was 
added to 50µM cortisol and 150µM NADH in 200µl of buffer. For the oxidative reaction, 50 nM 
enzyme was added to 50 µM 20β-dihydrocortisol and 150 µM NAD+ in 200 µl of buffer. For 
each reaction, the decrease or increase in NADH in the reaction mixture was measured 
continuously for 5 min, and the data were used in calculating the initial velocities. 
 
Enzyme activity assays and determination of kinetic parameters 
r20β-HSDH WT and mutant activities were measured spectrophotometrically by 
monitoring the reductive biotransformation of cortisol to 20β-dihydrocortisol as well as the 
reverse oxidative biotransformation of 20β-dihydrocortisol to cortisol by measuring the levels of 
NADH at 340 nm. The standard reaction mixture contained 50 mM sodium acetate trihydrate 
buffer (pH 5.0), 150 µM cofactor (NADH), 10 nM enzyme and a varied substrate concentration 
between 5 and 90 µM. GraphPad Prism was used to plot data, create Michaelis-Menten 
saturation curves, and Lineweaver-Burk plots and to calculate kinetic parameters. 
 
Substrate-specificity assay 
A saturating concentration of 50µM substrate, as determined by the enzyme activity 
analyses, was used as the concentration for analyzing various other steroid substrates and their 
activities. Similar to the enzyme activity assay, 20β-HSDH activity was measured 
spectrophotometrically by monitoring the biotransformation of substrate by measuring the levels 
of NADH at 340 nm. The standard reaction mixtures contained sodium acetate trihydrate buffer 





Determination of CD spectra for 20β-HSDH WT, its site-directed mutants, and the 
truncated derivatives was carried out using a J-815 CD spectropolarimeter (Jasco, Tokyo, Japan). 
Protein samples were prepared at a concentration of 0.2 mg/ml in 10 mM KH2PO4 buffer (pH 
7.9). For the measurements, a quartz cell with a path length of 0.1 cm was used. CD scans were 
carried out at 25 °C from 190 to 260 nm at a speed of 50 nm/min with a 0.1-nm wavelength 
pitch, with five accumulations. Data files were analyzed on the DICHROWEB on-line server 
(http://www.cryst.ac.uk/cdweb/html/home.html)39 using the CDSSTR algorithm with reference 
set 4, which is optimized for analysis of data recorded in the range of 190 to 240 nm. Mean 
residue ellipticity was calculated using millidegrees recorded, molecular weight, number of 
amino acids, and concentration of protein. 
Thermal denaturation studies were performed by monitoring CD (millidegrees) at 220.5 
nm from 25 to 95 °C at a rate of 1 °C/min. Each protein was run in triplicate with 0.2 mg/ml 
protein and 10 mM KH2PO4 buffer at pH 7.9. 
 
Isothermal titration calorimetry 
ITC analysis was performed with a VP-ITC microcalorimeter and 1.94-ml cell volume 
from MicroCal, Inc. The enzymes were dialyzed with 150 mM NaCl, 50 mM Tris buffer at pH 
7.8. The pyridine nucleotide (NADH) was dissolved in this buffer, and cortisol was dissolved in 
methanol. 50 µM protein was injected with 28 successive 10-µl aliquots of 2 mM NADH at 300-
s intervals. The protein and 2 mM NADH were then injected similarly with 1 mM cortisol. The 
data were fitted to a nonlinear regression model using a single binding site with the MicroCal 
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Origin software. The thermodynamic parameters were calculated using the Gibbs free energy 
equation (ΔG = ΔH - TΔS) and ΔG = -RTln(Ka). 
 
Crystallization 
WT 20β-HSDH crystals were obtained using the PEGRx HT kit from Hampton-
Research. Purified 20β-HSDH protein was concentrated between a range of 15 and 20 mg/ml. 
Sitting drops were prepared consisting of 30 µl of well-condition and 300 nl of protein mixed 
with 300 nl of well-condition. Crystallization screening was performed in 96-well trays using Art 
Robbins PHOENIX robot. Plates were placed in 4 °C and single crystals formed after 2 days 
using condition 69 of PEGRx HT containing 20% v/v 2-propanol, 0.1 M MES monohydrate (pH 
6.0), and 20% w/v PEG monomethyl ether 2000. The crystals continued to grow up to day 7. No 
further optimization was necessary. The crystals were overlaid with paraffin oil to prevent 
evaporation and 20% ethylene glycol as a cryoprotectant. Crystals were picked and immediately 
flash-cooled in liquid nitrogen.  
For the NADH-bound structure, mutant S181A 20β-HSDH– purified recombinant protein 
was incubated with 2.5 mM NADH and 0.25 mM or 0.5 mM cortisol for 2 h at 4 °C. Crystals 
were grown in condition 86 of the Hampton PEG/Ion screen containing 0.05 M citric acid, 0.05 
M Bis-tris propane (pH 5.0), and 16% w/v PEG 3350. The condition was then optimized in 
hanging-drop format using 18–20% w/v PEG3350. S181A crystals were frozen using the same 






X-ray data collection, processing, structure determination, and refinement 
X-ray data were collected on the ID-D beamline at the Life Sciences Collaborative 
Access Team of the Advanced Photon Source at Argonne National Laboratory. Data for the apo 
structure were processed and scaled in HKL2000.40 The crystal structure of the short-chain type 
dehydrogenase/reductase from M. marinum (PDB code 3R1I) was selected using the MORDA 
pipeline; Molrep and Refmac from CCP4 are used in this automation to test and refine initial 
models.41 The final molecular replacement model was rebuilt in Autobuild of the Phenix 
package.42 For the NADH-bound structure, data were processed in Autopro applying an 
anisotropy correction in Staraniso.43,44 Because of the highly anisotropic data, the completeness 
for this structure appears low when calculated conventionally (isotropic) but the Staraniso 
program utilizes ellipsoidal completeness to determine the resolution cutoff. Ellipsoidal 
completeness for these data are high, 92.1% overall and 63.3% for the outer shell. Additionally, 
the electron density maps are well-defined as shown in Supplementary Figure 4.2, A and B. 
The apo structure was used as the molecular replacement model in Phaser-MR of the Phenix 
package.45 Each structure was refined via multiple rounds of manual model building in Coot and 
refinement with Phenix.refine.46,47 The X-ray processing and refinement statistics are presented 
in Table 4.3. 
 
Protein Data Bank accession code 
The apo 20β-HSDH structure can be found in the Research Collaboratory for Structural 
Bioinformatics (RCSB) Protein Data Bank (PDB) under the accession number 6M9U. The 




Multiple sequence alignment 
The SDR family sequences were aligned using Clustal Omega (1.2.4) 
(https://www.ebi.ac.uk/Tools/msa/clustalo/).48 The secondary structural elements were rendered 
using the ESPript 3.0 web server.49 
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Figure 4.1. Cortisol-metabolizing reactions by B. adolescentis, C. scindens, B. desmolans, P. 
lymphophilum, and E. lenta. Boxed reaction shows 20β-HSDH oxidizes the coenzyme NADH 
to transform cortisol into 20β-dihydrocortisol. Cortisol + NADH ↔ 20β-dihydrocortisol + 
NAD+. This reaction reduces the double-bonded oxygen at C-20 (highlighted in red) on cortisol 





Figure 4.2. Whole-cell assays of B. adolescentis strain L2-32, B. desmolans ATCC 43058, 
and C. scindens ATCC 35704. A, B. adolescentis completely converts cortisol into 20β-
dihydrocortisol. 20α-Dihydrocortisol is not metabolized. In a highly reductive environment and 
without pressure from a steroid-17,20-desmolase, B. adolescentis does not convert 20β-
dihydrocortisol into cortisol. B, B. desmolans completely converts cortisol into 11β-OHAD and 
20β-dihydrocortisol into 11β-OHAD. 20α-Dihydrocortisol is not metabolized. C, C. scindens 
completely converts cortisol into 11β-OHAD and 20α-dihydrocortisol into 11β-OHAD. 20β-
Dihydrocortisol is not metabolized. Standards are reused in each panel for ease of comparison to 





Figure 4.3. Purified 20β-HSDH from B. adolescentis, strain L2-32. A, SDS-polyacrylamide 
gel of crude and purified 20β-HSDH showing a subunit size of 32 ± 0.12 kDa. Lane M, 






Figure 4.4. pH optimum and Michaelis-Menten saturation curve of WT 20β-HSDH. A, pH 
optimization of 20β-HSDH in the reductive (blue) and oxidative (red) direction. B, saturation 





Figure 4.5. Structural characterization of 20β-HSDH. A, apo structure of 20β-HSDH showing 
the SDR-characteristic Rossmann fold consisting of seven central β-strands (β3–β2–β1–β4–β5–
β6–β7) flanked by six α-helices. Right panel depicts the extended N terminus with no electron 
density before residue 17 and truncation sites. B, proposed tetramer of 20β-HSDH based on 
crystallographic arrangement. C, NADH-binding pocket showing five side chains and three 




Figure 4.5 (cont.) 
highlighting residues that make van der Waals contacts to NADH (yellow). The Gly-rich region 





Figure 4.6. CD analysis and relative activity of WT and truncated 20β-HSDH. A, relative 
activity based on spectrophotometric assay. B, thermal stability of WT, 17-, and 21-truncated 
20β-HSDH by temperature-dependent CD. C, percentage secondary structure calculated with 





















Wild-type 21.08 ± 1.13a 24.07 ± 3.80 668.30 ± 50.54 100 27.77 ± 3.65 100 
S181A - b - - - - - 
S183A 4.70 ± 0.10 9.49 ± 2.60 148.70 ± 11.24 22 15.68 ± 2.06 56 
a Values represent the means ± SD based on three or more replications. 




Table 4.2. Substrate specificity of 20β-HSDH 
Steroid Trivial Name Coenzyme Relative Activity (%) 
4-pregnen-11β,17,21-triol-3,20-dione Cortisol NADH 100.00 ± 0.77a 
4-pregnen-17,21-diol-3,20-dione 11-Desoxycortisol NADH 66.03 ± 0.75 
4-pregnen-11β,21-diol-3,20-dione Corticosterone NADH 39.32 ± 0.25 
5β-pregnan-3α,11β,17,21-tetrol-20-one Tetrahydrocortisol NADH 44.29 ± 0.29 
4-pregnen-11β,17,20β,21-tetrol-3-one 20β-Dihydrocortisol NAD+ 0.23 ± 0.04 
4-pregnen-17,20β-diol-3-one 17α,20β-Dihydroxyprogesterone NAD+ 0.09 ±0.05 
4-pregnen-11β,20β,21-triol-3-one 20β-Dihydrocorticosterone NAD+ - b 
4-pregnen-17,20α-diol-3-one 17α,20α-Dihydroxyprogesterone NAD+ - 
4-pregnen-11β,17,20α,21-tetrol-3-dione 20α-Dihydrocortisol NAD+ - 
a Values represent the means ± SD from three or more replications. 




Table 4.3. Crystallographic data collection and refinement statistics 
Structure Apo NADH-bound 
PDB ID 6M9U 6OW4 
Resolution range (Å)  50.69 - 2.2 (2.279 - 2.2) 103.71 - 2 (2.045-2) 
Space group  I 4 2 2 C 1 2 1  
Unit Cell 168.371 168.371 126.961 90 90 
90 
165.078 134.71 96.396 90 
100.15 90 
Total no. of reflections  338597 (33468) 353360 (16341) 
No. of unique reflections  46287 (4574) 73226 (3662) 
Multiplicity 7.3 (7.3) 4.8 (4.5) 
Completeness (%)  99.57 (99.72) 54.3 (8.7) 
Mean I/sigma (I)  9.52 (1.66) 6.3 (1.7) 
Wilson B-factor 41.11 16.22 
R-merge 0.140 (1.715) 0.147 (0.806) 
R-meas 0.151 (1.845) 0.178 (0.976) 
R-pim 0.055 (0.673) 0.072 (0.412) 
CC1/2 0.998 (0.492) 0.995 (0.670) 
Reflections used in refinement 46144 (4561) 69583 (174) 
Reflections used for R-free 1997 (198) 3673 (9) 
R-work 0.196 (0.381) 0.187 (0.279) 
R-free 0.231 (0.410) 0.238 (0.146) 
Number of non-hydrogen atoms 4192 17642 
     macromolecules 3853 16839 
     ligands 179 352 
     solvent 160 451 
Protein residues 501 2227 
RMS(bonds) 0.011 0.013 
RMS(angles) 1.46 1.64 
Ramachandran favored (%) 96.70 94.43 
Ramachandran allowed (%) 3.09 5.44 
Ramachandran outliers (%) 0.21 0.14 
Rotamer outliers (%) 3.24 0.80 
Clashscore 6.46 2.37 
Average B-factor 59.99 26.73 
     macromolecules 58.89 26.85 
     ligands 84.00 25.91 







Supplementary Figure 4.1. Active site mutant thin layer chromatography (TLC) isothermal 
titration calorimetry (ITC) and circular dichroism (CD). (A) Wild-type and active site  
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Supplementary Figure 4.1 (cont.) 
mutant 20β-HSDH overnight reaction products separated by TLC. (1) Cortisol standard, (2) 20β-
dihydrocortisol standard, (3) 11β-hydroxyandrostenedione standard, (4) WT + NADH + cortisol, 
(5) WT + NADH + 11β-OHAD, (6) S181A + NADH + cortisol, (7) Y200A + NADH + cortisol. 
(B) Ligand binding order of S181A and Y200A studied by ITC. Left panel is 2 mM NADH 
binding to S181A, middle panel is 1 mM cortisol binding to S181A with 2 mM NADH, right 
panel is 2 mM NADH binding to Y200A. (C) CD spectra of purified recombinant 





Supplementary Figure 4.2. Structural analysis of 20β-HSDH. (A) Fo-Fc omit map of NADH 
from Chain A and E shown at 2 sigma. (B) 2Fo-Fc map of NADH and surrounding backbone 
chains from Chain A and E shown at 2 sigma. (C) Alignment of 5 of the monomers from the 
NADH-bound structure showing the flexibility of loop 235-245 near where cortisol is predicted 
to bind. The 3 monomers not shown look similar to those shown. (D) Comparison of 20β-HSDH 
(green) to 3α,20β-HSDH from Streptomyces hydrogenans (pink). The Gly-rich region is 
highlighted in brighter colors near the adenine of NADH and the side chains of the residues 
making up the catalytic tetrad are shown. Ser181 of the catalytic tetrad has been mutated to an 
alanine in 20β-HSDH. (E) Superposition of apo (yellow) and S181A mutant holo structure with 





Supplementary Figure 4.3. Sequence alignment of 20β-HSDH found in B. adolescentis and 
other structurally similar SDR members. Red highlights indicate identical residues, green 
highlights and stars indicate active site residues, blue boxes indicate conserved residues. 
Secondary structural elements of apo-20β-HSDH are displayed on the top of the alignment. The 
abbreviations of protein names are as follows: adol, 20β-HSDH from Bifidobacterium 
adolescentis strain L2-32; desm, 20β-HSDH from Butyricicoccus desmolans ATCC 43058;  
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Supplementary Figure 4.3 (cont.) 
remaining labels correspond to PDB IDs. The sequences were aligned with Clustal Omega 





Supplementary Figure 4.4. SDR family subset with extended N-terminus multiple sequence 
alignment. A Clustal Omega (1.2.4) alignment was performed with 555 sequences labeled as 
SDR family, hydroxysteroid dehydrogenase, and of bacterial origin from the UniProt database. 
This excerpt from the total sequence alignment includes 39 sequences with a ≥10 amino acid 
residue extended N-terminus. Conserved residues are highlighted, bolded residues indicate the B. 
adolescentis 20β-HSDH extended N-terminus, and the line indicates the beginning of the B. 





Supplementary Figure 4.5. Gel filtration chromatography of 20β-HSDH truncation 
mutants. Native molecular weight estimates were based on elution time of 10 mg/ml WT and 
truncated 20β-HSDH from a Superose 6 10/300 GL analytical column. Fractions were collected 
and analyzed on SDS-PAGE for visualization. (A) WT, (B) 17-truncated, (C) 21-truncated, (D) 
38-truncated. Numbers indicate elution time of standard proteins (1) thyroglobulin, (2) γ-





Supplementary Figure 4.6. Model of 20β-HSDH N-terminal truncation effects. 
Oligomerization is shown by the number of blue circles, or subunits, and enzymatic activity is 
depicted by the color of the explosion shape. WT 20β-HSDH has 100% relative activity and is 
likely tetrameric. When the first 17 residues are truncated, the protein exhibits 62% activity, but 
remains a tetramer. When 21 residues are truncated, the protein loses quaternary structure and 
has only 2% activity. The full 38-residue truncation results in no activity and a mixed dimeric 
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BACTERIA ON STEROIDS: THE ENZYMATIC MECHANISM OF AN NADH-
DEPENDENT DEHYDROGENASE THAT REGULATES THE CONVERSION OF 
CORTISOL TO ANDROGEN IN THE GUT MICROBIOME 
 
ABSTRACT 
The ability to metabolize both endogenous and exogenous compounds to a variety of 
metabolic products is not exclusive to our human cells. In fact, the bacterial communities that 
inhabit our digestive system are responsible for a network of steroid transformations that can 
produce hormones in the gut, which are then absorbed by the host, potentially affecting host 
physiology. These communities have been shown to impact our health in numerous ways, 
affecting disease predisposition, pathogenesis, physical fitness, and dietary responsiveness. 
Steroid biotransformations by gut bacteria are predicted to impact the host endocrine system. A 
particular set of transformations facilitated by microbial enzymes has been shown to  result in the 
formation of 11-oxy-androgens from host-derived cortisol. Since androgens have been 
implicated in disease and immune modulations, understanding the structure and catalytic 
mechanism of enzymes involved in cortisol metabolism is a key step towards developing 
strategies to reduce disease-promoting bioactive steroids in certain individuals. Here, we 
combine experimental and computational techniques to describe DesC, a 20-hydroxysteroid 
dehydrogenase (HSDH) capable of creating 20-dihydrocortisol and siphoning cortisol away 
from pathways that produce androgens. DesC diverges significantly from previously described 
bacterial and eukaryotic counterparts, catalyzing an NADH-dependent 20-HSDH reaction but 
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presenting little sequence and structure similarity to them. The structural information obtained by 
X-ray crystallography and hybrid quantum mechanics/molecular mechanics (QM/MM) 
simulations, validated through mutagenesis studies, suggest the reaction occurs through a multi-
step proton relay mechanism. Free energy calculations were then used to describe the kinetics of 
the reaction mechanism. The mechanistic information presented here can be employed in the 
development of therapeutics to divert microbial pathways away from disease-promoting steroids. 
 
INTRODUCTION 
Bacterial communities have a wide influence on human health and play important roles in 
disease predisposition, pathogenesis, immune regulation, and dietary responsiveness.1–4 Gut 
microbes are estimated to be numerically equal to mammalian host cells, although their gene 
content is estimated to dwarf our own with 99% of functional genes in the human body being 
microbial. It is no surprise then that the gut microbial consortium has evolved biochemical 
pathways to biotransform, synthesize, or regulate the production of host endogenous signaling 
molecules. The contribution of host-associated bacterial metabolism of steroid hormones is 
coming into focus. Steroid hormones are essential for regulation of various physiological 
functions, including cellular communication, metabolism, inflammatory response, and stress 
response.5 One class in particular, the endogenous glucocorticoids, is synthesized from 
cholesterol in the adrenal cortex6 and released into the blood to influence cells throughout the 
body. Upon binding to host nuclear receptors they affect cellular processes through genomic and 
non-genomic mechanisms.5 Thus, investigating the chemistry of steroid biotransformation in the 
gut microbiome is crucial for a better understanding of the symbiotic relationship between us and 
our microbiota.7  
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Cortisol, the major glucocorticoid in humans, is converted to various derivatives by 
enzymes throughout our body. The local concentrations of cortisol are regulated by enzymes that 
reversibly modify functional groups on the steroid nucleus and side chain, saturate the steroid 
rings, and conjugate the steroid with sulfate or glucuronide.8–10 In this way, ratios of active vs. 
inactive glucocorticoids can be locally and rapidly altered in peripheral tissues. Intriguingly, gut 
microbes possess multiple cortisol-altering enzymes that have co-evolved separately from 
eukaryotic counterparts.10–15 Microbes are therefore expected to play an important role in the 
complex steroid metabolome of the host. Indeed, accumulating evidence demonstrates human 
gut microbes are an important component of the host endocrine system.9 Of particular relevance 
is the observation that peripheral side-chain cleavage of cortisol to 11β-hydroxyandrostenedione 
(11β-OHAD) occurs by some combination of host and microbial input.16–18 The androgens 
produced from cortisol side-chain cleavage function similarly to testosterone by binding and 
activating androgen receptor.19 Recently, these novel androgens have been shown to be relevant 
to human physiology and pathology, including castration-resistant prostate cancer18,20, polycystic 
ovary syndrome19,21, and potentially hypertension11,22–25. 
The human gut bacterium Clostridium scindens ATCC 35704 was previously shown to 
side-chain cleave cortisol26. However, the lack of knowledge about the metabolic pathway 
responsible for androgen production severely limits our ability to mechanistically study androgen 
formation by the human microbiome in vivo. We previously discovered a cortisol-inducible gene 
cluster (desABCD) in C. scindens ATCC 35704, encoding NADH-dependent 20α-hydroxysteroid 
dehydrogenase (20α-HSDH; DesC)27 and heterotetrameric steroid-17,20-desmolase (DesAB)28 
which produce 20α-dihydrocortisol and 11β-OHAD from cortisol, respectively. Furthermore, the 
DesC product, 20α-dihydrocortisol, is not a substrate for DesAB28, suggesting DesC acts as a 
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metabolic “switch” regulating side-chain cleavage of cortisol. DesC activity is relatively rare and 
the only gene reported thus far is from C. scindens.27,29 Importantly, pharmaceutical 
glucocorticoids such as prednisone are substrates for side-chain cleavage, generating metabolites 
that drive prostate cancer cell proliferation.30 Therefore, understanding the structure and catalytic 
mechanism of enzymes involved in cortisol metabolism is key to hasten the development of 
strategies to reduce drug metabolism and alter androgen formation by the human microbiome. 
Here, we combine multiple experimental and computational approaches to investigate the 
enzymatic mechanism of C. scindens ATCC 35704 DesC, a potential regulator of the pro-
androgenic DesAB pathway (Figure 5.1). Our findings reveal the structure of this enzyme with 
atomistic detail as well as its interaction with both NADH and cortisol substrates. Classical and 
hybrid quantum mechanics/molecular mechanics (QM/MM) molecular dynamics simulations 
indicate an intricate reaction mechanism including a hydride transfer from NADH to cortisol and 
a proton relay that finally leads to a 20α-dihydrocortisol enzymatic product.  
 
RESULTS AND DISCUSSION 
X-ray crystallography 
To understand the structure and mechanism of DesC, the apo-form of the recombinant 
enzyme (rDesC) was crystallized via vapor diffusion sitting drop at pH 6.75 in a buffer 
containing 0.2M MgCl2, 24% PEG 400, 0.1M HEPES, resulting in a resolution of 2.0Å. X-ray 
diffraction data can be found in Supplementary Table 5.1. Our attempts to obtain crystals of the 
binary and ternary DesC complex were unsuccessful. DesC is a member of the zinc-dependent 
medium-chain dehydrogenase/reductase (MDR) family that catalyzes zinc-dependent oxidation 
of primary and secondary alcohols using NAD(P)+ as the proton and hydride acceptor.31 DesC 
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displays the typical bilobal topology comprised of a nucleotide-binding Rossmann fold domain 
and a catalytic domain32,33 (Figure 5.2A). Across the alcohol dehydrogenase superfamily, the 
size and architecture of the catalytic domain varies greatly, with the MDRs having a larger and 
more complex catalytic domain.31 While this family of enzymes varies in sequence conservation, 
the Rossmann fold is the most conserved feature among short-, medium-, and long-chain 
dehydrogenases.31 In the two-domain structure of DesC, the Rossmann fold is located proximal 
to the C-terminus, and comprised of -strands 11-16 and flanked by -helices 6-11 (Figure 
5.2B). The predicted catalytic Zn2+ ion (Figure 5.2C) is octahedrally coordinated by two water 
oxygens and residues of the catalytic domain including the side chains of His73, Glu74, Glu156, 
and a cysteinesulfonic acid at Cys45. 
 Like many prokaryotic alcohol dehydrogenases, DesC is a tetramer (Figure 5.2A). The 
enzyme crystallized with one monomer in the asymmetric unit, and the tetrameric assembly is 
formed by crystallographic symmetry; therefore, no differences are observed among the 
monomers that comprise the biological assembly of DesC in this model.  
The tetramer displays the catalytic domains at the periphery of the complex. Two 
Rossmann folds align along the first two-fold axis to create a continuous  -sheet comprised of 6 
-strands from each monomer across the dimeric interface. The second two-fold axis situates two 
adjacent catalytic domains such that a helical loop created by 4 and a 310 helix and stabilized by 
a second Zn2+ (Zn finger) extends towards the adjacent monomer (Figure 5.2D). Referred to as 
the lobe loop, this structural feature is conserved among many alcohol dehydrogenases including 
those from mammals.34–36 The Zn2+ at this position is located ~21Å from the catalytic cleft and is 
tetrahedrally coordinated by 4 Cys (105/108/111/119). Single alanine substitutions of Cys105, 
Cys108, Cys111, Cys115 residues composing the zinc-finger were sufficient to result in loss of 
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quaternary structure (Supplementary Table 5.2), confirming the structural role of the zinc-
finger in dimer-dimer interaction. 
The MDRs that are close structural and sequence homologs of DesC include the 
threonine dehydrogenases (TDH) from Pyrococcus horikoshii (PhTDH; Protein Data Bank 
(PDB) 2DFV, 2.0Å RMSD for 333 Ca, Z=40.5) and Thermococcus kodakaraensis (TkTDH; 
PDB 3GFB, 2.3Å RMSD for 334 Ca, Z=39.4), see Supplementary Figure 5.1. The mechanism 
for the TDHs and many MDRs is believed to proceed via an ordered bi-bi reaction whereby 
NAD+ binds first and is the last to leave.34,35,37 Binding of NAD+ likely initiates the 
conformational change that in part closes the active site to engage the catalytic machinery. The 
crystal structures of PhTDH and TkTDH were determined with NAD+.34,35 An overlay of DesC 
and TDH structures (Supplementary Figure 5.1) demonstrates conservation of the structural 
and catalytic Zn2+-binding residues (Supplementary Figure 5.2) as well as the NADH binding 
pocket. Not shared between these two is a hydrophobic patch of four tryptophan residues that is 
positioned near the lobe loop and conserved among the thermophilic TDHs.34,35  
Conserved features among the NADH binding pocket include Asp204 in DesC which is 
Glu199 in PhTDH and hydrogen bonds with the O-2 and O-3 of the adenosine ribose. This 
residue is shared among bacterial alcohol dehydrogenases and imparts specificity for the 
cofactor.34,38 Also of importance is Arg204 of PhTDH, which extends towards the pyrophosphate 
and is equivalent with K209 in DesC, though in our model this residue is positioned somewhat 
further from the predicted location of the pyrophosphates. Mutagenesis of Glu199 and Arg204 in 
PhTDH demonstrates these residues are significant determinants in NAD(H) binding. The 
nucleotide-binding GxGxxG motif is also conserved among these enzymes although Pro178 of 
PhTDH is replaced by Gly183 in DesC. Finally, in PhTDH, Thr44 and His50 are believed to be 
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part of the proton relay that connects the active site with bulk solvent, and these are conserved in 
DesC as Ser47 and His50. However, in the current crystal structure of DesC Ser47 and His50 are 
not aligned to interact. While the structures of DesC, PhTDH and TkTDH share a very similar 
fold and conservation of important catalytic residues, our overlay reveals a longer extension of α-
helix (residues 58-66) and the loop connecting β1/2 (residues 9-19) in DesC.  This region is near 
the entrance to the active site cleft, but ~20Å from the predicted site of hydride transfer to the 
nicotinamide ring. It is possible that this loop plays some role in selecting or restricting substrate. 




Since structural data was obtained only for apo-DesC, we used homologous structures 
available within the PDB in order to fit an NADH molecule to the binding pocket of a monomer 
of DesC, employing a previously established protocol.40 With BLAST41, we obtained 
homologous structures (PDB IDs: 4ILK, 4EJ6, 4A2C, 3QE3, 3GFB, 2DQ4, 2DFV, 2D8A, 1PL7, 
1E3J) from the PDB.  The alignment (Figure 5.3A,B) and placing of the NADH molecule on the 
DesC binding site was performed using VMD.42 Leveraging advanced run options of QwikMD43, 
the structure of the ligand was minimized in the pocket together with atoms of nearby DesC 
residues, while maintaining a static DesC structure  as much as possible.  
The structure of cortisol was also fitted to the most probable binding site using VMD 
(Figure 5.3C). The docking was performed by a combined manual and computational 
approach44, where VMD was used to position some of the reference atoms of cortisol, while 
NAMD45, through its QwikMD interface43, was used to minimize changes in structure of the 
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complex. As reference atoms we chose the cortisol atoms that were known to participate in the 
enzymatic reaction, positioning them near the Zn2+ and the NADH hydride donor (Figure 5.3E). 
Also, cortisol was aligned in a cleft (Figure 5.3D), which was shown to contain a more 
hydrophobic character, typical of ligand binding sites. The complex was then solvated, and the 
net charge of the system was neutralized in a 0.15 mol/L sodium chloride solution, using 
QwikMD to follow predetermined protocols employed in previous enzymatic studies.40 The 
solvated system was subjected to 100 ns of equilibrium molecular dynamics (MD) simulation, 
using the CHARMM36 force field46, along with the TIP3 water model47. The simulations were 
performed with periodic boundary conditions, in the NpT ensemble, with temperature 
maintained at 300 K and pressure at 1 bar. Long-range electrostatic interactions were treated 
using the particle-mesh Ewald (PME) method.48 All MD simulations were executed with the 
GPU-accelerated NAMD molecular dynamics package.45  
A MD simulation protocol can be used to investigate the stability of a molecular system, 
as well as predict the behavior and function of proteins or protein domains.49 Here, after 100 ns 
of MD simulation, we observed that cortisol was stable in the predicted catalytic cleft. After 
analyzing the MD trajectory, we observed that the cortisol molecule was stabilized by 
interactions with two tyrosine residues, namely Tyr101, and Tyr124 (Figure 5.3F). Simulations 
revealed that the mostly hydrophobic cleft was fundamental in maintaining the complex structure 
stability, with cortisol fluctuating very little in the cleft. To validate the importance of Tyr101 
and Tyr124 in substrate-binding, we performed site-directed mutagenesis, observing loss of 
enzyme activity at 96.01 ± 0.67% and 81.82 ± 0.31% activity, respectively, without altering 
secondary structural features as determined by circular dichroism (CD) spectroscopy (Figure 
5.3G). Isothermal titration calorimetry (ITC) experiments showed that there was no effect on 
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NADH binding with rDesCY101R (Kd = 35.08 µM) and rDesCY124R (Kd = 39.06 µM). 
However, binding affinity of cortisol to rDesCY101R and rDesCY124R was ablated, based on 
ITC data (Figure 5.3). Additionally, mutation of tyrosine to arginine in the putative binding 
pocket altered activity and kinetic parameters (Supplementary Table 5.3). The experimental 
data support the binding of cortisol to the hydrophobic pocket predicted by the computational 
study. Particularly, the experimental data shows that by mutating the aforementioned residues, 
the structure did not change, but interactions with cortisol did as evidenced by altered ITC and 
kinetic constants which were not observed with NADH. 
 
Reaction mechanism 
After examining the enzyme active site, we sought to determine the catalytic mechanism 
involved in 20-dehydrogenation. For that, we employed a combination of hybrid quantum 
mechanics (QM) and classical molecular mechanics (MM) simulations. We also integrated a 
state-of-the-art enhanced sampling method, which was recently implemented in NAMD.50 
Hybrid QM/MM has been the main tool used to study processes that cannot be explained by 
classical MM methods alone.51–53 In biological contexts, QM/MM calculations are often used in 
enzymology54,55 as well as to investigate polarizable molecules in different environments.56,57 In 
the QM/MM molecular dynamics (MD) approach, the system of interest is typically investigated 
in a water bath (Figure 5.4A), as in a regular classical MD simulation, with the exception that 
part of the system is treated at the quantum-mechanical level.50 This approach offers an 
augmented MD simulation, where a selection of atoms is investigated at sub-atomic resolution in 
order to account for electronic effects. Specifically, we employed an electrostatic embedded 
QM/MM approach, where the classical part of the system was treated with the CHARMM36 
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force field46, while the QM part of the system was treated at semiempirical PM7 level58. The QM 
region was chosen to be relatively large, with 573 atoms, because of the elongated shape of the 
catalytic pocket, and large presence of aromatic groups that could affect the electronic structure 
near the reaction site. To ensure the presence of a shell of QM atoms around the reaction site, a 
total of 36 QM-MM bonds were created using a link-atom approach.59 Our computational studies 
were then supported by biochemical assays. 
To investigate possible reaction mechanisms, we ran a 20 ps long QM/MM MD 
equilibration to prepare the system, and used a QM/MM steered MD (SMD) approach50 to 
induce the reaction to occur according to the chosen mechanisms we describe below. These 
selected reaction mechanisms were designed to determine multiple aspects of this complex 
reaction, one being the participation of a water molecule to mediate the interaction between the 
Zn2+ ion and substrates, as previously suggested for similar enzymes.60  Our QM/MM SMD only 
forced the initial steps of the reactions, allowing the remaining steps to occur freely in case they 
were energetically favorable. The simulations revealed that the most probable scenario would be 
the reaction mechanism without the participation of a water molecule, having a concerted proton 
transfer from Ser47 and a hydride from NADH to the C-20 ketone oxygen of cortisol. The 
QM/MM SMD simulations revealed a proton relay that was responsible for reestablishing the 
amino acid protonation states in the catalytic site (Figure 5.4B). The proton relay was composed 
of the replenishing of Ser47 by a proton transfer from the ribosyl of NAD+, followed by the 
protonation of the ribosyl group by His50 (which was previously in a protonated state). His50 
can once again become protonated when NAD+ leaves the catalytic pocket for a new enzymatic 
cycle, a situation in which His50 becomes largely exposed to the bulk solvent.  
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To test this mechanism, we generated S47A and S47T mutations that resulted in loss of 
catalytic function (100% vs. 98.52 ± 0.08 % loss of activity, respectively) (Figure 5.5A,E). 
While S47T mutant bound NADH (Kd = 66.67 M), cortisol lost binding affinity (Figure 5.5D). 
By contrast, S47A showed high affinity for cortisol based on ITC measurements (Kd =11.56 M) 
in the presence of NADH (Kd = 97.0 nM) (Figure 5.5C). Hydrogen-bonding between the C-
21hydroxy group of cortisol and the NADH is predicted to be responsible for the orders of 
magnitude difference in binding affinity between S47A, which binds cortisol, and S47T, which 
does not. There are no statistically significant differences in CD spectra between DesCWT and 
S47A and S47T (Figure 5.5B). 
With the experimental validation of the possible mechanism, we moved to optimize the 
reaction pathway and understand the atomistic details of the enzymatic mechanism. The string 
method61 was chosen for the task. This method is an optimization algorithm that relies on 
iterations of biased QM/MM MD simulations to find the chemical reaction path with the smallest 
energetic barrier. It does so by tracking “collective variables”, a set of measurements made on 
the system to describe the transformation being examined. In our case, the collective variables 
were chosen to be distances between relevant atoms in the QM region of the simulation.  
The string method was initialized with the QM/MM SMD simulation as a first hypothesis 
for the reaction path. A set of representative snapshots of the chemical reaction was selected to 
describe the entire process, from initial to final state, creating a set of “images” that represent a 
copy of the entire simulated system at a different stage of the reaction. At each iteration, multiple 
independent MD simulations are initiated from each image, allowing the atomic systems to 
explore the energy surface and drift to local minima. Next, average values for the collective 
variables are determined. Here, these values are cartesian coordinates, that are then used to 
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constrain the systems to keep consecutive images approximately equidistant in the collective 
variables space, smoothing the reaction coordinate. Convergence is achieved when the iterations 
do not produce significant changes in the mean values of the collective variables. Taking 
advantage of NCSA’s Blue Waters supercomputer, we ran 750 replicas for our string 
optimization, revealing the pathway of the reaction (Figure 5.4C). The string optimization 
shows that the initial reaction that triggers the enzymatic process is the hydride donation to the 
cortisol side-chain C-20, followed by the Ser47 proton donation to cortisol. The formation of 
20-dihydrocortisol triggers the proton relay we described above. 
 
Free energy calculation 
To investigate the free energy barrier that limits the start of the reaction, namely the 
activation free energy (Gact), we perform a parallel extended-Adaptive Biasing Force (eABF) 
calculation62, following established protocols.50,63 Using the final images of the optimized string 
we can define a continuous path that represents the entire enzymatic reaction. The eABF method 
can then be used to calculate the free energy changes along this path by constraining the system 
to path collective variables S and Z, where S indicates progression along the reaction path, and Z 
indicates a perpendicular distance to the path. Using NCSA’s Blue Waters supercomputer, we 
used a parallel strategy that initiated 600 walkers from the different images and were thus able to 
conduct extensive sampling over the defined path. The multiple-walker method is so-called due 
to the fact that each replica executes a random walk along the path.64 Here, 10,000 MD steps 
were performed by each walker, accumulating 6,000,000 QM/MM ABF steps, or 3 ns of 
QM/MM MD simulation.  The simulations revealed that only the initial step of the reaction, 
namely the hydride transfer from NADH to cortisol C-20, imposes an energetic barrier in the 
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order of 6 kcal/mol (Figure 5.4D). The 3 proton transfers that follow the hydride transfer were 
found to be energetically favorable. The entire reaction process was found to be exergonic, with 
a free energy difference between reactants and products (G) in the order of -25 kcal/mol. It is 
worth mentioning that this free energy difference only accounts for the reaction itself, and not for 
binding and rearrangements of the structure that occur prior and after the catalytic reaction. The 
ITC data however has also shown that the binding is exothermic, making the initial binding 
event, as expected, part of the overall favorable energy of the reaction. 
The enhanced sampling protocol adopted here greatly accelerated the dynamics of the 
system, allowing us to balance the gain in precision and the increased cost of QM/MM 
simulations. The simulations revealed that all reaction steps can occur in quick succession due to 
a stabilization of the reaction site, which is partially imposed by the presence of a Zn2+ ion. After 
the initial reaction step, all reactions in the proton relay are highly favorable because all protons 
are already aligned in hydrogen bonds. This stability is noticeable in the snapshots shown in 




Here we report the crystal structure and propose a catalytic mechanism for DesC, a 
glucocorticoid NADH-dependent 20α-HSDH expressed by Clostridium scindens ATCC 35704. 
Bacterial metabolism of host and synthetic glucocorticoids may have wide ranging effects on the 
immune system65–68, the cardiovascular system9, the structure of the gut microbiome69,70, and the 
urogenital tract.30,71 Their importance for human health brings enzymes biotransforming 20-
hydroxysteroids significant pharmaceutical value.  
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The expression of DesC by C. scindens ATCC 35704 highlights its importance as a 
member of the human ‘sterolbiome’28,72, the collective gene pathways responsible for steroid 
biotransformations by host-associated bacteria. In addition, DesC is part of a gene cluster 
encoding steroid-17,20-desmolase encoded by desA and desB genes.27 Steroid-17,20-desmolase 
catalyzes side-chain 17,20-lyase activity, which is the first step to converting cortisone (inactive 
form of cortisol) to 11-keto-androstenedione, an androgen-receptor ligand30. Thus, C. scindens 
ATCC 35704 contributes to the sterolbiome through the formation of 11-oxy-androgens and 20-
oxy-steroids. Importantly, C. scindens steroid-17,20-desmolase (DesAB)28 and 20α-HSDH 
(DesC) emerge as potential therapeutic targets. 
In nature, reversible conversion of the C-20 oxygen of C21 glucocorticoids is catalyzed by 
diverse pyridine nucleotide-dependent 20α-hydroxysteroid dehydrogenases. DesC, the NAD(H)-
dependent 20α-HSDH described in the present study, diverges significantly from previously 
described bacterial counterparts. Strains of Escherichia coli (DH5α, K12, E132) encode a 
homotetrameric (28 kDa monomer) complex with NADH-dependent 20α-HSDH activity 
belonging to the classical short-chain dehydrogenase/reductase (SDR) family, which does not 
require metal ions73. The enzyme was previously reported as a 2-dehydro-3-deoxy-D-gluconate 
5-dehydrogenase (KduD) and has broad substrate specificity for both sugars and C21-
glucocorticoids. Interestingly, KduD and DesC share only 16% amino acid identity. A second 
example is the dimeric (34 kDa monomer) NADPH-dependent 20α-HSDH purified from the 
protozoan Tetrahymena pyriformis, which was structurally and functionally distinct from 
bacterial as well as mammalian 20α-HSDHs.74 The T. pyriformis 20α-HSDH was highly specific 
for 17α-progesterone, which inhibits the growth of this protozoan. Mammalian enzymes reported 
to have 20α-HSDH activity are monomeric with Mr values between 33 kDa to 55 kDa, except for 
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estradiol 17-dehydrogenase (dual 20α-HSDH activity), which is a dimer. Many mammalian 
enzymes are polyfunctional, catalyzing several regio- and stereospecific reactions at more than 
one steroid keto group (e.g. 3α,20α-HSDH from human liver dihydrodiol dehydrogenase). Thus, 
the DesC represents a unique and now well-characterized bacterial 20α-HSDH. 
In summary, we have employed a combination of state-of-the-art computational tools and 
experiments to reveal the structure and proposed catalytic mechanism of DesC, a key steroid-
metabolizing enzyme found in the gut microbiome (Figure 5.1). X-ray crystallography was 
utilized to obtain the apo-DesC structure (Figure 5.2), which was then used as the starting point 
of a computational study that involved the identification of the DesC catalytic pocket, as well as 
the docking of both NADH and cortisol to this pocket (Figure 5.3). To confirm the proposed 
reaction mechanism, additional structural information with cofactor and substrate bound is 
needed. However, attempts to crystallize the binary and ternary complex were unsuccessful. 
Therefore, site-directed mutagenesis and biochemical assays were then employed to validate the 
key amino acid residues in the catalytic pocket. As it was hypothesized for the TDHs and many 
MDRs, our ITC data shows that NADH is the first substrate to bind the enzyme, given that 
cortisol does not bind to DesC unless NADH is present at the catalytic pocket. With the structure 
of DesC and its ligands now available, a hybrid QM/MM MD approach50 was applied to 
investigate the reaction mechanism of DesC. The approach, which combined steered molecular 
dynamics, string method optimization, and extended adaptive biasing force, with hybrid 
QM/MM calculations, then revealed that NADH first donates a hydride to cortisol, which 
triggers a proton relay that provides a proton to cortisol, forming the 20-dihydrocortisol 
enzymatic product. The proton relay then stabilizes the reaction pocket by a series of proton 
transfers that starts in a protonated histidine (Figure 5.4). The mechanism was validated by 
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biochemical assays, where amino acids that were revealed critical in the simulations were 
mutated (Figure 5.5). The enzymatic process was found to be exergonic, although the free 
energy difference calculated between reactants and products only accounts for the reaction itself 
and not for other steps of the DesC mechanism. Our findings can be applied in the development 
of approaches to modulate DesC activity, while our protocols can be employed to investigate 
other enzymes that are biomedically and biotechnologically relevant. The successful 
combination of experimental and computational approaches presented here reinforces the power 
and the need of combining these techniques.  
 
MATERIALS AND METHODS 
Bacterial Strains and Materials 
Clostridium scindens ATCC 35704 has been maintained as -80°C glycerol stocks in our 
laboratory. Escherichia coli DH5α (turbo) competent cells were from New England Biolab 
(Ipswich, MA), E. coli  BL21 CodonPlus (DE3)-RIPL was purchased from Stratagene (La Jolla, 
CA). The pET-51b vector was obtained from Novagen (San Diego, CA). Restriction enzymes 
were purchased from New England Biolab (Ipswich, MA), QIAprep Spin Miniprep kit was 
obtained from Qiagen (Valencia, CA). Isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
purchased from Gold Biotechnology (St. Louis, MO). Strep-Tactin® resin  was purchased from 
IBA GmbH, (Goettingen, Germany). Cortisol and 20a-dihydrocortisol were purchased from 
Steraloids (Newport, RI).  Amicon Ultra centrifugal filter units with 10-kDa MWCO were 
obtained from Millipore (Billerica, MA). All other reagents were of the highest possible purity 




Gene cloning, expression, and protein purification 
The open reading frame (EDS07887) encoding 20α-hydroxysteroid dehydrogenase (20α-
HSDH) amplified from C. scindens genomic DNA with primers reported in Supplementary 
Table 5.4, using high fidelity Phusion polymerase and cloned into pET51b as previously 
described. The sequence correctness of DNA insert in the recombinant plasmid was confirmed 
by DNA sequencing at W. M. Keck Center for Comparative and Functional Genomics at the 
University of Illinois at Urbana-Champaign.  
For protein expression, the correct recombinant plasmid extracted from the E. coli DH5α 
cells was transformed into E. coli BL21 CodonPlus (DE3)-RIPL chemically competent cells by 
the heat shock method and grown overnight at 37 °C on LB agar plates supplemented with 
ampicillin (100 µg/mL) and chloramphenicol (50 µg/mL). After 16 hours, five isolated colonies 
were used to inoculate 10 mL of fresh LB medium supplemented with antibiotics and grown at 
37 °C for 6 hours with vigorous aeration. The pre-cultures were then added to fresh LB medium 
(1 L), supplemented with the same antibiotics at the same concentrations, and grown with 
vigorous aeration at 37 °C. At OD600 of 0.3, isopropyl β-D-thio-galactopyranoside (IPTG) was 
added to each culture at a final concentration of 0.1 mM and the temperature was decreased to 16 
°C. Following 16 hours of culturing, cells were pelleted by centrifugation (4,000 x g, 30 min, 4 
°C) and re-suspended in 30 mL of binding buffer (20 mM Tris-HCl, 150 mM NaCl, 20% 
glycerol, 10mM 2-Mercaptoethanol pH 7.9). The cell suspension was subjected to four passages 
through an EmulsiFlex C-3 cell homogenizer (Avestin, Ottawa, Canada), and the cell lysate was 
clarified by centrifugation at 20,000 x g for 30 min at 4°C. 
The recombinant 20α–HSDH was then purified using Strep-Tactin® resin (IBA GmbH, 
Goettingen, Germany) as per manufacturer’s protocol. The recombinant protein was eluted using 
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an elution buffer composed of 20 mM Tris-HCl, 150 mM NaCl, 20% glycerol, 10mM 2-
mercaptoethanol pH 7.9 and 2.5 mM d-desthiobiotin. The protein purity was assessed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and protein bands were 
visualized by staining with Coomassie brilliant blue G-250. The protein concentrations were 
calculated based on the molecular mass and computed extinction coefficient. 
 
Protein Crystallization 
Selenomethionine derivatized DesC protein from C. scindens ATCC 35704 yielded 
crystals from JCSG Core Suite (Qiagen Sciences, MD) using a drop volume of 0.2 mL and a 1:1 
(vol/vol) ratio of reservoir to protein in 20 mM HEPES pH 8.0 solution equilibrated against 100 
mL of reservoir solution. The apo-form of the recombinant DesC crystallized via sitting drop 
vapor diffusion at 20ºC against a crystallization solution containing 0.2M MgCl2, 24% PEG 400, 
0.1M HEPES at pH 6.75. The crystals were cryoprotected with addition of 10% 1,2 ethanediol 
before harvesting and flash- freezing with liquid nitrogen.  X-ray data were collected at BL14-1 
at the Stanford Synchrotron Radiation Lightsource.  The x-ray data were indexed and integrated 
with XDS75 and scaled with XSCALE76. Multiwavelength anomalous dispersion (MAD) from 
the selenium signal used to determine the structure using the programs with SHELX77,78. Model 
refinement was performed with Refmac79,80. 
 
Mutational analysis of DesC to identify key residues for its activity and binding to substrate  
In order to identify the key amino acid residues that may be involved in both activity and 
binding to cortisol, an amino acid sequence alignment was carried out with known zinc 
dependent medium chain dehydrogenase sequences obtained from NCBI. Mutations were made 
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in the pET-51b containing the wild type DesC using QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent, Santa Clara) according to the manufacture’s protocol. The primers 
used in the site-directed mutagenesis study are summarized in Supplementary Table 5.4. 
Mutated plasmids were transformed into E. coli XL10 competent cells by heat-shock and plated 
onto lysogeny broth (LB) solidified with Bacto-agar (Difco) containing 100 μg/mL ampicillin 
sodium salt, and the plates were incubated at 37 °C overnight. Individual colonies were 
cultivated in 5ml of LB medium supplemented with ampicillin (100 μg/mL) overnight at 37 °C, 
and plasmids were extracted using a QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA). 
Plasmids containing the expected mutations were confirmed by DNA sequencing (W.M. Keck 
Center for Comparative and Functional Genomics, University of Illinois at Urbana-Champaign). 
The mutated proteins were expressed and purified using the same procedure described above for 
wild type. The proteins were quantified based on their molecular mass and theoretical extinction 
coefficient. 
 
Determination of structural integrity of the DesC wild type and mutants by circular dichroism 
(CD) spectra 
Determination of circular dichroism (CD) spectra for both DesC wild type and its site-
directed mutant proteins was carried out using a J-815 circular dichroism spectropolarimeter 
(Jasco, Tokyo, Japan). Protein samples were prepared at a concentration of 0.2 mg/ml in 10 mM 
KH2PO4 buffer (pH 7.5). For the measurements, a quartz cell with a path length of 0.1 cm was 
used. CD scans were carried out at 25°C from 190 nm to 260 nm at a speed of 50 nm/min with a 
0.1-nm wavelength pitch, with five accumulations. Data files were analyzed on the 
DICHROWEB online server (http://dichroweb.cryst.bbk.ac.uk/html/home.shtml) using the 
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CDSSTR algorithm with reference set 4, which is optimized for analysis of data recorded in the 
range of 190 nm to 240 nm.  
 
Isothermal titration calorimetric analysis of the DesC 
Isothermal titration calorimetric (ITC) analysis was performed using a VP-ITC 
microcalorimeter with a 1.4 mL cell volume from MicroCal, Inc. The proteins were dialyzed 
with phosphate buffer (50 mM sodium phosphate, 150 mM NaCl, 10% glycerol, pH 7.5) and the 
pyridine nucleotide (NADH) and cortisol were dissolved in the same buffer. The proteins 
(50 μM) with and without pyridine nucleotide were then injected with 28 successive 10 μL 
aliquots of cortisol (0.5 mM) at 300-s intervals. The data were fitted to a nonlinear regression 
model using a single binding site (MicroCal Origin software). The thermodynamic parameters 
were calculated using the Gibbs free energy equation (ΔG = ΔH−TΔS), and the relationship 
ΔG = −RTln(Ka). 
 
DesC enzyme assay 
DesC enzyme activity for both wild type and mutants was determined as described 
previously. Linearity of enzyme activity with respect to time and enzyme concentration was 
determined aerobically by monitoring the oxidation of NADH at 340 nM (ε=6,220 M-1•cm-1) in 
the presence of cortisol. The standard reaction mixture contained 50 mM phosphate buffer, pH 
7.5, 50 μM of cortisol, 150 μM NADH, 0.05 μM enzyme, and buffer to a final volume of 0.5 ml. 
The reaction was started by the addition of the enzyme. The initial velocities of enzyme were 
plotted against the substrate concentrations, and the kinetic parameters were estimated by fitting 
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the data to the Michaelis-Menten equation by non-linear regression method using the enzyme 
kinetics module in GraphPad Prism (GraphPad Software, La Jolla, CA). 
 
NADH and cortisol docking to DesC 
Using BLAST41, we obtained homologous structures (PDB IDs 4ILK, 4EJ6, 4A2C, 
3QE3, 3GFB, 2DQ4, 2DFV, 2D8A, 1PL7, 1E3J ) within the PDB.  The alignment and placing of 
both NADH and cortisol molecules on their binding sites was performed using VMD42. 
Employing advanced run options of QwikMD43, the structure of the ligands was minimized in 
the pocket together with the nearby DesC residues while maintaining the structure of most of 
DesC static. PyContact81 was then used to analyze the contact interface.  
 
Classical molecular dynamics simulations 
MD simulations were performed employing the GPU-accelerated NAMD molecular 
dynamics package.45 The simulations were performed assuming periodic boundary conditions in 
the NpT ensemble with temperature maintained at 300 K using Langevin dynamics for 
temperature and pressure coupling, the latter kept at 1 bar. A distance cut-off of 12.0 Å was 
applied to short-range non-bonded interactions, whereas long-range electrostatic interactions 
were treated using the particle-mesh Ewald (PME) method.48 The equations of motion were 
integrated using the r-RESPA multiple time step scheme82 to update the van der Waals 
interactions every step and electrostatic interactions every two steps. The time step of integration 
was chosen to be 2 fs, and before MD simulations, the system was submitted to an energy 
minimization protocol for 5,000 steps. An MD simulation with position restraints in the protein 
backbone atoms and ligands non-hydrogen atoms was performed for 10 ns. To allow for a total 
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relaxation of the system and to make sure ligands were stable in the DesC pocket, a 100 ns 
simulation in equilibrium, where no external forces were applied, was performed. The MD 
protocol served to pre-equilibrate the system before the hybrid QM/MM simulations. 
 
Hybrid QM/MM calculations 
Quantum mechanics (QM) is crucial to investigate subatomic mechanisms that occur in 
biology. However, studying entire biomolecular systems quantum mechanically is 
computationally prohibitive. Traditionally, NAMD45 employs classical molecular mechanics 
(MM) to determine the movement of a molecule, solving Newton's equations of motion and 
treating atoms as spheres and bonds as springs. Combining both approaches, hybrid QM/MM 
methods employ the quantum mechanics formalism to key regions of the biological system, 
while using molecular mechanics approach to include the effects of the surrounding area. 
NAMD's QM/MM interface50 can be combined with many molecular dynamics protocols, such 
as enhanced sampling and free energy calculations.63 This combination was crucial in solving the 
mechanism of DesC. Employing advanced run options of VMD’s42 QwikMD43 plugin, our in 
silico approach followed established protocols that were previously employed to investigate the 
mechanism of setting of the genetic code.50  
In summary, we first preform a short 20 ps long hybrid QM/MM MD simulation using 
NAMD50 and MOPAC83,84, with a 2.0 fs integration time step. This equilibration simulation was 
followed by a hybrid QM/MM SMD simulation, with 0.5 fs integration time step, where possible 
reaction mechanisms were probed. The most favorable reaction mechanism was them tested 
experimentally and also using more advanced enhanced sampling techniques, namely string 
simulations. All simulations were carried out using the charge-shift method to treat link atoms, 
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and a “shift” function was applied to surrounding classical partial charges in the electrostatic 
embedding scheme.50 
 
Hybrid QM/MM string simulations 
To study a transformation that occurs in a biomolecular system, such as a chemical 
reaction50 or a conformational change85,86, one defines collective variables such as distances 
between atoms or between centers of mass of groups of atoms, or even angles between 
subdomains of a molecular structure87,88. The collective variables are used to track the changes in 
the system as it undergoes the transformation being studied and can be used to define a reaction 
coordinate. 
The reaction coordinate defined in this study describes the chemical reaction carried out 
by DesC, and it was optimized by the string method, an iterative method that adapts the reaction 
coordinate as to fit it to the path of least resistance. Collective variables were defined as 
distances between atoms relevant for the reaction. From the initial state, before the chemical 
reaction has occurred, to the final state, after all transformations have taken place, multiple 
“images” are selected as representative stages of the overall transformation. Over multiple 
iterations, the string method initiates sets of short, unbiased, and independent QM/MM MD 
simulations from each image, creating full copies of the system that explore conformations the 
system can explore along the reaction coordinate. Then, each set of QM/MM MD simulations is 
used to re-define the image, leading to a smooth path from initial to final state. Iterations are 
performed until average consecutive changes converge to a stable value. 
Here we have launched 750 multiple independent MD simulations per image, for a total 
of 25 images. The total simulation time was 4.5 ns, which was enough to converge the 
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simulations in the collective variables space. Collective variables were analyzed using in-house 
python scripts implemented in Jupyter notebooks.  
 
Hybrid QM/MM free energy calculations 
After optimizing the reaction coordinate, we applied the extended adaptive biasing force 
(eABF) method to estimate the free energy change along the reaction. In eABF, the QM/MM 
MD simulation is constrained to occur along the reaction coordinate using two new collective 
variables called “path collective variables” S and Z. The former describes the transformation of 
the system from start to end, and latter describes transformations “perpendicular” to the reaction 
coordinate, allowing minor adjustments and optimizations not obtained during the string 
optimization. We leveraged NAMD’s scalability to initiate multiple QM/MM MD simulations 
along the reaction coordinate, leading to a multiple-walker eABF calculation that produced 
extensive sampling over the chemical reaction path. 
This approach allowed us to perform 3 ns of hybrid QM/MM simulation, which would 
not be feasible without the parallel distribution of eABF sampling. Specifically, 375 NCSA Blue 
Waters XE nodes were used to simulate 750 replicas (walkers) of the system in order to 
streamline the free energy calculation process. 
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Figure 5.1. Overview of the metabolism of cortisol by the gut bacterium Clostridium 
scindens. The obligate anaerobic bacterium, C. scindens ATCC 35704, resides in the large 
intestine. This bacterium expresses a gene cluster (desABCD) encoding DesAB (no structure 
available) which removes the side-chain of cortisol, forming 11β-hydroxyandrostenedione. DesC 
(new structure presented in this manuscript) is an NAD(H)-dependent 20α−hydroxysteroid 
dehydrogenase that catalyzes the reversible oxidoreduction of the C20 ketone. The androgenic 
end product of DesAB is implicated in prostate cancer and may affect innate and adaptive 
immune function because many immune cells express androgen receptor. By inhibiting the host 
enzyme 11β-hydroxysteroid dehydrogenase 1 & 2 isoforms, these metabolites may also affect  
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Figure 5.1 (cont.) 
blood pressure and inflammation in the GI tract. The formation of 20α-dihydrocortisol in the host 
is associated with disorders such as Cushing’s syndrome; however, little is known about the 
physiological or pathophysiological role of 20-reduced forms of cortisol. Moreover, DesC 




Figure 5.2. Depiction of DesC highlighting functional features. A. DesC structure with amino 
acid chains shown in cartoon representation and colored differently to show the bilobal topology. 
Structural waters are shown in red spheres, and two catalytic Zn2+ ions are shown as gray 
spheres. B. Same view of the complex colored by secondary structures: a-helices in purple and b-
strands in green. C. Detailed view of the catalytic Zn2+ ion in octahedral coordination by water 
molecules and catalytic site residues. Amino acid residues are shown in licorice representation 
where carbon atoms are colored in gray, oxygen in red, nitrogen in blue and phosphorous in 




Figure 5.3. Characterization of the cortisol binding pocket of DesC. A. Homologous proteins 
from the PDB were superimposed to highlight structure similarity and binding pose of multiple 
ligands. All proteins are shown in cartoon representation while ligands are shown in orange 
licorice representation. B. Same as previous, with alternate view of the binding site. C. Final 
binding poses of NADH and cortisol to DesC. The protein is shown in cartoon representation. D. 
Space-filling representation of DesC shows the alignment of cortisol deep in a cleft. E. Detailed  
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Figure 5.3 (cont.) 
view of cortisol and NADH binding near the Zn2+ in the active site. Substrates are shown in ball-
and-stick representations. Carbon atoms in gray, oxygen in red, nitrogen in blue and hydrogen in 
white. F. Detailed view of tyrosines 101 and 124 stabilizing cortisol’s binding pose. G. 
Comparison of circular dichroism spectra (190-260 nm) between wild type (WT) recombinant 
DesC, Y101R mutant, and Y124R mutant. H. Isothermal titration calorimetry of Y101R mutant 
in the presence of 1.5 mM NADH (upper left panel), and 1.5 mM NADH + 0.5 mM cortisol 
(upper right panel) and Y124R mutant in the presence of 1.5 mM NADH (lower left panel), and 
1.5 mM NADH + 0.5 mM cortisol (lower right panel). I. Effect of binding pocket mutations on 
Km for cortisol in the presence of saturating NADH. J. Relative activity (%) of WT vs. binding 




Figure 5.4. Description of QM/MM calculation of the reaction catalyzed by DesC. A. 
Depiction of the entire simulated system, showing DesC in a simplified water box. B. Detailed 
view of the active site showing all proton transfers that take place during the reaction. DesC is 
shown in cartoon representation, while atoms in the QM region are shown in ball-and-stick 
representations. Carbon atoms in gray, oxygen in red, nitrogen in blue and hydrogen in white. C. 
Plot showing the progression of all collective variables tracked during the string method  
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Figure 5.4 (cont.) 
optimization of the reaction coordinate. Collective variable pairs labeled with shades of the same 
color describe the distance between a hydrogen atom and its donor and acceptor carbon or 
oxygen atoms. The numbers correspond to the labelled reactions in section B of the figure. The 
interatomic distances show the proton relay progression during the catalytic process. D. 
Matching plot showing the same reaction coordinate and the results of the eABF free energy 
calculation. The first energy barrier corresponds to the proton exchange from NADH to cortisol. 
E. Multiple detailed views of the active site show the progression of the overall reaction. Blue 




Figure 5.5. Role of Serine 47 in catalysis. A. Depiction of active site with bound reactants. The 
two residues highlighted were mutated to confirm their importance to binding and enzymatic 
activity.  B. Comparison of circular dichroism spectra (190-260 nm) between wild type (WT) 
recombinant DesC, S47A mutant, S47T mutant, and H50A mutant. C. Isothermal titration 
calorimetry of S47A mutant in the presence of 1.5 mM NADH (left panel), and 1.5 mM NADH 
+ 0.5 mM cortisol (right panel). D. Effect of active-site mutations on Km for cortisol in the 
presence of saturating NADH. E. Relative activity (%) of WT vs. active-site mutants when 






Supplementary Figure 5.1. Structure refinement. A. Ribbon structure of DesC. Zinc ions are 
displayed as purple spheres with coordinating residues in green sticks. B. Close-up of Zn2+ 
within the catalytic site. C. Close-up of Zn2+ at the lobe loop extension. D. Overlay of DesC  
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Supplementary Figure 5.1 (cont.) 
(gray ribbon), with Pyrococcus horikoshii threonine dehydrogenase (2DFV, blue ribbon) and 
Thermococcus kodakaraensis threonine dehydrogenase (3GFB, cyan ribbon). Zinc is displayed 
as purple spheres and NAD+ bound to the threonine dehydrogenases is shown in green sticks. E. 





Supplementary Figure 5.2. Electron density. A. Electron density for Zn2+ bound at the active 
site. The |Fo-Fc| density for Zn2+ is  colored red and contoured at 7 σ. The |2Fo-Fc| density for 
Zn and the coordinating residues is colored blue and contoured at 1.3 σ. B. Electron density for 
Zn2+ bound at the lobe loop. The |Fo-Fc| density for Zn2+ is  colored red and contoured at 5 σ. 








Supplementary Table 5.1. Data collection and refinement statistics. 
PDB code 4OH1 
Space group I222 
Unit cell (Å) a= 63.87, b=85.60, c=149.09 
Resolution (Å) 29.4 – 2.0 (2.05 – 2.00)a 
Total Reflections 27918 (1995) 
Completeness (%) 99.5 (98.1) 
Mean I/sigma (I) 10.15 (1.4) 
Rmerge 0.05 (0.61) 
Rcrystal/Rfree 0.168/0.216 (0.311, 0.297) 
Rfree test set 1403 reflections (5.00%) 
Wilson B-factor (Å2) 35.5 
Fo-Fc correlation(free) 0.97 (0.95) 
Total number of atoms 2918 
Average B, all atoms (Å2) 49 
Ramachandran outliers 0 
RMS bonds (Å)  0.02 
RMS angles (o) 1.8 
Sidechain outliers 1.40% 
RSRZ outliers 7.90% 
Numbers in final Model  
Residues 351 
Protein Atoms 2704 
Catalytic Zn2+ 2 
Water Molecules 193 
Chloride 3 
1,2-ethanediol 1 
tetraethylene glycol 1 
Mean B-values (Å2)  
Protein atoms 36.2 
tetraethylene glycol 67.75 
1,2-ethanediol 72.75 
Zinc 1 47 
Zinc 2 49 
Chloride 1 45 
Chloride 2 57 
a Values in parenthesis are for the highest resolution shell unless otherwise indicated.  
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Blue dextran 2000 1 
Thyroglobulin 670 1.00795 
Gamma-globulin 158 1.028038 
Ovalbumin 44 1.045358 
Myoglobin 17 1.057496 
Vitamin B12 1.35 1.079074 
DesC mutants Ve/Vo Estimated MW 
(Kda) 
C105A 0.997871 >2000 
C108A 0.997445 >2000 
C111A 0.997658 >2000 
C119A 0.998935 >2000 
C105A-C119A 0.999148 >2000 
C108A-C119A 0.999219 >2000 
WT 1.0264 164 
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Supplementary Table 5.3. Kinetic parameters for DesC activity.  
Enzyme Km                                 
(mM) 
Vmax                
(nmol.min-1.mg-1) 
Kcat                
(min-1) 
Kcat/Km              
(min-1. mM-1) 
Activity loss     
(%) 
WT 128.34  5.26 1122.3  64.19 44.33  2.54 0.35  0.03 0 
S47A NA NA NA NA 100 
H50A 23.99  0.26 316.36  67.55 12.5  0.89 0.52  0.04 71.81  6.02 
S47T 77.78  1.78 16.66  0.90 0.66  0.04 0.0085  0.0006  98.52  0.08 
Y101R 628.65  29.96 44.80  7.54 1.77  0.30 0.0028  0.0006 96.01  0.67 




Supplementary Table 5.4. Primers employed in the study. 
Gene 5’-forward primer-3’ 
 5’-reverse primer-3’ 
DesC WT ATATATCCATGGCAATGAGACAATTATTTGTTACTTCCA 
 ATATATAAGCTTCTACTTTTCGAACTGCGGGTGGCTCCATTCGTCCATCTTAATTACG
ATC 
DesC S47A GTTTATGCGTCCATTTGTGGTGCGGATACACATATTCTTACCGG 
 CCGGTAAGAATATGTGTATCCGCACCACAAATGGACGCATAAAC 
DesC S47T GCGTCCATTTGTGGTACCGATACACATATTC 
 GAATATGTGTATCGGTACCACAAATGGACGC 
DesC H50A CATTTGTGGTTCCGATACAGCGATTCTTACCGGAAATCTG 
 CAGATTTCCGGTAAGAATCGCTGTATCGGAACCACAAATG 
DesC Y101R CAGAAGGTTGTTGCAAACCGTGCAAAATACTGTGGATG 
 CATCCACAGTATTTTGCACGGTTTGCAACAACCTTCTG 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
BILE ACID 12α- AND 12β-HYDROXYSTEROID DEHYDROGENASE 
 Bile acid 12α-hydroxysteroid dehydrogenase (HSDH) activity was characterized in the 
high-activity 7α-dehydroxylating organisms Clostridium scindens, C. hylemonae, and C. 
hiranonis (reclassified as Peptacetobacter hiranonis).1 The first gene encoding bile acid 12β-
HSDH, which together with 12α-HSDH completes the epi-bile acid pathway, was also 
discovered from Clostridium paraputrificum.2 Phylogenetic analysis of 12α-HSDH suggests that 
this activity is widespread across human gut microorganisms while 12β-HSDH is less 
ubiquitous. Through phylogenetic analysis of 12β-HSDH, two additional genes encoding this 
activity were validated. Importantly, by comparing sequences within the 12α- and 12β-HSDH 
trees, two Collinsella strains were identified that share both activities. These organisms represent 
the first identification of potential C-12 epimerizing strains. 
 12α- and 12β-HSDH may be of therapeutic importance in the future because the epi-
pathway substrate, deoxycholic acid (DCA), has been mechanistically associated with cancers of 
the liver and colon.3,4 The paired 12α- and 12β-HSDH activities in Collinsella tanakaei and C. 
stercoris strains evolved together and would likely be the best targets for favorable conversion of 
DCA to epiDCA. Thus, these enzymes may be used for future mechanistic studies on the effects 
of the epi-bile acid pathway and its products on the host. Currently, there are no crystal structures 
of 12α- or 12β-HSDH. Their structural biology will be important in the rational engineering of 
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these enzymes for optimal conversion of DCA to epiDCA, or for alteration of substrate 
specificity. 
 
CORTISOL 20α- AND 20β-HYDROXYSTEROID DEHYDROGENASE 
 20β-HSDH from Bifidobacterium adolescentis strain L2-32 was biochemically and 
structurally studied.5 The cortisol 20β-HSDH was crystallized in the apo-form and binary 
complex. A long, flexible N-terminal region was identified within the structure and investigated 
further, revealing its role in protein stability. The partner of 20β-HSDH with opposite 
stereospecificity, cortisol 20α-HSDH, from Clostridium scindens ATCC 35704 was also 
characterized and crystallized.6 This HSDH structure represents the first of its specificity. A 
reaction mechanism was proposed using quantum mechanical simulations with validation 
through amino acid mutagenesis studies. Two additional putative 20α-HSDHs from 
Denitratisoma oestradiolicum DSM 16959 and Intestinibacillus sp. Marseille-P4005 were 
identified through BLASTP search based on high sequence similarity to C. scindens 20α-
HSDH.2 
 Both 20α- and 20β-HSDH are putative regulators of the pro-androgenic cortisol steroid-
17,20-desmolase (DesAB) pathway.7,8 The product of the DesAB pathway can be further 
converted to potent androgens9, which may be a previously unknown contributor to androgen-
related diseases, such as castration-resistant prostate cancer and polycystic ovary syndrome10. 
While research must be done to first confirm the pro-androgenic role of microbial DesAB 
activity in vivo, 20α- and 20β-HSDH pose important therapeutic targets for androgen-related 
disease. Future research may entail utilizing their crystal structures and site-directed mutagenesis 
to optimize competitive conversion of cortisol away from the DesAB pathway. Subsequently, 
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gnotobiotic animal studies may be performed to determine the role of 20α- and 20β-HSDH 
products within the host and test competition with DesAB in vivo. 
 
THE FUTURE OF HYDROXYSTEROID DEHYDROGENASES 
 The collection of studies herein identifying and characterizing new HSDH enzymes 
strengthens the foundation for future mechanistic work on the impacts of HSDHs on host 
physiology. Indeed, linking HSDH activity to host phenotypes is an important next step to the 
study of these diverse enzymes.11,12 The development of HSDH gene knockouts, or alternatively 
integrating HSDH genes into genetically tractable microorganisms, along with gnotobiotic 
animal experiments will allow exploration of HSDH mechanisms. 
 The therapeutic HSDHs, confirmed by mechanistic studies, may then be leveraged 
against steroid-driven disease states. For example, recent advances in synthetic biology are 
allowing for the construction of genetically engineered bacteria for therapeutic and diagnostic 
purposes. Current applications of preclinically tested engineered bacteria include expression of 
drugs, drug-activating enzymes, and antimicrobial peptides.13 These approaches generally focus 
on alleviating disease symptoms, not potential sources of disease progression within the body. In 
contrast, the therapeutic promise of HSDHs may come from their modulation of endogenous 
disease-promoting steroids. Thus, rationally designed HSDH-encoding probiotic microorganisms 
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